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1.1 Historical perspective 
 
“What is there that is not poison? All things are poison and nothing is without poison. Solely 
the dose determines that a thing is not poison.”  
 
This famous dictum of the Swiss scientist Paracelsus (1493-1541) lies at the core of the 
research described in this thesis. Even though he only held a position for less than a year at 
the university of Basel due to his unpredictable temperament, during his life he lay the 
foundation for modern safety/toxicity research and assessment [1]. His most prominent 
studies showed that the body’s response to a foreign substance could be beneficial or 
harmless when given in low concentrations whereas toxic at high concentrations.  
One of the earliest application of this concept can be traced back to the Olympic Games in 
Greece during the third century BC. Eager to win the games, athletes relied on natural 
performance enhancing “drugs” such as for example hallucinogenic mushrooms to 
overcome fatigue and injuries or also “analgesic bread” which was prepared with opium 
from poppies and relieved pain. The emergency for doctors and cooks to prescribe the 
exact dosage to the athletes was paramount in winning and avoiding any deleterious effects 
during the games which nevertheless did occur from time to time [2]. More than 500 years 
later Paracelsus concept has become one of the most fundamental principles in toxicology 
and it is daily applied to determine the toxicity of a substance by identifying the dose-
response correlation.  
Over time we became aware that apart from the crucial function of dose in toxicity 
assessments several other essential factors contribute to determining the fate of a substance 
to be harmful to our body or not. For instance, the type of dose (e.g. inhaled, ingested, 
intravenous, dermal), the intrinsic physicochemical properties of the substance (e.g. 
solubility, molecular weight, flexibility), or exposure frequency (e.g. duration and 
single/multiple times, circadian rhythms) can impact its toxic potential. Also the organism 
itself can have an impact on the substance; gender (e.g. differences in body weight), age 
(some chemicals are more toxic to children), genetic predisposition (the genetic make up of 
a person can increase their susceptibility towards a chemical), the microbial enzyme 
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composition in our gut or also the type of species (human or animal) can again influence the 
degree of toxicity [3,4]. Regulations and guidelines have been tailored by governmental 
institutions such as the US Federal Drug Administration (FDA) and European Medicine 
Agency (EMA) that should prevent or limit adverse effects of chemicals (e.g. drugs, food 
additives, or cosmetics) we daily interact with and might form a potential health risk. Foreign 
substances (xenobiotics) that found a way into our body usually encounter one of our first 
lines of defence at the liver, the cytochrome P450 superheme family. The enzymes 
selectively recognise xenobiotics and metabolize them into more hydrophilic compounds 
which facilitates their secretion mainly by the kidneys.  
We have gradually unravelled parts of these truly extraordinary and complex functioning 
enzymes. The wealth of information we gathered helped to solve parts of the giant P450 
puzzle and answer questions such as what their function is, where they are located or how 
the catalysis cycle is organized. The first experimental piece of evidence that has proven the 
existence of this unique superheme family dates back to the late 1940s [5]. Millers and co-
workers studied the metabolism of the aminoazo dye N-N-dimethyl-4-aminoazobenzene 
and its correlation with the formation of tumours. During the experiments, they discovered 
that a particulate fraction of rat liver cells was able to catalyze the metabolism of the 
aminoazo dye studied [6].  Around the same time, similar in vitro metabolism experiments 
were performed at the Brodie Laboratory. Julius Axelrod, who was awarded the medicine 
Nobel prize in 1970, uncovered the presence of an enzyme system found in rabbit liver 
microsomes which could oxidize psychoactive drugs (e.g. amphetamines and ephedrine). 
The metabolism process required a soluble factor, which he identified to be NADPH [5,7]. 
The official “P450” part of the family name came from spectrophotometric studies 
performed in the Chance Laboratory. The prime focus of the lab was to understand the 
reactions of oxidative phosphorylation catalyzed in the liver and heart mitochondria. After 
identifying the existence of a heme-binding protein in the supernatant of the rat liver 
mitochondria (now known as cytochrome b) by spectrophotometric studies in 1954, their 
discovery four years later was determining for the P450 research field. The German physical 
chemist Klingenberg observed that when carbon monoxide was gassed through a cuvette 
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containing rat liver microsomes and a reducing agent (e.g. NADPH), a spectrum with 
maximum absorbance at 450 nm was recorded [8]. This initiated several studies aimed to 
characterize the found pigments in the rat liver microsomes. Sato and Omura determined 
the pigments as heme-proteins in 1962 [9]. They designated the pigments “cytochromes”.   
 
1.2 CYPs in drug discovery and medical treatment 
 
“It is more important to know what sort of person has a disease than to know what sort of 
disease a person has.” As the Greek physician Hippocrates already pointed out 2500 years 
ago, determining the genetic profile (genotype) of a person to personalize the medication 
accordingly is crucial for effective treatment and avoid side effects. Metabolism of drugs, 
the process in which a non-polar compound (parent drug) is chemically modified into a polar 
compound (metabolite) occurs mainly in the liver [10]. The reaction is catalysed by various 
enzymes and divided into phase I (oxidation, reduction and hydrolysis) and phase II 
(conjugation). During phase I the parent drug is chemically modified into a more polar 
metabolite by introduction of a polar group (e.g. OH or SH). The produced phase I 
metabolite(s) can be pharmacologically inactive, active (parent drug is inactive, called 
prodrug), or some of the metabolites are active but less than the original drug. During phase 
II, the phase I produced metabolites are conjugated with a charged group (e.g. 
glutathionide or glycine) which further increases their solubility and promotes the secretion 
mainly by the kidneys. CYPs are the major drug-metabolizing phase I enzymes and their 
activity is genetically determined. Inter-individual CYP-genotype variability can alter drug 
metabolism (faster, slower or none) after administering the same drug dose to different 
patients [13]. Slower drug metabolism results in increased plasma concentrations and 
overexposure of the drug thereby increasing toxicity risks. On the other hand, faster 
elimination of the drug prevents it from reaching sufficient bioavailability and efficacy [14]. 
Therefore, drug discovery, clinical trials and personalized therapy include CYP-related 
assessments to determine the drug metabolism profile (which isoforms are involved) and 
potentially identify the the CYP genomic profile of patients to adjust the drug therapy 
accordingly and minimize the chance on unexpected adverse reactions. 
13  
1.2.1 The famous P450 family member CYP2D6 
 
The human P450 cytochrome superfamily is encoded by 57 functional genes of which 
primarily members of family 1, 2 and 3 (particularly CYP1A2, CYP2E1, CYP3A4, CYP2C9, 
CYP2C19 and CYP2D6) account for the metabolism of therapeutic drugs (>75%) whereas 
other family members are involved in metabolism of endogenous substrates such as fatty 
acids, eicosanoids and vitamins [10]. CYP2D6 is responsible for about 25% of overall drug 
clearance despite its low share of 2% of the liver cytochrome pool (concentration) [11]. In 
addition, CYP2D6 is highly polymorphic with over 100 variant alleles known 
(http://www.PharmVar.org). This number is still growing with the ongoing P450 sequencing 
projects worldwide [12].  
Pharmacogenetic variation of the P450 encoding genes (duplication, base pair 
insertions/deletions, copy number variations and single nucleotide polymorphisms (SNPs) 
[13] has often a dramatic impact on the expression and functional activity of the enzyme [14] 
which will be discussed in section 1.2.2. The CYP2D6 variants CYP2D6*4, CYP2D6*5, 
CYP2D6*10, CYP2D6*17 and CYP2D6*41 are among the most frequently observed allelic 
variants throughout populations worldwide [11,15,16]. The overall P450 fold is conserved 
among the different CYP families [17,18]. The structure is composed out of twelve a-helices 
(A-L) and four small b-sheet domains (Figure 1.1A). The P450 family carefully conserved the 
region around the heme in order to perform the generally uniform P450 catalytic cycle. The 
conserved cavity is formed by helices D, E, I, J, K, L, b-sheet 1 and 2, and the meander loop 
[18]. The most variable regions are the domains that are involved in the formation of the 
channels and control the passage of ligands and co-factors through the cytochrome. 
Currently, several channels are known based on X-ray studies and Molecular Dynamics (MD) 
simulations [19,20]. Cojocaru et al. performed a channel study on 26 P450 (mammalian, 
bacterial and archaea) X-ray structures and provided a general nomenclature. The naming 
is based on the lining of the secondary structure elements involved. The five most commonly 
observed channels (solvent, 2a, 2ac, 2c, and 2f) are located within the region of helices F 
and G [21,22]. Six general substrate recognition sites (SRS) are known (Figure 1.1B, 1.1C) 
[23]. Important CYP2D6 residues directly involved in the binding include (i) Glu216 and 
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Asp301 associated with recognition and positioning of the ligand, and (ii) Phe120, Phe381 
and Phe483, suggested to control orientation of the aromatic rings found in most 
substrates. From the two essential recognition residues, Glu216, not found in any other 
CYP2 subfamily, is thought to be foremost responsible for initial ligand binding, which is 
supported by experimental and modeling studies [24,25]. 
 
Figure 1.1 Cytochrome P450 2D6 (CYP2D6) structural characteristics. A) CYP2D6 (PDB ID 3QM4) is 
displayed with annotated secondary structural elements. The α-helices are shown in white, β-sheets in pink, 
and loops in cyan. The FG and BC loop, important for regulation of the binding cavity access, are highlighted 
in orange. The CYP2D6 core of the active site cavity is formed by amino acids located on helices I, F, G, loop 
KL and FG, and the heme. B) Same CYP2D6 structure as shown in (a) but rotated to match the orientation 
shown in c. C) The six major substrate recognition sites (SRS) are displayed and located around: The B’ helix 
(SRS1, gray), the F helix (SRS2, orange), the G helix (SRS3, pink), the I helix (SRS4, green), b 4-1 (SRS5, yellow), 
and b 4-2/3-2 (SRS6, blue) 
 
1.2.2 Clinical relevance of CYP2D6 pharmacogenetics  
 
The amount of clinical evidence regarding which CYP2D6 allelic variants may predispose an 
individual to a higher risk of developing a disease or guide drug choice and/or dose is 
continuously growing [26]. Therapeutic areas where CYP2D6 polymorphism has shown a 
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major impact are psychiatry (ADHD, depression) and pain treatment [27]. Other areas where 
CYP2D6’s role is still controversial include oncology (e.g. breast cancer), cardiology (e.g. 
cardiac arrhythmias) and neurological disorders (e.g. Parkinson disease) [28–30]. The 
presence of any other phenotype (ultrarapid (UM), intermediate (IM) or poor (PM) 
metabolizers) than the normal (NM) one can lead to treatment failure, life-threatening 




Figure 1.2 CYP2D6 polymorphism distribution among Caucasians. A) the genetic modification is shown 
(normal = black; impaired = red gene; explained in table B) with the corresponding phenotype, enzyme 
activity, and its relative frequency. Depending on the genetic differences among patients, the phenotypes are 
categorized as ultrarapid (UM), normal (NM), intermediate (IM), or poor (PM) metabolizers. B) Overview of 
different phenotypes and the corresponding genotypic description. 
 
In case of Schizophrenia and Parkinson disease, CYP2D6 polymorphism has been suggested 
to increase susceptibility towards the development of these diseases [29,32]. Improving our 
general understanding of CYP2D6 polymorphism and the mechanisms underlying CYP2D6 
functioning can contribute to the development of improved tools that support the currently 
changing practice of physicians to more frequently incorporate the patient 
pharmacogenetic profiling for determining the appropriate drug and its dose in order to 
avoid aforementioned risks [33]. A predictive in silico CYP2D6 tool would ideally provide 
information on the likelihood of a drug-CYP2D6 interaction and give an indication (score) 
on the potential toxicity. SNPs based amino acid changes could be incorporated into the 
CYP2D6 model as well to evaluate the impact of CYP2D6 polymorphism-induced structural 
changes on drug-cytochrome interactions. 
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However, even if the CYP2D6 phenotype is unambiguously identified, there are additional 
relevant factors which need to be assessed for establishing an accurate clinical phenotype: 
(i) defining the overall contribution of the CYP2D6-mediated pathway and of other possible 
pathways in the clearance of the drug from the body, (ii) the activity of the parent molecule 
and the metabolite(s), (iii) co-administered drugs (or herbs) and (iv) the therapeutic index of 
the drug [34]. All of these factors would require assessment by the pharmacokinetic 
modelling experts during the drug design process. 
For clinical cases where a drug depends on CYP2D6 metabolism, polymorphisms can have 
various consequences for the metabolism and activity of the drug [30,35]. The drug can be 
either administered as an active compound (e.g. S-metoprolol), which frequently will be 
metabolized into an inactive metabolite for easier clearance from the body or as a prodrug 
(e.g. codeine) requiring CYP2D6 metabolism to form the active compound needed for 
reaching its pharmacological effect (e.g. pain relief). If the patient’s phenotype deviates 
from normal CYP2D6 activity, the enzyme activity can either be higher, lower or absent 
(Figure 1.2A,B). Subjects with PM and IM phenotypes are characterized by little to no and 
decreased CYP2D6 activity respectively and compromise drug metabolism. In contrast, 
subjects with an UM phenotype (usually three or more functional copies of CYP2D6) show 
increased enzyme activity and metabolize drugs at a higher than the normal rate [35].  
For a prodrug, poor metabolism can potentially lead to poor drug efficacy with an increased 
risk of a therapeutic failure. Moreover, the prodrug might accumulate in the body increasing 
the chance of drug-induced side effects. On the other hand, ultrarapid metabolism of the 
prodrug can lead to sudden elevated (toxic) quantities of the active metabolite that can 
result in death as for instance was the case with codeine [36]. For an active drug, the 
potential consequences are slightly different. Good drug efficacy might be achieved for 
slow metabolizers, nevertheless, gradual accumulation of the active drug increases again 
the risk of drug-induced side effects and may require dose lowering. Ultrarapid metabolizers 
usually suffer from poor drug efficacy leading to an increased risk of treatment failure [31]. 
In some cases, increasing the dose might be an option depending on the drug dosage 
index. If ample evidence is found that proves a clear link between CYP2D6 allelic variation 
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and the clinical treatment outcome, a standard genotype test might be implemented that 
would help to determine the optimal patient dose and enhance the chance on a successful 
treatment outcome.  
To address this issue, the Clinical Pharmacogenetics Implementation Consortium (CPIC), 
established in 2009, procure dosing guidelines for over 90 drugs for which genetic variants 
(and the corresponding phenotype) showed to have an impact on drug response [37]. The 
guidelines (https://cpicpgx.org, https://www.pharmgkb.org) are based on different types 
and levels of evidence and help physicians to justify the use of pharmacogenetic tests in the 
clinic. Currently, 12 drugs are listed with CYP2D6 guidelines and more convincing proofs 
need to be collected for over 40 drugs as the number of cases with adverse responses is 
still insufficient. A clinical example of ‘codeine’ (one of the CPIC listed CYP2D6 drugs) which 
illustrates the complexity of determining the correlation between CYP2D6 allelic variation 
and drug metabolism unambiguously and also the potential added value that 
recommendation of CYP2D6 testing can have to lower adverse responses in patients and 
optimize the choice and strategy of the clinical treatment can be found in reference 38.[38] 
 
1.3 Enzymology of CYP2D6 
 
The word “enzyme” was derived from the greek word “ἔνζυμον” which means “leavened” 
or “in yeast”. An enzyme (a protein) enables catalysis of a compound (substrate) by 
transforming it into a new product. The speed-up of the reaction requires the presence of 
the enzyme, also called the catalyst. Without the enzyme the activation barrier of the 
reaction would usually be too high and the chance on a spontaneous reaction would be very 
low. In addition, the enzyme is not consumed during the reaction, hence can be smartly 
recycled all times. Thus enzymology studies focus on understanding the overall chemical 
reaction process and its environmental setting. 
 
1.3.1 P450 catalytic cycle 
 
The P450 catalytic reaction depends on the presence of several co-factors including the 
ligand(s), molecular oxygen, water and the cytochrome P450 reductase (CPR, also known as 
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POR). The latter is responsible for the electron delivery by interaction of its FMN domain 




Figure 1.3 CYP2D6 Microenvironment displaying the three major components required for the catalytic 
cycle. Molecular environment of cytochrome P450: CYP2D6 (497 aa) anchored (drawn part) to the membrane 
(endoplasmic reticulum) at its N-terminus side (pink, PDB ID 4WNUi) together with its redox partner NADPH-
Cytochrome P450 Reductase (CPR, 676 aa) (cyan, PDB ID 1AMOi). CPR shuttles the electrons from 
nicotinamide adenine dinucleotide phosphate (NADPH) to the CYP where they are used for the catalytic 
oxidation of tamoxifen into 4-hydroxtamoxifen (afimoxifene). It is proposed that lipophilic substrates can 
access the active site directly through the membrane (pathway II) in addition to the cytosolic entry (pathway I) 
[40]. 
 
The consensus P450 catalytic cycle can be seen in Figure 1.4; at the beginning of the cycle, 
CYP2D6 is in a resting state in which a water molecule is covalently bound to the iron (III) 
(A). Upon binding of a substrate to the ferric enzyme, the distal water is displaced as the 
sixth heme ligand (B). The first reduction of the iron (III) complex reduces the iron to the 
(deoxy)iron (II) state, also known as “the ferrous state” (C). This enables the binding of a 
molecular oxygen, forming a ferrous oxyiron(II) complex (D). The second reduction results 
in an activated oxygen species (E). Being a very strong base, it abstracts a proton and forms 
the iron(II)-peroxide intermediate (F). A second protonation follows, which usually occurs at 
the distal OH group, enabling heterolytic oxygen-oxygen bond scission and a water 
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molecule leaves (one oxygen atom with two protons and electrons) resulting in the iron (IV) 
coupled porphyrin radical cation (G). This highly reactive oxyferryl intermediate incorporates 
an oxygen atom into the substrate, producing the oxidized product (R-OH) (H). Dissociation 
of the product turns the cytochrome back to its initial resting state (A). The second reduction 
can however also sometimes occur on the proximal oxygen and a so-called ‘uncoupling’ 
reaction occurs. During the catalytic disruption, a hydrogen peroxide is formed which leaves 
the active site and the ferri-heme intermediate is regenerated (B). Whenever the delivery of 
the second proton is inhibited (e.g. by mutation of an involved active side residue) the 
uncoupling reaction will occur [41]. 
 
Figure 1.4 Consensus cytochrome P450 catalytic cycle.  
 
1.3.2 Hydrogen abstraction 
 
The majority of drugs metabolized by CYP2D6 usually have a rather hydrophobic character 
and contain one or more aromatic rings (e.g. warfarin or codeine). Understanding the 
mechanism(s) underlying the oxidation reaction is of importance to avoid undesired 
metabolites causing toxicity and improve our ability to develop computational tools that are 
able to predict the most likely metabolites.   
Hydroxylation of a strong aliphatic or aromatic C-H bond by CYPs is mediated through its 
high-valent oxo-ferryl species, known as compound I (Cpd I). In order to understand the 
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catalytic mechanism, characterization of the major reactive intermediate(s) is crucial to know 
before studying the reactive pathways. Due to the highly reactive nature of Cpd I, it took 
several years before Rittle and Green successfully characterized Cpd I of CYP119 in 2010 
[42]. Their results confirmed that Cpd I exists as an oxoiron(IV) porphyrin cation radical and 
is the key intermediate species for hydrogen abstraction. An important other intermediate 
is the hydroxoiron(IV) complex, known as compound II (Cpd II) or rebound intermediate. It 
has been shown that the reactivity of the metal-oxo system towards C-H bond scission is 
correlated to the reaction driving force; the free energy difference between the broken C-
H bond and the formed O-H bond in the ferryl oxygen. Hence, the more basic the ferryl in 
Cpd II (pKa ~12), the stronger the ferryl-hydroxy bond, and the more effective the oxidation 
reaction [43,44]. Within this context it has been suggested that the proximal Cysteine ligand 
plays an essential role in increasing the basicity of Cpd II (the ferryl-oxygen) by pushing 
electrons towards it. Thus this tight basicity regulation enables the enzyme to achieve a 
feasible reduction potential for C-H bond scission without causing oxidative damage to 
itself.  
Aliphatic or aromatic C-H hydroxylation is generally thought to be primary catalyzed by the 
high-valent oxo-ferryl species, compound I (Cpd I). The now generally accepted rebound 
mechanism for aliphatic hydrogen abstracted was proposed by Groves et al in 1976 [45]. 
The mechanism in shown in Figure 1.5. In the first step, the oxoiron (IV) porphyrin cation 
radical intermediate abstracts an aliphatic hydrogen from the substrate and a FeIV – OH (Cpd 
II) species and a radical substrate is formed. 
 
 
Figure 1.5 Rebound mechanism for aliphatic hydrogen abstraction.  
 
In the second step, the “rebound” of the substrate radical to the iron hydroxyl forming the 
product. During the reaction, the transition state reaches a collinear Fe-O ---- H-C geometry 
[45]. Camphor hydroxylation by P450cam was among the first QM/MM studies that supported 
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the proposed rebound mechanism [45]. Values for the activation barrier are generally found 
to be in a range of 11 kcal/mol to 25 kcal/mol. Depending on the used QM method (e.g. 
DFT or B3LYP) force field and system set-up (environmental residues included in the QM 
region and water) the activation barrier can be slightly higher or lower.  
Aromatic oxidation by CYPs has shown to produce both phenolic and benzene epoxide 
products (Figure 1.6) [47,48]. The latter product can induce toxic effects in our body as it 
likely will react with nucleophiles such as DNA or proteins and should be avoided if possible. 
Initially it was suggested that the epoxide (Figure 1.6, pathway C) was a necessary 
intermediate based on the observed shift of the hydrogen from the hydroxylation side to 
the closest carbon (Figure 1.6, pathway B) [49]. The product of this reaction will be the 
epoxide but when non-enzymatic ring-opening occurs of this group, a phenol can also be 
formed. Later experimental and computational studies provided evidence for an additional 
pathway without epoxide intermediate, which is now known as the addition-rearrangement 





Figure 1.6 Three proposed rearrangement pathways for aromatic hydrogen abstraction [49].  
 
Moreover, the step with the highest energy barrier is found to be the addition of Cpd I to a 
substrate carbon that leads to the tetrahedral intermediate s-complex [49]. From this state, 
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different products can be formed depending on the rearrangement of the intermediate. 
Another possible pathway based on DFT studies proceeds through an N-protonated 
porphyrin intermediate. From this intermediate, the ketone and/or direct phenol complex 
formation is possible [52,53]. Which products will be formed will be the outcome of the 
interplay between active site geometry and/or the substrate reactivity which is well 
illustrated by a study of Oláh et al [54]. Experimental studies on the oxidation of 
dextromethorphan by CYP2D6 did not lead to any aromatic hydroxylation of the compound. 
Though MD simulation and docking studies demonstrated that the putative reaction sites 
all were viable since they were energetically accessible for the heme-oxo, QM/MM studies 
provided the key to the experimentally only observed O-demethylation. The activation 
energy for the aromatic carbon oxidation (around 14 kcal/mol – 17 kcal/mol) had a much 
higher activation energy compared to the aliphatic hydrogen abstraction (around 10 
kcal/mol – 12 kcal/mol). 
 
 
1.4 State-of-the art CYP2D6 modeling  
 
The journey that a potential drug has to take before entering the market is tough and takes 
on average between 10 and 15 years and costs millions [55]. The computer-aided drug 
design (CADD) unit of a pharmaceutical company has become indispensable to assist in the 
drug design and development process and largely contributes to lower R&D costs [56,57]. 
Typically, the initial discovery stage involves the identification of a therapeutic target against 
which a drug needs to be developed. Subsequently, if lucky, several lead compounds are 
identified and multiple cycles of optimization follow. Here bioinformatics approaches as well 
as structure-based - and/or ligand-based modeling approaches are applied (Figure 1.7) [58]. 
The best lead candidates continue to a preclinical in vivo and in vitro testing phase and if 
positive results return clinical trials (phase 1-3) follow. During the three clinical phases, 79% 
of the clinical failures can be attributed to safety or efficacy issues as an clinical drug study 
found over the time period 2016-2018 [59]. Accurate drug metabolism prediction, especially 
of CYP2D6, is one of the crucial aspects during the drug design process as this may 




Figure 1.7 Overview of the drug discovery and development stages and the major computational methods 
that are applied in the different pipeline phases.  
 
In silico modeling of drug metabolism can provide the most comprehensive atomic-level 
data that can assist medical chemists early on in the drug development process. The 
potential toxicity attributable to CYPs can be predicted by assessing the probability and 
degree of compound interaction with the enzyme [60–62]. Currently, the modeling 
approaches in predictive toxicology typically rely on information about the wild type 
protein, but in case of highly polymorphic targets such as CYP2D6 an accomplished study 
should simultaneously consider all important allelic variants (SNPs). The approach can 
employ a ligand- or structure-based strategy (or both) depending on the available structural 
data, computational resources and the toxicology endpoint(s) to investigate (Figure 1.8) 
[60,61]. The next sections will discuss both CADD CYP2D6 approaches (sections 1.4.1 and 
1.4.2) and describe the basic concepts of MD simulations and QM/MM methods (sections 
1.4.3 and 1.4.4) as they were the major techniques used for studying CYP2D6 in this thesis. 
 
1.4.1 Ligand-based strategies  
 
These are commonly applied to predict for instance the site of metabolism (SoM), 
biotransformation(s), binding affinity or the produced metabolite(s) using physicochemical 
and biological data (Figure 1.8). Pharmacophore modeling methods require a set of 
compounds with known activity which are aligned on a selected template by matching their 
molecular properties [63]. A hypothetical structure-activity model is then built by 
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mathematically extracting the critical structural and electronic features from the molecules, 
which are required for their interaction with the target and correlation with their biological 
activity. Such a model can cover predictions regarding the SoM or the CYP2D6 ligand 
character (inhibitor, substrate). In drug discovery, the pharmacophore approach can be 
conveniently used as a filter to screen large compound databases for ligands with particular 
desired or undesired properties (High Throughput Screening (HTS)). The main drawback of 
this otherwise fast and powerful approach is the uncertainty about the bioactive 
conformation and the assumption that all compounds interact with the target following a 
similar binding mode without inducing any substantial rearrangement of the target (induced 
fit), which is not always the case [64,65]. An advanced version of the pharmacophore 
abstraction, the three-dimensional (3D) Quantitative Structure-Activity Relationship (QSAR) 
modeling, relies on the ligand 3D structures. The main advantage of this approach is its 
ability to predict, in addition to the qualitative properties, also quantitative properties, 
especially the ligand binding affinity [64]. Nevertheless, inherent lack of any 3D structural 
information regarding the highly flexible target renders pharmacophore methods less suited 
for studying the impact of SNPs on drug-enzyme interactions.  
 
 
1.4.2 Structure-based strategies  
 
If (along with known ligands) also structural data of atomic-resolution is available for the 
cytochrome, the ligand and the structure-based approach can be advantageously combined 
to search and subsequently obtain a consensus outcome. If two methodologically different 
approaches provide the same result (e.g. suggest favourable binding interaction) then such 
a result can be considered more reliable (Figure 1.8). In case of cytochromes, information 
about the target can be integrated in the assessment of possible toxicologically relevant 





Figure 1.8 Overview of computational strategies applied in cytochrome P450 2D6 toxicology modeling. 
If experimental atomic data on the target is available, a structure-based or combined (ligand- and structure-
based) approach is advantageous. This enables the modeling of the ligand in the native binding pocket with 
increased accuracy.  
 
Modeling of the native CYP2D6 active site enables addressing possible issues related to 
different phenotypes (SNPs), identifying likely ligand binding mode(s) and exploring the 
dynamic features of the ligand-enzyme complex. For building such an advanced model a 
well-resolved structure of the complex is required. Before 2005, no experimental 
coordinates of CYP2D6 were available in the Protein Data Bank (PDB), hence the structure 
had to be predicted by homology modeling. Introducing a ligand into the cytochrome is 
known to trigger conformational changes of the active site [66]. Therefore, molecular 
docking and MD simulation studies usually rely on a X-ray or homology model based on a 
holo-determined CYP structure [67]. A very important step is the validation of the model. 
This is typically done by assessing the ability of the model to reproduce known ligand 
binding mode(s) and by cross-docking. The first CYP2D6 homology model was built based 
on the cytochrome P450 101 (from organism Pseudomonas putida) although it contained 
only a part of the active site [68]. Several more complex homology models followed based 
on template structures that converged with the cytochrome species X-ray release history 
(from easier bacterial towards more complex mammalian/human). However, studies based 
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on homology modeling must be always interpreted with caution: even if a high sequence 
similarity exists between the template and query sequences, a certain degree of uncertainty 
about the position of the active site residues is still unavoidable [69]. This can have a major 
impact on modeling results, especially if delicate information is sought for (e.g. ligand 
binding modes featuring complex pattern of weak intermolecular interactions). A more 
comprehensive explanation of pitfalls in homology modeling can be found in the literature 
[70–72]. In general, the homology models were used to investigate the enzyme fold, active 
site composition, ligand-CYP2D6 interactions and to predict ligand SoM specificity [24,73–
76]. 
 
Molecular Docking. With a CYP2D6 3D model in hand, energetically favourable binding 
conformations of the ligand can be explored towards wild-type and variants using molecular 
docking. This procedure can be divided into two phases. In the first phase, an algorithm 
generates a pool of possible binding poses. In the second phase, the generated poses are 
scored and ranked based on the contribution from various energy components (e.g. H-
bonding, electrostatics, van der Waals, entropy, desolvation, etc.). When applying this 
method to CYP2D6, several critical points need to be addressed as they can significantly 
impact the reliability of the results and the overall docking performance: 
(i) flexibility of the active site: since the majority of docking algorithms still does not feature 
full protein flexibility (with a few exceptions e.g. HADDOCK [77]) popular strategies applied 
to CYP2D6 that can deal with this challenge to some extent are ensemble docking [78] or 
induced-fit docking [79]. Ensemble docking utilizes a strategy in which multiple protein 
conformations are used to represent the flexibility of the protein. The ensemble can be 
collected for example from an MD trajectory or determined experimentally (e.g. NMR 
spectroscopy). The ensemble is explicitly treated during the docking and besides movement 
of the side chains it can also account for the protein backbone flexibility [80]. This is an 
advantage compared to the induced-fit approach, in which only readjustment of the side 
chains in the active site is allowed. Upon ligand docking, the induced-fit algorithm then 
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typically searches for the most stable binding site arrangement by a combinatorial scan of 
the side chain rotamer libraries [81,82]. 
(ii) importance of including structural water molecules during the docking: most water 
molecules present in the X-ray structure are fundamental for the enzyme function and 
important for ligand recognition [81,82]. However, the majority of the previous CYP2D6 
docking studies removed the solvent from the active site before docking. Including water 
into the CYP docking procedure is still questionable since the outcome of several studies 
assessing the impact of in- or excluding water molecules upon docking ligands to CYP2D6 
(or other isoforms) is not consistent [73,81].  
(iii) conformation of the ligand: the lowest energy pose is not necessarily the most reactive 
one and the ligand might be able to bind in multiple orientations within the cytochrome. 
This fact should be kept in mind when selecting liganded CYP2D6 X-ray structures for 
computational studies [65]. If the docking approach heavily depends on the co-crystallized 
ligand template or the shape of the cavity associated with this particular ligand, the pose 
accuracy for dissimilar compounds might be very likely compromised. Instead of focusing 
too much on searching for the pose with the most favourable energy terms, a suitable 
clustering approach can be used to identify the representative binding pose(s) within a 
reasonable energy window that orients the possible SoM more closely toward the heme.  
(iv) scoring function: no universal scoring function exists so far and different strategies are 
applied for their parameterizing (knowledge-based, empirical, force-field based or 
consensus). Considering the numerous approximations on which the force fields are based, 
obtaining directly realistic binding free energies of chemical accuracy for the docked ligands 
is extremely challenging. Quantum mechanical (QM) calculations or hybrid approaches offer 
a more accurate treatment of intermolecular interactions, however at an increased 
computational time cost which usually disqualifies them from a large scale application (e.g. 
virtual screening) [83]. With regard to the hydrophobic nature of the CYP2D6 active site, a 
scoring function that underestimates the lipophilic contribution would also likely suffer from 
loss of accuracy during the filtering and ranking process [84]. Furthermore, special 
parameterization of the metal-ligand interactions (the cytochrome heme group) is required 
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to represent the contacts between the ligand groups (lone pair donor) and the heme iron 
atom. The choice of the heme state (covalently bound to dioxygen or not) requires the 
corresponding heme parameter set to equilibrate well with all the energy terms within the 
scoring function. Nowadays, several functions exist that are parameterized for cytochrome 
studies including Chemscore, Gold and Glide (OPLS_2005 force field) [84,85]. The most 
popular molecular docking programs and scoring functions used for CYP2D6 studies are 
Autodock, Gold (Chemscore, Goldscore), FlexX, DOCK and Cscore [61,86]. 
 
Site of metabolism. In order for the catalytic reaction to occur, the ligand needs to be in 
close vicinity of the heme-oxo iron atom and present a matching intrinsic reactivity group 
towards the activated oxygen species. A cut-off value of 6 Å is recommended for use during 
the pose assessment. The value is based on the assumption that the oxidation reaction is 
initiated by the extraction of a hydrogen atom, located at the ligand SoM, forming the 
radical iron-oxo species (compound I). This requires a SoM-oxyferryl distance bellow 3 Å, 
but taking thermal motion into account the upper limit might extend to a maximum distance 
of 6 Å [87]. More sophisticated approaches such as MetaSite [88] or IDSite [89] use a 
combined strategy which takes also into account the reactivity of the ligand by means of 
quantum mechanics calculations (in addition to the geometric criteria). In addition, DR-
Predictor combines flexible docking, reactivity calculations and machine-learning algorithms 
to predict CYP mediated SoMs (addressing the regioselectivity as well) [90].  
 
Molecular dynamics. Though automated docking protocols are eagerly used due to their 
speed and low cost, the dynamics-related properties such as binding affinity calculations, 
residence time, flexibility and channel formation remain in the twilight zone or out of reach 
without using Monte Carlo - or molecular dynamics (MD) simulation methods. The latter 
allows for studying the enzyme-ligand complex’s multidimensional energy landscape over a 
given time period and capturing its thermodynamic and kinetic fingerprint by determining 
the relative probability of various states and the energy barriers separating them. 
Thoroughly sampled time-evolved conformations can be used to predict the free energy 
difference between CYP2D6 ligand-bound and unbound states. This way useful insights can 
be gained on the dynamic character of the ligand-cytochrome interaction, thus 
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simultaneously addressing flexibility and binding affinity. Most commonly used methods are 
thermodynamic integration (TI), free energy perturbation (FEP) or linear interaction energy 
(LIE) [91,92]. The latter has proven to be of particular value for fast (1 ns production time) 
and accurate CYP2D6 binding affinity predictions (RMSD error < 1 kcal.mol-1) [93]. 
Several studies have employed MD simulations to investigate channel formation [21], water 
dynamics [81], effect and importance of the membrane on CYP behaviour [94–97], binding 
and reaction mechanisms [76,98], refinement of docking results, and CYP2D6 polymorphism 
[21,99,100]. These studies are essential for extending our current CYP2D6 knowledge and 
subsequently seamlessly integrate this information into advanced CYP2D6 in silico 
techniques. The most frequently used MD programs are GROMACS, GROMOS, AMBER, 
CHARMm, and Desmond [61,86]. The technique is limited by the trade-off between 
accuracy and simulation time: the more detailed and complex the model system, the more 
demanding the calculations and hence the longer the computational time required. The 
usefulness of the data generated from short time trajectories (bellow 100 ns) might be 
doubted considering the uncertainty of the time needed for most biological phenomena to 
occur (e.g. large conformational changes develop on a micro-second time scale). A detailed 
description of MD simulation challenges can be found in ref [101]. Nevertheless, for studying 
protein-ligand movements and calculation of properties that do not require electron 
transfer between atoms (e.g. bond formation or polarization), the method can be accurate 
enough to generate data of sufficient quality. In addition, the computational power available 
to perform a large number of calculations within an acceptable time frame and at reasonable 
costs is levelling the last couple of years and becomes more attractive for industrial use as 
well (e.g. APO A1 protein with 92’000 atoms, 118 ns/day, on 1 GeForce GTX Titan Xp GPU) 
[102].  
 
QM/MM. Deciphering the dynamical aspects of P450 by use of molecular mechanistic (MM) 
force fields has proven to be of tremendous value. As described in the previous section, 
many important physiological P450 processes have been studied such as the binding of 
ligands, flexibility of the binding pocket and tunnel formation, but for some events MD 
simulations are not suitable. The classical additive force fields treat atoms as point charges 
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and bonds as harmonic oscillators, changes in electronic structure caused by a chemical 
reaction can not directly be modeled using this technique.  
To study the reactivity of P450s, ab initio methods such as quantum mechanics (QM) are 
favorable. Considering the fact that increasing system size increases the computational time 
and resources needed, initial P450 studies were performed on a small iron-porphyrin system 
using primarily density functional theory (DFT) to describe the electronic system [103]. These 
studies contributed largely to our understanding of the electronic structure of the active 
species, the different intermediate states, and also its specificity. However, the necessity of 
including the protein environment in the active site calculations is crucial as it was found to 
be the defining factor for the different specificity of the CYP isoforms [104,105]. Therefore, 
the hybrid quantum mechanical/molecular mechanical (QM/MM) approach is more suitable 
to study reactivity patterns. Schöneboom performed the first QM/MM study using P450cam 
(also known as CYP101) and revealed that the oxo-heme moiety is stabilized by specific 
hydrogen bonding interactions between the cysteine sulfur and nearby residue thereby 
sustaining the Fe-S bond and preventing the sulfur from oxidation [106]. Subsequently, 
following QM/MM studies have been mainly focused on elucidating the electronic 
structures of all the species in initially P450cam but later on also for the human isoforms, and 
the reaction mechanism underlying the oxidation of several organic molecules 
[46,49,104,107–110]. The major metabolism reactions studied using a QM/MM approach 
include hydroxylation (aliphatic or aromatic) [111], double bond epoxidation [52,112] and 
sulfoxidation [113,114]. 
 
1.4.3 Computer simulation  
 
Molecular Dynamics (MD) simulation is a powerful method to explore structure and 
dynamics of biomolecular systems complementing experimental studies. In order to 
calculate and predict properties of the system under study, a reliable model and accurate 
algorithm is indispensable. In addition, carefully post-processing the simulation trajectories 
is crucial as well. A protein can be viewed at from four different layers: 1) its primary structure 
which is defined by its amino acid sequence, 2) its secondary structure, composing the a-
helices and b-sheets, 3) its tertiary structure, defining the spatial relationship of at least two 
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secondary structural elements and thus its overall monomeric protein fold and 4) its 
quaternary structure which is the arrangement of multiple folded monomeric proteins into 
a multi-subunit. Such an assembly enables flexibility and movement of the protein and can 
be rather seen as a Boltzmann-weighted ensemble of poses/configurations instead of just 
one rigid configuration. MD and Monte Carlo (MC) simulations are two methods to generate 
such a Boltzmann-weighted ensemble of e.g. CYP2D6 poses. MC generates moves of atoms 
based on the change in potential energies and momentum conservation is not preserved. 
MD simulations on the other hand, solve Newtons equations of motion: 
 
   𝑭" = 𝑚"𝒓"                           (1.1) 
 
where mi is the mass -, ri the position - and Fi the force on the particle (atom) i. This makes it 
a more suitable choice to study the movement of proteins over time. Depending on the 
computational power available and the size of the biomolecule studied, the simulation time 
scale can vary from ns to several µs.  
Before starting MD simulation, four basic choices need to be made in order to obtain a 
reliable outcome [115]; 
i) Selecting the appropriate degrees of freedom set is essential to avoid sampling irrelevant 
space or simulating for prohibitive time to obtain maximal accuracy and precision of the 
calculations.   
The most fine-grained degrees of freedom possible in MD simulations are models in which 
atoms are treated as particles as done in quantum-chemical (QM) calculations. This 
approach allows to study the interactions between nuclei and electrons which is necessary 
for instance to determine chemical reactivity as demonstrated in chapter 2. On the other 
end of the scale are coarse-grained (CG) models which largely reduce the degrees of 
freedom by grouping atoms into larger ‘pseudo’ atoms or beads. Therefore, CG MD 
simulations can lower the computational costs by several orders of magnitude enabling 
numerical simulations over longer time scales [116]. The classical atomistic model lies in 
between the two previous described models and treats one atom as one particle.   
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Finding an appropriate model to address the problem in question is thus a delicate matter 
that needs a suitable balance between accuracy and speed. 
ii) Another related choice that will influence the outcome of the calculations strongly is the 
type of force field and parameter set used.  The classical Hamiltonian is usually referred to 
as force field can be divided into a kinetic K (p) and a potential V (r) energy term: 
 
  𝐻	(𝒑, 𝒓) = 𝐾(𝒑) + 𝑉(𝒓)                        (1.2) 
 
in which p = (p1, p2,…,pN) and r =(r1, r2,…,rN) and the 3N-dimensional vectors of the particle 
momenta and positions for a system of N particles. The kinetic term is independent from 
the particle position: 
 




𝑚"𝒗16"746"74                          (1.3)    
 
mi is the mass of particle i and the 3N-dimentional vector of the particle velocities, v = (v1, 
v2,…,vN) which is the time derivate of the position vector v = r.  
The potential energy term in Equation 1.2 is the sum of several bonded (b) and nonbonded 
(nb) particle interactions for a given configuration: 
 
 
       𝑉(𝒓) = 𝑉8	(𝒓) +	𝑉98	(𝒓)                                     (1.4)    
 
Depending on the force field, the (non)bonded terms can vary. Commonly the bonded 
interaction terms include bond-stretching, dihedral-angle bending and bond-angle bending 
terms to preserve planarity of the groups and e.g. chirality. The non-bonded terms include 




𝑉98(𝒓) = ∑ :;<=>(",?)
@3A


















          (1.5)   
 
rij denotes the distance between particle i and j, the C12 (i,j) the repulsive and C6 (i,j) the 
attractive LJ parameters, qi and qj the partial charges of particle i and j, e0 the permittivity 
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of the vacuum, e1 the relative dielectric permittivity of the system, and Crf and Rrf the 
reaction field parameters. 
The force acting on particle i is defined by the negative of the gradient of the potential 
energy term V (r). Combined with Equation 1.1 this results in: 
 
 
                   𝑚"𝒓" = 𝑭" = −
Y
Y@3
	𝑉(𝒓) = − Y
Y𝒓3
	(	𝑉8(𝒓) + 𝑉98(𝒓)	)	               (1.6)    
 
The parameters for the terms in the force field are derived from different sources. For an 
atomistic model, the bond-length and bond-angle potential energy terms parameters can 
be obtained from quantum chemical calculations, spectroscopic or X-ray diffraction data. 
Parameters for the non-bonded torsional-angle interaction term and the partial charges are 
usually derived from quantum-chemical calculations on small molecules in the gas phase. 
The fitting of the parameters is also a factor which can be done in different ways. For 
example, OPLS2005 (largely based on OPLS-AA) or GROMOS fit the parameters of the non-
bonded terms (Lennard-Jones parameters and charges) in such a way that they reproduce 
experimental thermodynamic properties (heats of vaporization, densities) [109,117]. The 
fitting of the charges can also be done by reproducing the electrostatic potential obtained 
from QM calculations as done by CHARMM11 or AMBER [118,119].  
iii) Most real-life biomolecular systems are a mix of proteins and/or other molecules in an 
aqueous solution which would be far too large to sample all the degrees of freedom from 
with the current computational power. However, treatment of the spatial boundary 
conditions is crucial to avoid a negative impact of the surface on the calculated properties. 
This can be circumvented by using periodic boundary conditions in which the box with the 
molecular system is surrounded by an infinite number of copies of itself, mimicking the 
presence of an infinite bulk environment. The infinite copies introduce at the same time 
periodic contributions of long-range interactions which is an artefact of the method. The 
introduced error is negligible small for the Lennard-Jones interactions but larger for the 
electrostatic Coulomb interactions and needs to be corrected. The reaction-field method 
truncates the non-bonded interactions beyond a certain cut-off radius after which a 
homogeneous medium of constant dielectric permittivity is presumed. 
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iv) Ensuring adequate sampling of the relevant configurational space is a nontrivial task but 
crucial for accurate calculation of properties such as the free energy of the system or its 
enthalpy. For a biomolecular system the degrees of freedom can be as large as 104 to 106 
or even larger and the corresponding movements can evolve on a femtosecond to 
millisecond time scale [115]. The diversity of movements is captured by the potential energy 
function and reflected in the free energy surface of the system containing energy hills and 
basins with varying heights and depths. Identifying the global minimum and sampling the 
regions that are most relevant in defining the free energy of the system can therefore 
become a difficult task. The phase space probability distribution function P(r,p) defines the 
probability of occurrence for a certain state of the system and for a canonical ensemble 
(NVT) can be expressed as: 
 
 






	                     (1.7)    
 
 
where b is the inverse of the Boltzmann constant, kB, multiplied by the temperature, T, N is 




   𝑍(𝑁, 𝑉, 𝑇) = 4
cQd6!∬ 𝑒
Rkl(𝒓,𝒑)𝑑𝒑𝑑𝒓	                                (1.8)    
 
 
the factor N! is used in case of indistinguishable particles. At constant temperature, T, and 
pressure, p, (referred to as the isothermal-isobaric ensemble) the phase-space probability 
becomes volume dependent; 
 
 
   𝑃(𝒓, 𝒑, 𝑉) = ]
^_`(𝒓,𝒑)nop
cQd6!f(6,𝒑,[)
	                                           (1.9)    
 
 
and the partitioning function becomes: 
 
   𝑍(𝑁, 𝑝, 𝑇) = 4
cQd6!∭𝑒
Rkl(𝒓,𝒑)sV\𝑑𝒑𝑑𝒓𝑑𝑉	                   (1.10)    
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Subsequently, the desired quantity (Q) can be calculated as the expected value (average 
indicated by the angular brackets) of the property over the whole phase space for the 
isothermal-isobaric or the canonical ensemble by: 
 
 
   〈𝑄〉6\[ = ∬𝑄(𝒓, 𝒑)	𝑃(𝒓, 𝒑)	𝑑𝒑𝑑𝒓	                              (1.11)    
 
 
Which proves the fact that an efficient algorithm can generate an ensemble by sampling 
enough configurations within an acceptable amount of time. In order to accomplish this, the 
time step used in the integration of the equations of motion is key. Increasing the time step 
size enables to visit more configurations within the same number of integration steps. 
However, too large time steps can lead to inaccuracies, therefore this parameter needs to 
be selected carefully. In this thesis, the Desmond package implemented in Schrödinger suite 
was used for all MD simulations which applies the Velocity Verlet algorithm for integration:  
 
 
	𝒓𝒊	(𝑡 +	∆𝑡) = 	𝒓𝒊(𝑡) +	∆𝑡𝑣"	(𝑡) +	
∆{>
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	𝑓"(𝑡) + 𝑂∆𝑡~	                         (1.12) 
𝒗𝒊	(𝑡 +	∆𝑡) = 	𝒗𝒊(𝑡) +	
∆{
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(𝑓"(𝑡) + 𝑓"(𝑡 +	∆𝑡) + 	𝑂∆𝑡~	                         (1.13) 
 
 
A time step of 0.002 ps has been used as recommended. In addition, the isothermal-isobaric 
(NPT, T=298, p = 1 atm) ensemble was used for simulations since most biological system 




The biochemical systems that can be described at any level of ab initio theory are limited 
because most of the quantum mechanics (QM) methods scale linear (or worse) with system 
size. However, to model processes in which chemical bonds are formed or broken a purely 
molecular mechanics (MM) approach will neither be successful since the force fields do not 
treat electrons explicitly but together with the nuclei as effective atoms. Focussing only on 
the active site to model e.g. enzymatic reactions is also not satisfying because neglecting 
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the environment and solvent effects will reduce the accuracy of the calculations [120]. One 
popular strategy is the combination of multiple resolutions within one simulation thereby 
creating a powerful synergy that overcomes the limitation of the individual methods. In such 
a hybrid approach, the system is usually divided into a smaller part (inner subsystem), where 
the chemical reactivity occurs and a larger part (outer subsystem) containing the rest of the 
system. Subsequently, the inner subsystem (e.g. the reactive heme and molecule) is 
modeled at the level of QM, whereas the larger subsystem (e.g. the protein environment) 
by MM, which is computational much cheaper in use. This hybrid QM/MM concept was first 
introduced by Warshel and Levitt in 1976 [121]. Studying biochemical systems using this 
approach gained popularity after the later performed studies by Karplus and coworkers 
[122].  
Before preparing and starting a QM/MM simulation, five key aspects need to be considered: 
(i) the size of the QM region, (ii) the choice of the QM Hamiltonian, (iii) the choice of force 
field used for the MM region, iv) boundary and coupling of the QM/MM regions, and (v) 
boundary conditions for the MM region.  
Defining the optimal QM region is necessary as different system sizes can considerably 
affect the energies and potentially cause convergence issues [123]. For QM/MM geometry 
optimization it has been shown that a QM system size of 6 to 13 residues can reach 
convergence, larger systems have frequently convergence problems and large varying 
energies (up to 70 kJ/mol) [124].  
The inner QM region can be described at various levels. The basic concept behind QM 
calculations is that by providing the coordinates, the net charge and total spin of a 
biochemical system, the total energy and wave-function can be determined by solving the 
Schrödinger equations. From this result measurable properties (e.g. heat of vaporization, 
activation barrier energies) can be calculated. However, the Schrödinger equation can solely 
be analytically solved for single electron systems. For larger systems only approximate 
numerical solutions can be calculated. The Hartree-Fock (HF) is the most basic approach but 
due to its rather approximate result more accurate approaches have been developed using 
it as a starting point such as the perturbation theory (e.g. Møller-Plesset second-order 
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perturbation (MP2)) or the series expansions (e.g. coupled cluster calculations with single, 
double and perturbatively treated triple excitations). A very frequently used approximation 
is the density functional theory (DFT) which is not based on the wave-function but on the 
electron density. Hence the calculations are a function of only the three coordinates of 
Cartesian space, and not of all involved particles as the case is for the wavefunction. A great 
variety of DFT approximations exists such as PBE [125], TPSS [126] or BP86  [127]. In 
addition, hybrid DFT methods exist that involve a part of the exchange from the HF method; 
B3LYP or M06-2x [128,129] both hybrid meta-generalized gradient approximations (GGA’s). 
The quality of the DFT calculations are usually comparable to MP2 results while 
computational much more inexpensive [130]. The electronic wave function is represented 
by a set of functions, the basis sets. In general, the more extensive the basis set, the more 
accurate the electrons of the involved atoms in the system are described and the more 
reliable the results. Semi-empirical QM approaches can speed up the calculations largely by 
using a minimal basis set and substituting the integrals by empirical parameters. Examples 
are AM1 [131], PM3 [132], OM1-3, or SCC-DFTB [133]. One prominent shortcoming of both 
HF and DFT approximations is the lack of a proper treatment of the London dispersion 
interactions. Several methods have been developed to account for this short-coming 
including the DFT-D2 or B3LYP-D3 [134–136]. 
For the outer MM region, the most popular force fields applied are: the Chemistry at 
Chemistry at HARvardMolecular Mechanics (CHARMM) [137,138] force field, the Optimized 
Potentials for Liquid Simulations – All Atoms (OPLS-AA/OPLS3) force field [139,140], the 
Amber force field [119,141], and the Groningen Molecular Simulations (GROMOS) force 
field [142,143].The coupling of the inner and outer region is the most critical aspect of the 
QM/MM approach. To calculate the total energy of the complete system (S), two coupling 
schemes exists that incorporate the inner (I), outer (O) and the linking (L) region (also 
referred to as boundary region) [144].  
The energy for the subtractive (Sub) coupling scheme is expressed by: 
 
 
	𝐸/𝑺𝒖𝒃 = 𝐸(𝑆) + 𝐸(𝐼 + 𝐿) − 𝐸(𝐼 + 𝐿)                                   (1.14)       
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The energy for the most commonly used additive (Add) coupling scheme is expressed by: 
 
 
	𝐸/𝑨𝒅𝒅 = 𝐸(𝑂) + 𝐸(𝐼 + 𝐿) + 𝐸R(𝐼, 𝑂)                                   (1.15)       
 
  
in which  
 
 
𝐸R(𝐼, 𝑂) = 	𝐸	R89b]b − 𝐸	Rb − 𝐸	R]]                                    (1.16)       
 
This is the so-called ‘coupling term’ which describes the bonded, van der Waals (vdW) and 
electrostatic (elec) interactions between the QM and MM region. The electrostatics is the 
most dominant interaction type between the regions and is handled by different levels of 
approximations: Mechanical embedding treats the interactions at the MM level and is 
therefore less accurate and often used compared to electrostatic embedding. Here the 
electrostatics interactions are fully treated at the QM level and the two other types of 
interactions (vdW and bonded) both at the MM level. The point charges on the MM atoms 
are included in the QM calculations. Therefore, polarization of the QM region by the MM 
region is explicitly accounted for. However, to obtain polarization both ways (MM on QM 
and QM on MM) a polarizable force field is required for the MM part and a QM program 
which can deal with polarizabilities which are both not yet too common. One remaining 
challenge is the treatment of covalent bonds in the linking/boundary region which need to 
be correctly truncated. A very specific treatment would be by placing hybrid orbitals 
[121,145,146] or using frozen localized orbitals [121,147,148] at the boundary to saturate 
the bond but more commonly applied is the hydrogen-link-atom scheme. In this approach 
a link atom (hydrogen) is placed to saturate the bond. Positional restraining can be applied 
to keep the geometrical constraints of the former bond. One important artefact of the link 
approach is over-polarization caused by the partial charges close to the QM region. Several 
methods have been developed to deal with this artefact [149,150]. For example, the charge 
shift scheme shifts the MM charges that are located at the boundary region of the covalent 
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bonds to the next layer of MM atoms, thereby preserving the total charge and dipole 
moment [151,152]. 
Both mechanical and electrostatical embedding can be used for the additive or subtractive 
scheme. The advantage of using an additive scheme is that the MM calculations do not 
require parameters for the QM region and link atoms as they are not part of the MM 
calculations. The subtractive scheme does require accurate parameters for the full system 
because MM calculations also cover the QM region. It is therefore also considered to be 
more difficult in preparing the system for the QM/MM calculations [153].  
Different QM/MM programs are nowadays available in several QM and or MM software 
packages including Q-site [154], Gaussian (ONIOM) [155] or CHARMM [156]. In addition, 
ChemShell [157] or ComQum [158] are independent interfaces that combine different QM 
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Abstract  
The xenobiotic metabolizing enzyme CYP2D6 is the P450 cytochrome family member with 
the highest rate of polymorphism. This causes changes in the enzyme activity and specificity, 
which can ultimately lead to adverse reactions during drug treatment. To avoid or lower CYP-
related toxicity risks, prediction of the most likely positions within a molecule where a 
metabolic reaction might occur is paramount. In order to obtain accurate predictions, it is 
crucial to understand all phenomena within the active site of the enzyme that contribute to 
an efficient substrate recognition and the subsequent catalytic reaction together with their 
relative weight within the overall thermodynamic context. This study aims to define the 
weight of the driving forces upon the C-H bond activation within CYP2D6 wild-type and a 
clinically relevant allelic variant with increased activity (CYP2D6*53) featuring two amino acid 
mutations in close vicinity of the heme. First, we investigated the steric and electrostatic 
complementarity of the substrate bufuralol using well-tempered metadynamics simulations 
with the aim to obtain the free energy profiles for each site of metabolism within the different 
active sites. Secondly, the stereoelectronic complementarity was determined for each SoM 
within the two different active site environments. Relying on the well-tempered 
metadynamics simulation energy profiles of each SoM, we identified the binding mode that 
was closest to the preferred transition state geometry for efficient C-H bond activation. The 
binding modes were then used as starting structures for the quantum mechanics/molecular 
mechanics calculations performed to quantify the corresponding activation barriers. Our 
results show the relevance of the steric component in orienting the SoM in an energetically 
accessible position towards the heme. However, the corresponding intrinsic reactivity and 
electronic complementarity within the active site must be accurately evaluated in order to 
obtain a meaningful reaction prediction from which the predominant sites of metabolism can 
be determined. The F120I mutation lowered the activation barrier for the major site and one 
of the minor sites of metabolism. However, it had neither impact on the CYP2D6 
enantioselectivity preference of the oxidation reaction nor on the stereoselectivity from the 




Cytochrome (CYP) P450 monooxygenases are thiolate-ligated heme enzymes that have a 
crucial function in the detoxification of xenobiotics in our body [1–3]. Catalytic reactions, 
including aliphatic and aromatic hydroxylation, epoxidation, and heteroatom oxidation, 
introduce polar functional groups to the substrate molecule increasing the solubility of 
potentially harmful compounds [4–6]. The biotransformation of such compounds is essential 
to facilitate their secretion in kidneys and to avoid bioaccumulation and toxicity. Moreover, 
numerous marketed drugs rely on this oxidation mechanism to achieve the bioactivation 
[5,7]. However, during drug therapy, the fact that drugs can act as substrates, inhibitors or 
both towards CYPs requires careful monitoring of the substance fate within the organism as 
otherwise e.g. unexpected drug-drug interactions may lead to manifestation of toxicity, 
possibly even with a fatal outcome [8]. Hence, from the early drug development phase on, 
potential CYP-related toxicity issues need to be addressed.  
Computational techniques which are able to provide information regarding the predominant 
binding modes, binding affinities and therefrom site(s) of metabolism (SoMs) at CYPs can be 
of high value to improve the therapeutic and safety profile of lead compound and avoid late-
stage undesired CYP-mediated adverse reactions [9]. The better we understand the forces 
that contribute to driving the catalytic reaction and their weight in the overall balance, the 
more accurate and reliable we can develop CYP-related predictive tools. However, the 
complete framework in which CYPs operate is complex. To start, the lead compound (ligand) 
can be metabolized by one or several P450 subtypes (isoforms) [10]. Depending on the 
selectivity of the isoform, a preference for the oxidation at a particular functional group 
(chemoselectivity), a stereoisomer preference (stereoselectivity) or particular part of the 
compound (regioselectivity) will apply. State-of-the-art computational metabolism prediction 
tools commonly used include FAME [11,12], GLORY [13], SOMP [14] or CYPreact [15]. A 
comprehensive overview on computational CYPP450 metabolism prediction tools can be 
found in the recent review of Tyzack et al. [16]. Moreover, it is postulated that the substrate 
oxidation occurs when CYP is in the so called compound I (cpd I) intermediate state [4,17]. 
Reaction of the iron(IV)oxo species with the functional group of the ligand requires a 
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particular geometry to reach an optimal orbital overlap for an efficient biotransformation 
[18,19]. For example, for aliphatic or aromatic carbon hydrogen abstraction (also referred to 
as C-H bond activation) the ideal Fe=O·····H-C distance is around 2 Å and the Fe=O·····H 
angle around 120° [18,20]. Docking methods commonly predict the binding modes and the 
corresponding binding affinity based on the interaction and conformational energies 
together with a distance criterion between the SoM and the heme-iron [21]. Challenges such 
as the large flexibility of the binding pocket and multiple binding modes of the substrate 
increase the complexity of this task. Molecular dynamics (MD) simulations can partially aid to 
validate the stability of the docking poses, introduce flexibility and confirm which of the 
substrate’s sites can approach the heme-bound oxygen in a favorable orientation enabling 
its biotransformation [22–26]. If the lowest energy pose of the substrate also corresponds to 
the conformation, in which the SoM is positioned such that it is energetically most accessible 
for its biotransformation, remains an open question. Nevertheless, even if binding mode(s) 
and corresponding one or more SoMs are identified using a docking and/or MD simulations 
approach, the other essential question that needs to be answered is reactivity, which is 
defined as the sum of the substrate’s intrinsic reactivity and the protein environment (enzyme 
cavity) effects. In order to determine this, a quantum mechanics/molecular mechanics 
(QM/MM) modeling approach is frequently used [27]. Previous QM/MM studies have 
provided valuable insights on CYP450 selectivity by investigating activation energies for e.g. 
CYP2D6 dopamine formation [28] or dextromethorphan CYP2D6 metabolism [20]. Both 
studies confirmed the importance of including the protein environment for successful 
metabolite predictions as it stabilizes the ligand-heme complex [29]. Hence, for an accurate 
isoform specific metabolism prediction the contribution of both the binding affinity and the 
reactivity needs to be properly assessed. In this study we have investigated (i) the interplay 
between the enzyme binding pocket and ligand pose (shape complementarity) by 
performing well-tempered metadynamics (WT-MTD) simulations to obtain the free energy 
surfaces (FES) for each of the SoMs of a well characterized classical CYP2D6 substrate 
(bufuralol) in CYP2D6 wild-type (WT) (Figure 2.1). In addition, an increased activity 
(CYP2D6*53, F120I/A122S) [30] and diminished-to-non-functional (E216Q/F483G) [31] 
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CYP2D6 variant have been included to examine the impact of amino acid mutations on the 
binding mode(s) and subsequent SoM positioning with regard to the oxyferryl species; the 
altered activity variants have both two mutations within close vicinity of the heme which will 
have an impact on the steric and electronic component of the catalytic reaction. However, 
from the two variants, only CYP2D6*53 is clinically relevant. Until today, no clinically relevant 
variant with diminished-to-no activity has been identified that harbours mutations only within 
the active site. Therefore, the non-functional CYP2D6 variant was selected from a 
combinatorial mutation study aimed at identifying improved activity variants [31]. 
Determining the FES profiles of bufuralol SoMs within the three different active site variants 
will provide new insight on the reliability of using solely the lowest ranked energy pose(s) 
from docking for the prediction of the most likely SoMs and its capability in distinguishing 
major SoM(s) from minor ones. In a second step, we wanted to explore (ii) the electronic 
complementarity of bufuralol and the binding pocket by determining to what extent the 
point mutations influence the protein-ligand interaction. For each SoM in CYP2D6 WT and 
CYP2D6*53 we deduced from its earlier determined WT-MTD energy profile the binding 
mode that was closest to the preferred reaction state geometry and calculated the 
corresponding activation barrier by performing QM/MM calculations on reactant, products 
and their transition states. To our knowledge, this is the first in silico study performed probing 
the driving forces within both CYP2D6 WT and the clinical allelic variant CYP2D6*53 upon 
C-H bond activation. The results of the combined WT-MTD and QM/MM approach will 
contribute to improved understanding of CYP2D6 selectivity and guide the further 






Figure 2.1 Overview of the CYP2D6 substrate bufuralol and its experimentally confirmed sites of 
metabolism (SoMs S1-S3) [10]. A) CYP2D6 regio-selectivity predictions (SoMs) by SMARTCyp [32,33]. The 
red/yellow areas correspond well with the experimentally determined SoMs. Some deviation is found for the 
yellow-green areas predicted by SMARTCyp. B) The SoMs (S1-S3) and non-reactive control site (C1) 
investigated in this study. C) The CYP P450 metabolites of bufuralol predicted by GLORY [13]. 
 
Results & Discussion 
Free energy potentials of the wild-type SoMs and altered activity variants 
In order to explore the free energy profile of each SoM within close distance of the oxyferryl 
group, WT-MTD was used as an enhanced sampling technique. Two different sets of 
collective variables (CVs) were chosen initially to determine the CV set representing most 
accurately the pathway of the oxidation reaction studied. The first CV set (referred to as CV-
set 1) used as CVs the distance between the SoM carbon and the oxyferryl (its O atom) (CV1) 
and the angle between the Fe=O and the hydrogen for the aliphatic carbon positioned SoM 





Figure 2.2. Free energy surface (FES) graphs displayed for the sites of metabolism (SoMs, S1-S3) of bufuralol 
as well as an non-reactive control site (C1) using CV-set 1 calculated over 200 ns WT-MTD simulation.  
 
The second CV set tested (referred to as CV-set 2) included the same CV1 as in the CV-set 
1 but as CV2 the angle between the oxyferryl and the hydrogen and carbon of the SoM 
(O·····H-C) (CV2) (Figure S2.1). The motivation for selecting these CVs is that the positioning 
of the substrate’s hydrogen towards the oxyferryl is critical for  hydrogen abstraction reaction 
efficient proceeding. As explained before, an optimal orbital overlap between the 
substrate’s hydrogen and the oxyferryl (Fe=O·····H) is achieved with a distance of around 2 
Å, an angle close to 120° and a linear angle between the oxyferryl and the hydrogen-carbon 
bond of the substrate (O·····H-C) of 180° [18,20,34]. Monitoring the distance and one of the 
two angles will show how energetic favorable it is for the substrate to adopt the geometry 
required to initiate the oxidation reaction in which the hydrogen atom is abstracted. For 
selecting the CV-set that enables to distinguish well between the two different states 
(reactant and transition state geometry during the C-H bond activation reaction) the system 
needs to diffuse in the entire phase space to be able to reach convergence. Most efficient 
sampling of space for each CV over time was found for CV-set 1 (Figures S2.2-S2.3) and the 
system showed to diffuse efficiently in the CV space (not being stuck in a local minimum 
(Figure S2.4). Additional convergence evaluations performed for CV-set 1 ensuring efficient 
sampling can be found at the Materials and Methods section (Figures S2.5-S2.11). 
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For all CYP variants studied, an unfavourable FES area (red) for each SoM is observed bellow 
an Fe-O·····H angle of 60°, which is as expected since steric hindrance prevents it from 
reaching a lower value (Figure 2.2). The lowest energy area for the monitored angle (CV2) 
varies between 70° and 160° (Figure 2.2, dark blue area). The FES profiles of the CYP2D6 
wild-type (WT) indicates that based on the distance between the SoM and the oxyferryl 
group, the major SoM can be distinguished from minor; site S1_H2 is most likely to get in 
close vicinity of the heme with a preferred Fe-O·····H angle of about 120°. Sites S2 and S3 
reach CV1 values of approximately 5 Å which is similar to the control (C1) CV1 distance 
meaning that the minor SoMs cannot be assigned any ranking priority. The FES profiles of 
the increased activity variant (F120I A122S) show that there is no difference between major 
or minor site; S2 and S3 reach a SoM to oxyferryl group distance of approximately 3 Å (dark 
blue area, Figure 2.2) whereas S1_H1 and S1_H2 reach only a distance of approximately 4 
Å. The closest SoM to oxyferryl group distance for the variant with no activity (E216Q F483G) 
was found for its S2 SoM (~ 4 Å) all other SoMs remain further away (~ 5 Å). The experimental 
setup for this variant only monitored and quantified the metabolism of the major metabolite 
(S1: 1’hydroxybufuralol), therefore production of S2 or S3 metabolites cannot be excluded 
[31]. Overall, the analysis of the FES profiles suggests the following: (i) the lowest energy 
poses (Figure 2.2, dark blue areas) are for all SoMs located further than 3 Å away from the 
heme oxygen. This may be interpreted as an indication that using only the lowest energy 
(top-ranked) poses from docking would give a non-conclusive SoM prediction. (ii) using 
solely the free energy profile of a substrate pose in the active site to classify the SoM as a 
major or a minor site can be possible as shown for the wild-type enzyme, however for the 
two altered activity variants it gave an ambiguous answer. To improve the reliability of such 
a classification prediction, including the intrinsic reactivity of the ligand and its electronic 
complementarity with the active site will enhance the accuracy of the SoM predictions as 
shown by other studies [18,29,34]. To access this second aspect, the frames closest to the 
favored transition state geometry for an efficient oxidation reaction (deduced from each SoM 
FES profile) were selected from each SoM WT-MTD simulation for CYP2D6 WT and the 
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clinically relevant variant CYP2D6*53. Subsequently, the frames were used as input (reactant 
structure) for the QM/MM calculations to determine the activation barrier of each.    
 
QM/MM calculations 
Typically CYP2D6 substrate recognition in the active site occurs through a salt-bridge 
interaction between the substrate’s protonated nitrogen atom and the carboxyl group of the 
active site residue(s) D301 and/or E216. This allows orienting the substrate  SoM(s) for a more 
or less favorable orbital overlap with the reactive oxyferryl group which thus lowers or 




Figure 2.3. QM/MM minimized reactant structures of all SoMs within CYP2D6-WT (top) and CYP2D6*53 
(bottom). Important CYP2D6 active site residues interacting with bufuralol are displayed; black labelled 
residues indicate direct contact, whereas blue labelled residues indicate water-mediated contact. In addition, 
water molecules within 3 Å of the heme-iron are highlighted in orange. 
 
This recognition mechanism is observed in all the starting structures; a direct salt bridge 
between the protonated aliphatic nitrogen atom of bufuralol and the carboxyl group of the 
active site residue D301 could be identified in all structures, except for the S2 SoM CYP2D6 
WT in which the D301 interaction was bridged by two water molecules (Figure 2.3). For the 
anchoring residue E216, a direct salt bridge between bufuralol’s basic nitrogen and the E216 
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carboxyl group was found  in S2 CYP2D6 WT. Water-mediated interactions between 
bufuralol’s hydroxyl group and the carboxyl group of active site residue E216 were identified 
in S1_H1, S1_H2 CYP2D6 WT, and S2 CYP2D6*53. It has been observed before that the 
substrate’s benzene ring can be positioned such that its plane approaches a perpendicular 
angle with the plane of the heme group, called “side-on” or such that both planes are 
parallel, called “face-on” [18,20,37]. All the reactant structures are “side-on” positioned. 
Previous QM/MM studies for benzene oxidation within CYP2C9 found similar barrier heights 
for both orientations of the benzene ring (18.1-21.7 kcal/mol) [37]. For SoMs S1_H1, S1_H2, 
and S2 in CYP2D6 WT and CYP2D6*53 one or two water molecules were found to be within 
3 Å of the oxyferryl group oxygen atom (Figure 2.3, highlighted orange). It has been earlier 
determined that water molecules can lower the activation barrier (on average by 3-4 
kcal/mol) if they stabilize the transition state structure [38]. However, all the transition state 
structures were inspected and this was not the case. A more detailed overview of the type 
of interactions between bufuralol and the active site residues including the distances can be 
found in Table S2.3. Furthermore, the (dis-) similarity of the reactant SoM binding poses in 
CYP2D6 WT and CYP2D6*53 was determined by calculating the ∆RMSD of bufuralol in place 
after superposition of the QM region (Table 2.1). The most similar binding pose was found 
for the major S1_H1 SoM, ∆RMSD of 1.8 Å. For the minor SoMs S2 and S3 more dissimilar 
binding poses were identified with ∆RMSD values of 6.4 Å and 4.0 Å respectively. In 
addition, the C1 SoM binding poses were quite dissimilar as well with a ∆RMSD of 4.7 Å. A 
focused view on the binding modes of the reactants displaying the QM region without the 




Figure 2.4. Important Focused view on the interaction of F120 CYP2D6 WT (colored light-blue) or I120 
CYP2D6*53 (differently colored for each SoM) within the minimized reactant structure. CYP2D6 WT, F120: π-π 
stacking with the aromatic group of bufuralol is observed for S1_H1 and S1_H2, π-cation interaction for S3 and 
C1, in S2 bufuralol is positioned more distant and unfavourable. CYP2D6*53: S1_H1 is oriented most optimal 
and closest to I120, S1_H2 and S2 are oriented less optimal and S3 and C1 are positioned furthest away from 
I120.  
 
QM/MM energy barriers. An overview of the determined activation barriers can be found in 
Table 2.1, the most important geometric values (indicative of a good orbital overlap) of the 
input (reactant) and minimized reactant and TS structures can be found in Table 2.2. A 
detailed overview on the interaction types between bufuralol and the residues within the two 
different active sites environments determined in the starting structure (reactant) used for 






Table 2.1. QM/MM activation barriers (kcal/mol, M06-2X/LACV3P*) of the hydrogen abstraction of bufuralol’s 
SoMS studied in CYP2D6 WT and CYP2D6*53. The activation barrier was calculated using the quartet spin 
state. The last column displays the RMSD difference between each SoM binding pose of CYP2D6 WT and 
CYP2D6*53. 




SoM CYP2D6 WT CYP2D6*V53 bufuralol 
S1_H1 13.3 12.4 1.8 
S1_H2 22.8 31.9 2.7 
S2 22.9 21.2 6.4 
S3 28.8 61.8 4.0 
C1 57.2 42.4 4.7 
 
For both CYP2D6 WT and CYP2D6*53 the aliphatic hydrogen abstraction led to the lowest 
activation barriers, 13.3 kcal/mol and 12.4 kcal/mol respectively, with a regioselectivity for 
S1_H1. The reaction enantioselectivity at S1 remained the same upon the F120I mutation (R-
hydroxylation). This is in contrast with the F120A mutation, which reverses the 
enantioselectivity from R to S [39]. A possible explanation is that isoleucine is similar in size 
(volume) compared to phenylalanine, whereas alanine is much smaller thus offering space 
for different binding modes. The activation barriers of the aromatic (minor) SoMs displayed 
a trend consistent with experiment; S2 was found to be less reactive than the major SoM 
with an activation barrier of 22.9 kcal/mol in the CYP2D6 WT and 21.2 kcal/mol in 
CYP2D6*53, but more reactive than S3; the activation for the CYP2D6 WT was 5.9 kcal/mol 
higher and 40 kcal/mol higher for CYP2D6*53. 
As a note, the transition state search for SoM S3 in CYP2D6*53 has been performed twice, 
using two slightly different intermediate structures as an input for the search. However, the 
single point calculations performed on the resulting transition state structure led to the same 
activation barrier. The large difference of 33 kcal/mol between the S3 SoMs may be caused 
by the dissimilar orientation of the aromatic moiety of bufuralol; in CYP2D6 WT it is placed 
more perpendicular towards the heme plane whereas in CYP2D6*53 it is more tilted (Figure 
2.3). The less favorable conformation likely contributes to the considerably larger distance 
of 2.59 Å between the cysteine thiolate group and the heme iron atom (Fe-S) (Table 2.2). 
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Table 2.2. Overview of the geometry parameters of the minimized reactant and transition state structures. The 
selected angles and distances are indicative for reaching optimal orbital overlap and subsequently an efficient 
catalysis reaction. The minimized value is indicated first, in the brackets the values of the input structure (before 















wt S1_H1       
R 2.66 (2.41) 1.10 (1.09) 2.37 (2.28) 1.77 (1.86) 116.6 (121.5) 114.1 (100.7) 
T 1.31 (1.26) 1.27 (1.32) 2.40 (2.36) 1.82 (1.85) 124.2 (120.6) 159.3 (166.3) 
wt S1_H2       
R 2.23 (2.09) 1.10 (1.24) 2.50 (2.94) 1.86 (2.03) 117.2 (120.6) 144.0 (158.8) 
T 1.30 (1.24) 1.26 (1.33) 2.65 (2.55) 1.76 (1.8) 117.3 (123.6) 170.1 (158.1) 
wt S2       
R 3.3 (2.61) 1.09 (1.08) 2.39 (2.39) 1.75 (1.78) 125.6 (126.4) - 
T 1.41 (1.9) 1.11 (1.10) 2.40 (2.50) 1.91 (1.7) 125.4 (125.6) - 
wt S3       
R 3.18 (2.33) 1.08 (1.08) 2.43 (2.44) 1.74 (1.64) 118.2 (122.7) - 
T 1.92 (1.88) 1.07 (1.09) 2.51 (2.43) 1.8 (1.78) 120.1 (127.3)  
wt C1        
R 3.03 (3.9) 1.08 (1.08) 2.38 (2.38) 1.77 (1.72) 151.8 (134.5) - 
T 1.89 (1.97) 1.08 (1.11) 2.50 (2.38) 1.81 (1.87) 131.0 (132.8) - 
V53 S1_H1       
R 2.67 (2.55) 1.10 (1.09) 2.37 (2.34) 1.78 (1.87) 110.9 (116.5) 105.6 (104.1) 
T 1.28 (1.29) 1.30 (1.32) 2.42 (2.50) 1.84 (1.74) 117.1 (123.1) 152.6 (159.9) 
V53 S1_H2       
R 2.71 (2.29) 1.10 (1.11) 2.35 (2.38) 1.77 (1.75) 119.1 (114.2) 130.8 (124.2) 
T 0.97 (0.97) 2.09 (1.40) 2.37 (2.38) 1.82 (1.75) 106.9 (125.6) 153.0 (123.1) 
V53 S2       
R 2.94 (2.67) 1.09 (1.08) 2.35 (2.35) 1.79 (1.68) 145.3 (139.5) - 
T 1.89 (1.95) 1.09 (1.04) 2.40 (2.36) 1.89 (1.76) 130.9 (130.5)  
V53 S2       
R 3.20 (2.94) 1.08 (1.06) 2.38 (2.49) 1.76 (1.78) 121. 0 (112.3) - 
T 1.87 (1.92) 1.08 (1.10) 2.59 (2.39) 1.80 (1.76) 120.2 (124.4) - 
V53 C1       
R 3.74 (3.32) 1.08 (1.08) 2.43 (2.44) 1.74 (1.76) 136.7 (125.9) - 
T 1.40 (1.89) 1.09 (1.10) 2.44 (2.45) 1.93 (1.77) 126.0 (125.9) - 
 
A The distance or angle displayed is between Fe=O····H for aliphatic hydroxylation (S1_H1, S1_H2) and between 
Fe=O·····C for aromatic hydroxylation (S2, S3, C1).  
 
The distance between the cysteine thiolate group and oxyferryl is one of the major driving 
forces in the cleavage of the C-H bond. Its electron pushing effect towards the oxyferryl 
lowers the redox potential and at the same time increases the basicity of the oxyferryl. 
Therefore, a larger Fe-S distance is unfavorable as it decreases the electron pushing effect 
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towards the oxyferryl and diminishes its capability to cleave the C-H bond [36] (see the 
materials and methods section for a more detailed description of the pull-push C-H cleavage 
mechanism). Also, it is generally known that a longer Fe=O and C-H bond distance whereas 
a shorter S-Fe and Fe=O·····H bond distance point towards a more product-like character of 
the TS structure [18]. Compared to the Fe-S bond distances determined for the other TS-
heme complexes, a larger distance (above 2.5 Å) appears to be one of the factors that will 
lead to a less reactive SoM (CYP2D6 WT: S1_H2, S3 and C1, CYP2D6, Table 2.2). Moreover, 
the impact of the F120I on the S3 SoM in CYP2D6*53 seems to give the aromatic moiety 
more freedom to adjust its orientation which in this case leads to a less optimal geometry 
for the oxidation reaction to proceed. This assumption is supported by the outcome from 
the single point calculations (M06-2X/LACV3P**) performed on the minimized reactant 
structure of only bufuralol and F120 or I120 (Table 2.3).  
 
Table 2.3. The QM interaction energy between ligand and the residue 120 calculated for each minimized 
reactant geometry. 
 
 Energetic contribution  
 [kcal/mol] 
SoM ∆E F120 ∆E I120 
S1_H1 -6.82 -5.21 
S1_H2 -5.56 -3.14 
S2 -2.79 -3.10 
S3 -11.25 -2.82 
C1 -8.71 -0.53 
 
All of the single point calculation values used to determine the energetic contribution of 
F120 or I120 can be found in Table S2.2. The results show that F120 has a larger energetic 
contribution than I120 within the binding poses (except for S2). Though both amino acids 
are hydrophobic and can stabilize bufuralol by van der Waals interactions, only the aromatic 
ring of phenylalanine can form stabilizing non-covalent interactions with bufuralol through π-
π stacking and/or cation-π interactions; particularly for S1_H1 and S1_H2 a face-to-face π 
stacking positioning can be seen (Figure 2.4). The less restraining influence of I120 is 
expected to give the major S1 and minor S2 SoM of bufuralol increased conformational 
freedom to position the SoM in a more favorable orientation (improved orbital overlap) 
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towards the oxyferryl, thereby lowering the activation barrier. However, for S3 the result was 
the opposite.  
Comparing the determined S3 CYP2D6*53 activation barrier to the non-reactive C1 control 
SoMs activation barrier values which reached values above 40 kcal/mol, it is very unlikely that 
S3 oxidation within the CYP2D6*53 variant will occur. As mentioned in the method section, 
the experimental set-up for the functional characterization of CYP2D6*53 only monitored the 
metabolism of the major SoM S1, not S2 or S3. It is therefore not possible to support the 
QM/MM results with experimental data and make any unambiguous statements regarding 
the impact on the F120I on orienting bufuralol more favorably. Nevertheless, based on our 
QM/MM study we predict S2 to be metabolized (though to a lesser extent than the major 
SoM) and S3 to be non-reactive in CYP2D6*53.  
In support of this outcome are the results found in other QM/MM studies focusing on 
aliphatic and aromatic C-H bond activation; Olah et al. studied dextromethorphan oxidation 
in CYP2D6 and determined an activation barrier of 12.4 kcal/mol for aliphatic carbon 
hydrogen abstraction and a value of 17.2 kcal/mol for the side-on aromatic carbon oxidation 
(quartet, B3LYP/LACVP**) [20]. In addition, several other QM/MM studies investigating C-H 
bond activation within different P450 systems found similar activation barrier values (Table 
S2.3). It should be kept in mind that the several factors will contribute to the variation found 
in the determined activation values from other QM/MM studies including (i) the (dis-
)similarity of the substrates studied (ii) different isoforms will have a different active site and 
steric effects, (iii) the method and set-up used (functional, basis set, inclusion of dispersion 
effects, size QM region, etc.). Moreover, the landmarking study of Mulholland et al. studying 
aliphatic and aromatic hydrogen abstraction within CYP2C9 clearly demonstrated that the 
activation barrier can span a considerable range (about 6.5 kcal/mol for aliphatic and 4.5 
kcal/mol for aromatic hydroxylation) depending on the binding mode used as an input for 
the QM/MM calculations. The lower energy barriers determined are suggested to be most 
representative of the reaction pathway taking place in the enzyme [34]. Analysis of the 
geometric values of the determined TS-heme complexes showed to be in accordance with 
the values found in other C-H bond activation QM/MM studies [20,40]. For QM gas-phase 
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calculations, the O·····H-C angle can reach the ideal linear angle (180°) [34]. However, for the 
QM/MM calculations the active site residues restrain the O·····H-C angle of the transition 
state and the angle ranges from 159° to 170°.  
 
Conclusion 
This study focused on improving our current understanding regarding the driving forces 
affecting the substrate C-H bond activation within different CYP2D6 active site environments 
known to induce altered enzyme activities. Learning to what extent a change in active site 
composition influences the kinetic behaviour of a ligand and its ability to adopt an orientation 
that favors oxidation, is essential in order to develop accurate computational metabolism 
prediction tools. Computational metabolite predictions are valuable for example within the 
early-stage drug design process where this information can be cost-efficiently obtained and 
applied  in the lead compound optimization. The first part of this study, utilizing well-
tempered metadynamics simulations, demonstrated that the lowest energy poses of the 
substrate studied (bufuralol) within different CYP2D6 active sites environments did not 
correspond to the energetically most accessible conformation for oxidation. Also, 
determining the significance of the binding pose in order to assign it major or minor SoM 
using solely the free energy profile of the substrate within the active site can lead to an 
incomplete answer as demonstrated by the altered-activity variants. In the second part of 
the study, QM/MM calculations for each SoM of bufuralol within CYP2D6 WT and the clinical 
relevant allelic variant CYP2D6*53 (F120I/A122S) were performed in order to determine the 
corresponding aliphatic and aromatic C-H bond activation barriers. The results show that the 
stereoelectronic complementarity of the substrate in the active site is an indispensable factor 
that needs to be quantified for obtaining a meaningful and reliable metabolism prediction. 
In particular, we observed and quantified that the F120I mutation in CYP2D6*53 had a less 
restraining influence on the kinetics of bufuralol, giving it more freedom to orient the 
dominant SoMs in a favorable geometry which contributed to a more efficient oxidation 
reaction (lower activation barrier). Furthermore, we found the mutation had neither impact 
on the CYP2D6 enantioselectivity preference of the oxidation reaction at bufuralol, nor on 
its stereoselectivity. We therefore postulate that depending on the type(s) of mutation(s) 
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within the active site, the reaction selectivity and efficiency can be modulated by enabling 
the substrate to reach a more or less favorable active site stabilized and energetically 
accessible conformation. The placement of the substrate regarding the oxyferryl group can 
in turn promote or impede the desired orbital overlap for transferring the electrons, thereby 
the probability of reaching the TS which subsequently increases or decreases the activation 
barrier. Within the CYP2D6 reaction balance studied the stereoelectronic complementarity 
seems to have predominant weight in determining its selectivity though the spatial binding 
mode is an essential driving force as well.  
 
Materials and methods  
Substrate selection. Bufuralol, a beta-adrenoceptor antagonist, was selected for studying the 
energetic accessibility of its three experimentally well-characterized SoMs (denoted as “S1-
S3” in this study). It is a typical CYP2D6 substrate having a basic nitrogen around 5-7 Å away 
from its site(s) of oxidation and an aromatic planar system [10]. The U.S. Food and drug 
Administration (FDA) recommends the substrate as in vitro marker for CYP2D6 studies 
(http://www.fda.gov/) [41]. The major metabolites formed are 1’-hydroxybufuralol (referred 
to as S1_H1 and S1_H2 for strereoselective reason), 1’-oxobufuralol and 1’2’-
ethenylbufuralol [10]. Minor metabolites are 6-hydroxybufuralol (referred to as S2) and 4’-
hydroxybufuralol (referred to as S3) [42,43]. The regio-selectivity predictor SMARTCyp 
confirmed 1-‘OH-bufuralol (S1) to be the major site of metabolism. The intrinsic reactivity of 
the two experimentally verified minor sites (S2 and S3) were also indicated (Figure 2.1A). An 
overview of the SoMs investigated in this study can be found in Figure 2.1B and the 
predicted metabolites by GLORY [13] in Figure 2.1C which are in agreement with 
experiment. As a negative control, the site referred to as C1 at the aromatic carbon located 
in the furan ring was selected. For the CYP2D6*53 variant, increased activity has been 
determined by measuring the activity of bufuralol 1’-hydroxylation (KM and Vmax) using a 
substrate concentration of 80 µM. Results indicated a 4-fold increase in intrinsic clearance 
(CLint) compared to CYP2D6 WT [30]. The minor SoMs (S2 and S3) were not monitored in this 
study.  
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Protein preparation. The CYP2D6 crystal structure with PDB ID 4WNW was retrieved from 
the Protein Data Bank (PDB: https://www.rcsb.org/) and processed using the protein 
preparation wizard of Maestro small-molecule drug discovery suite (v. 2017-2). Missing 
residues and hydrogen atoms were added assuming the pH of 7.4, bond orders were 
assigned, and waters, the co-crystalized ligand and co-factors were removed. Compound I 
state was modelled (Fe3+ bound to O2-, zero-order bond). The distance between the iron and 
the oxygen was set to 1.97 Å. Subsequently, a short heavy-atom restrained minimization was 
performed using the OPLS_2005 force field [44].  
 
Ligand preparation and docking. The three-dimensional (3D) conformation of bufuralol was 
obtained from DrugBank (accessed: October 2018). The structure was prepared using 
LigPrep wizard of Maestro small-molecule drug discovery suite (OPLS_2005 force field, 
Schrödinger v. 2017-2). The preparation procedure included bond order assignment, 
protonation evaluation (at pH 7.4), and a standard LigPrep minimization of the conformation. 
Bufuralol was subsequently docked to CYP2D6 wild-type using default docking protocol 
using Glide [45]. The best scored docking pose was used for subsequent simulations. After 
docking, the two amino acid mutations for each variant were introduced into the CYP2D6 
wild-type. This way the WT-MTD as well as were started from the same ligand 
pose/orientation.  
 
Well-tempered metadynamics simulations. The systems used for WT-MTD were prepared 
following the standard procedure for running MD simulations; the CYP2D6-ligand systems 
were solvated using the TIP3P water model in orthorhombic boxes of the periodic boundary 
system with 10.0 Å cutoff from the protein in each of the three dimensions. Net charge of 
the system was neutralized by addition of sodium ions. For the WT-MTD simulations, the 
OPLS_2005 force field was applied as implemented in Desmond (version 2016-4). Box 
dimensions were 68 x 85 X 83 Å3 with 39711 water atoms. Before starting the WTD-MD 
production runs of 200 ns in a NPT ensemble and standard conditions (T= 300 K, p= 101.325 
kPa), a relaxation phase was applied with the Nose-Hoover thermostat coupled with the 
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Martyna-Tobias-Klein barostat using a relaxation time of 1.0 ps and a time step of 2.0 fs at 
300 K. Long-range coulombic interactions were handled with the smooth particle mesh 
Ewald (PME) method with a cutoff for short-range interactions of 9 Å. The M-SHAKE 
algorithm was used to constrain bonds to hydrogens, no hydrogen mass partitioning was 
applied. Simulations were performed on a GeForce GTX Titan GPU. The compound I state 
of the heme-complex was modeled for the simulations as this enabled to analyse the FES 
profile associated with the orientation of the substrate SoMs with respect to the oxyferryl 
group which is critical for an efficient hydrogen abstraction reaction. 
 
Well-tempered metadynamics parameters. Two collective variables were chosen: (i) the 
distance between the oxyferryl and the SoM carbon atoms, (ii) the angle between the iron, 
the oxyferryl and the aliphatic hydrogen (Fe=O·····H) or the aromatic carbon (Fe=O·····C) 
atoms. In addition, as an alternative set (CV-set 2) the angle between the oxyferryl oxygen 
atom, the aliphatic/aromatic carbon hydrogen and the aliphatic/aromatic carbon (O·····H-C) 
atoms was monitored. Both angles need to reach an optimal geometry (around 120° and 
180° respectively, (Figure 2.5) for a most efficient reaction process [20].  
 
 
Figure 2.5. CYP2D6 The orientation of the substrate and cpd I for C-H bond activation is displayed which 
facilitates optimal orbital overlap and subsequently leads to low activation barriers [18,20,34].  
 
The width of the Gaussian was set to 0.05 Å for the distance CV1, and 2.5° for the angle 
CV2. The width was chosen by one-fourth of the average fluctuation of the CV which is 
needed to get out of the free energy minimum. The initial height of the Gaussians was set 
to 0.03 kcal/mol and the deposition time was 0.09 ps. For CV1 the exploration of CV space 
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was limited by adding an upper wall bias of 10 Å in order to keep the ligand within close 
vicinity of the heme and sampling the relevant region of the free energy surface. All 
simulations were run for 200 ns. The negative of the sum of the Gaussians gives the FES. 
Convergence of the WT-MTD simulations was evaluated by a) performing two replicas in 
which the seed was changed to assign different starting velocities for the major site of 
metabolism (S1) and the negative control (C1). The range of the FES profile minima (blue 
area) should be superposable. b) Verification of efficient sampling of space for each CV over 
time (Figures S2.2-S2.3). c) The height of the Gaussian deposited during the simulation time 
was evaluated to ensure that the simulation was not stuck in a local minimum and a smooth 
FES was achieved (Figure S2.4). d) Evaluation of the last 50 ns at 25 ns interval, to verify that 
the FES profile did not change significantly (Figures S2.6-S2.11). In addition, a visual 
inspection of the distribution of the frames over the FES was done, which supported that the 
simulation sampled the CV space efficiently and a smooth FES was reached and thus are an 
accurate representation of the free energies.  
 
QM/MM modelled hydrogen abstraction. A remarkable fact of CYP450 enzymes is that 
nature designed them as such that the heme-thiolate complex can oxidize a 
thermodynamically very stable C-H bond but it will not oxidize nearby residues (e.g. tyrosine, 
tryptophan or histidine) which would also destroy the functionality of the enzyme. In order 
to break a strong C-H bond (typically around 100 kcal/mol) and form a stronger O-H bond, 
both the basicity and redox potential of the Fe=O bond are important driving forces [46]. 
The cysteine thiolate group has a strong electron pushing effect towards the oxyferryl 
thereby lowering the redox potential but increasing the basicity of the oxyferryl oxygen (pKa= 
~12) which in turn leads to a greater pull for C-H cleavage [47]. Aliphatic hydrogen 
abstraction occurs through a rebound-mechanism shown in Figure 2.6. The hydrogen 
abstraction step is the rate-limiting step and is therefore the step modelled in this study for 





Figure 2.6. Aliphatic carbon hydrogen abstraction energy diagram. The different energy levels are shown for 
the doublet and quartet spin state [18]. For the quartet spin state, the reactant, intermediate and product states 
were modelled and geometrically optimized with QM/MM calculations. A transition state search was performed 
to find the first intermediate states (TS1) in order to calculate the activation barriers for all the different SoMs.  
 
For aromatic hydrogen abstraction, the reaction proceeds differently. Both a phenolic and 
benzene epoxide product can be formed through three major pathways; with a keto 
tautomer (Figure 2.7, pathway A), an N-protonated porphyrin (Figure 2.7 pathway B) or an 
epoxide as intermediate product (Figure 2.7, pathway C). The addition-rearrangement 
pathway (Figure 2.7, pathway A) has been found to be the lowest energy pathway [50,51]. 
The step with the highest energy barrier is found to be the addition of the Cpd I to the 
substrate carbon which leads to the tetrahedral intermediate s-complex [37]. Therefore, this 
step was modelled to determine the activation barrier of the aromatic oxidation. To quantify 
the impact of the mutations it is assumed that neither the reaction pathway is changed, nor 
other factors (e.g. substrate pathway, large-scale movements, etc.). The relative changes in 
activation barrier are thus the result of the differences in stabilizing inter- and intramolecular 
forces (electrostatic multipole, electrostatic penetration, exchange, induction and dispersion 
contributions) within the active site [52]. From the two point mutations, the F120I mutation 
(hydrophobic aromatic to hydrophobic aliphatic) is most relevant for the reaction barrier 
calculations considering its vicinity to the reactive heme center. Previous studies 
demonstrated the stereo- and regioselectivtity role of F120 and that the type of amino acid 
substitution and substrate influence the outcome [35,36,53,54].  
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Figure 2.7. Three proposed rearrangement pathways for aromatic hydrogen abstraction [37]. The step with the 
highest energy barrier is found to be the addition of the Cpd I to the substrate carbon which leads to the 
tetrahedral intermediate s-complex. Modeling of this state has been therefore the focus of this study in order 
to define the corresponding height of the activation barrier. 
 
For 1’hydroxylation of bufuralol (major SoM) the F120A mutation reversed the 
enantioselectivity from R to S whereas the metabolite stereoselectivity remained the same 
[39]. In addition, other studies using different substrates showed similar outcome (changed 
regio- and stereoselectivity) and highlighted the determining role of the intrinsic reactivity, 
in particular for molecules which have large mobility within the active site [35,36,53,54]. To 
determine the activation barrier which accurately represents the reactivity of the enzyme, 
selecting a starting structure with an energetically accessible geometry resembling closely 
the transition state is crucial [18]. A very precise study would use multiple starting structures 
for each SoM to obtain a realistic average barrier value through Boltzmann-weighted 
calculations [55]. However, the aim of this study was not to determine absolute activation 
barrier heights, but rather to perform a relative comparison study in order to identify how 
the ligand’s intrinsic reactivity is influenced by the mutation of surrounding residues. 
 
QM/MM procedure. QM/MM analysis was performed using the Qsite module implemented 
in the Schrödinger Suite (2016-4) [56,57]. It combines Jaguar (version 9.3, release 15) and 
Impact modules (OPLS force field) for the QM and MM calculations respectively [58] (Impact, 
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version 6.4, Schrödinger, LLC, New York, NY, 2014). The starting structures (reactant 
structure) for QM/MM optimization were obtained from the WT-MTD simulations. Structures 
which have a SoM that is in close vicinity of the oxyferryl oxygen atom (< 3 Å) and have an 
Fe=O·····H angle between 110° and 130° are considered energetically accessible for 
oxidation (Figure 2.8) [18,20,34]. Therefore, for each SoM, the frame that fulfilled these 
criteria was selected from the corresponding WT-MTD. The selected reactant structures for 
each SoM in CYP2D6 wild-type and CYP2D6*53 used for the QM/MM calculations can be 
found in Figure 2.3. 
 
 
Figure 2.8. Overview selection criteria applied to choose the frames from the well-tempered MTD for QM/MM 
calculations. The frames closest to the heme oxygen (d < 3 Å) and with an Fe=O·····H angle between 110° and 
130° were selected [18,20,34,59]. 
 
The criteria are based on the previously performed QM studies which determined the TS 
geometries for each oxidation pathway (aliphatic/aromatic) [18,20,60]. The QM/MM 
geometry optimization was performed with the M06-2X functional and the polarized basis 
set LACVP*, diffuse basis functions (LACVP*+) were added only for the negative charged 
atoms [18,20,61]. Single point calculations were performed at the M06-2X/LACV3P*+ level. 
The basis set selection is frequently a compromise between accuracy of the results and the 
feasibility of the computational time required for the calculations. The Minnesota effective 
core potential functionals have been parameterized such that they implicitly account for 
dispersion effects [62–64] and have previously shown to perform well for similar P450 systems 
[20,34,38,61]. The CYP2D6 WT QM region included the ligand, the heme and the binding 
pocket residue side chains (hydrogen caps between Ca and Cb bond) of PHE120 (or ILE 120 
in one of the variants), GLU216, ASP301 and CYS443. Residues beyond 6 Å from the selected 
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QM region were treated as frozen during the MM optimization. All waters were treated within 
the MM optimization also the water molecules within the active site. Our main motivation to 
exclude the active site water molecules from the QM region is that the number of water 
molecules varied among the starting structures which, depending on their position, may 
impact the results and diminish the impact of the mutated residue. Also, we inspected the 
positions of the water molecules to evaluated if they might be able to stabilize the transition 
state geometry by interaction with the oxyferryl or SoMs which was not the case. Previous 
studies showed that this can lower the activation barrier in the order of 3-4 kcal/mol on 
average [38]. The conjugate gradient algorithm was applied and tight MM optimization 
convergence criteria were used; maximum number of cycles 9999, initial step size of the 
minimization cycle 0.05, maximum step size 1, energy and gradient as convergence criterion 
with an energy change of 10-5 kcal / mol, and gradient criterion of 0.01 kcal/(mol Å). It has 
been shown before that for hydrogen abstraction the low (doublet) and intermediate 
(quartet) are very close in energy [18,65]. For computational reason we studied all structures 
using the quartet spin state.  
 
RMSD calculation. The RMSD difference between the minimized SoM reactant binding pose 
of the CYP2D6 WT and CYP2D6*53 variant was calculated by superposition of the Ca atoms 
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Figure S2.1 Free energy surface (FES) graphs is displayed for the experimentally known sites of 
metabolism (SoMs, S1-S3) and control site C1 of bufuralol and control using CV-set 2 calculated over 




Figure S2.2. Diffusion assessment of CV1 (Å) during WT-MTD. Convergence assessment of metadynamics 
simulation for the five monitored bufuralol SoMs in all CYP2D6 variants (wild-type (top row), F120IA122S 
(middle row) and E216QF483G (bottom row) by assessing the time-evolution behaviour of CV1 (distance SoM 




Figure S2.3 Diffusion assessment of CV2 (degrees) during WT-MTD. Convergence assessment of 
metadynamics simulation for the five monitored bufuralol SoMs in all CYP2D6 variants (wild-type (top row), 
F120IA122S (middle row) and E216QF483G (bottom row) by assessing the time-evolution behaviour of CV2 




Figure S2.4. Gaussian potential development over time (Fe·····H angle). Convergence assessment of 
metadynamics simulation for the five monitored bufuralol SoMs in all CYP2D6 variants (wild-type (top row), 




Figure S2.5. The RMSD (backbone) for the different simulations. In black the unbiased CYP2D6 wild-type 
(WT), the well-tempered metadynamics (MTD) of S1_H1 is shown for WT CYP2D6 (blue), F120IA122S (green) 






Figure S2.6. Reproducibility assessment of FES simulations (FeO -- H angle) for wild-type (WT) CYP2D6 
with bufuralol using the major site of metabolism (S1_H1) and control (C1) SoM. A) Convergence 
assessment of metadynamics simulation for bufuralol S1_H1 (top) and C1 (bottom) by FES analysis at 150 ns, 
175 ns and 200 ns. B) Replica simulations (R1 and R2) ran for bufuralol S1_H1 (top) and C1 (bottom) using 
different start velocities.  
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Figure S2.7. Reproducibility assessment of FES simulations (O·····H-C angle) for wild-type (WT) CYP2D6 
with bufuralol using the major site of metabolism (S1_1) and control (C1) SoM. A) Convergence assessment 
of metadynamics simulation for bufuralol S1_H1 (top) and C1 (bottom) by FES analysis at 150 ns, 175 ns and 




Figure S2.8. Reproducibility assessment of FES simulations (FeO·····H angle) for the increased activity 
CYP2D6 variant (F120IA122S) with bufuralol using the major site of metabolism (S1_H1) and control (C1) 
SoM. A) Convergence assessment of metadynamics simulation for bufuralol S1_H1 (top) and C1 (bottom) by 
FES analysis at 150 ns, 175 ns and 200 ns. B) Replica simulations (R1 and R2) ran for bufuralol S1_H1 (top) and 
C1 (bottom) using different start velocities.  
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Figure S2.9. Reproducibility assessment of FES simulations (O·····H-C angle) for the increased activity 
CYP2D6 variant (F120IA122S) with bufuralol using the major site of metabolism (S1_1) and control (C1) 
SoM. A) Convergence assessment of metadynamics simulation for bufuralol S1_H1 (top) and C1 (bottom) by 
FES analysis at 150 ns, 175 ns and 200 ns. B) Replica simulations (R1 and R2) ran for bufuralol S1_H1 (top) and 
C1 (bottom) using different start velocities.  
 
 
Figure S2.10. Reproducibility assessment of FES simulations (FeO·····H angle) for the no-activity CYP2D6 
variant (E216QF483G) with bufuralol using the major site of metabolism (S1_H1) and control (C1) SoM.  
A) Convergence assessment of metadynamics simulation for bufuralol S1_H1 (top) and C1 (bottom) by FES 
analysis at 150 ns, 175 ns and 200 ns. B) Replica simulations (R1 and R2) ran for bufuralol S1_H1 (top) and C1 




Figure S2.11. Reproducibility assessment of FES simulations (O·····H-C angle) for the no-activity CYP2D6 
variant (E216QF483G) with bufuralol using the major site of metabolism (S1_1) and control (C1) SoM. 
A) Convergence assessment of metadynamics simulation for bufuralol S1_H1 (top) and C1 (bottom) by FES 
analysis at 150 ns, 175 ns and 200 ns. B) Replica simulations (R1 and R2) ran for bufuralol S1_H1 (top) and C1 







































Table S2.1. Overview of CYP2D6 - bufuralol interactions within each starting structure (reactant) used for 
QM/MM calculations. Consensus amino acid (aa) interactions (direct) for CYP2D6 WT and the allelic variant 
(V53) are in bold. For water-mediated interactions the number of molecules is indicated in brackets and 














Major site     
wt S1_H1 D301 ionic 1.6 E216 (2) 
 F120 ππ stacking ~3.5  
 S304 H-bond 1.9  
V53 S1_H1 D301 ionic 1.6  
 S304 H-bond 2.0  
wt S1_H2 D301 ionic 1.5 E216 (1) 
    D301 (2) 
V53 S1_H2 D301 ionic 1.7  
Minor Sites      
wt S2 E216  ionic 1.7 D301 (2) 
 E216 ionic 1.9  
    Q244 (1) 
V53 S2 D301 ionic 1.9 E216 (1) 
    I120 (1) 
wt S3 D301 ionic 1.6  
 D301 H-bond (bb) 1.9  
 F120 ππ stacking ~3.8  
V53 S3 D301 ionic 1.7 E216 (1) 
Control     
wt C1 D301 ionic 1.7  
 S304 H-bond 2.2  
 F120 with N.. ~4.5  
 F483 ππ stacking ~4.0  























Table S2.2 Single point calculation (SPC) results performed on the reactant minimized structure of only 
bufuralol and F120 in CYP2D6 WT or I120 in CYP2D6*53 (M06-2X/LACV3P**). The ∆E value was 
determined after performing SPC on reactant binding pose of the bufuralol-F120 or bufuralol-I120 residues 
(hartrees) (A), only bufuralol (hartrees) (B), or only F120 or I120 (hartrees) (C) and subtracting A and B from C 
(kcal/mol).    
 
CYP2D6 WT A: buf-F120 B: buf C: F120 ∆E= (A - B - C) 
S1_H1 -1100.50233 -828.98965 -271.50182 -6.8 
S1_H2 -1100.49505 -828.98425 -271.50194 -5.6 
S2 -1100.48193 -828.97554 -271.50195 -2.8 
S3 -1100.50373 -828.98378 -271.50202 -11.2 
C1 -1100.50004 -828.98536 -271.50080 -8.7 
 
CYP2D6*53 A: buf-I120 B: buf C: I120 ∆E= (A - B - C) 
S1_H1 -987.39456 -828.98647 -158.39979 -5.2 
S1_H2 -987.38892 -828.98348 -158.40044 -3.2 
S2 -987.38807 -828.98361 -158.39952 -3.1 
S3 -987.39394 -828.98894 -158.40051 -2.8 
C1 -987.29627 -828.89776 -158.39767 -0.5 
 
 
Table S2.3. Overview of activation barriers determined by previous QM/MM P450 oxidation studies. The 
activation barriers (kcal/mol) displayed are for the quartet spin state (S=3/2) and side-on unless otherwise 
indicated.  
 
isoform Substrate Aliph HA Arom HA F-BS* Reference 
CYP2D6 dextromethorphan 12.4  17.2  B3LYP/LACVP**  [9] 
CYP2C9 benzene - 18.1/21.7 B3LYP/LACV3P/6-31G [37] 
CYP101 camphor   B3LYP/LACV3P** [52] 
CYP3A4 Phtalate 19.9 22.8 B3LYP/LACV3P+ [56] 
CYP102A1 N-Palmitoylglycine 18.2 - B3LYP/ LACV3P+/6-31G [53] 
CYP101 N-Palmitoylglycine 21.8 - B3LYP/ LACV3P+/6-31G [53] 
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Chapter  





Characterization of cytochrome P450 2D6 (CYP2D6) and the impact of the major identified 
allelic variants on the activity of one of the most dominating drug-metabolising enzymes is 
essential to increase drug safety and avoid adverse reactions. Microsecond molecular 
dynamics simulations approach has been performed to capture the dynamic signatures of 
this complex enzyme and five allelic variants with diverse enzymatic activity. In addition to 
the apo simulations, three substrates (bufuralol, veliparib and tamoxifen) and two inhibitors 
(prinomastat and quinidine) were included to explore their influence on the structure and 
dynamical features of the enzyme. Our results indicate that the altered enzyme activity can 
be attributed to changes in the hydrogen bonding network within the active site, and local 
structural differences in flexibility, position and shape of the binding pocket. In particular, 
the increased (CYP2D6*53) or the decreased (CYP2D6*17) activity seems to be related to a 
change in dynamics of mainly the BC loop due to a modified hydrogen bonding network 
around this region. In addition, the smallest active site volume was found for CYP2D6*4 (no 
activity). CYP2D6*2 (normal activity) showed no major differences in dynamic behaviour 
compared to the wild-type. 
 
Introduction  
Genetic polymorphism in CYP2D6, a monooxygenase enzyme metabolizing around 25% of 
the therapeutic drugs [1], frequently leads to altered enzyme activity (increased, decreased 
or none) which in turn has an impact on the drug efficacy and the occurrence of adverse 
reactions [2]. Depending on the genetic variant, four phenotypes can be assigned: (i) 
ultrarapid metabolizer (UR), (ii) normal metabolizer (NM), (iii) intermediate metabolizer (IM) 
and (iv) poor metabolizer (PM) [3]. During the last decade, increased awareness concerning 
the risks that CYP2D6 polymorphism can bear on treatment outcome has lead to relabeling 
of several CYP2D6 metabolized drugs with additional guidelines on drug dosage in case of 
polymorphism by the FDA [4]. In addition, the clinical pharmacogenetics implementation 
consortium (CPIC) has been procuring therapeutic guidelines for several drugs that have a 
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high risk of adverse reactions when administered to patients with a phenotype deviating 
from the normal CYP2D6 activity (wild-type) [5].  
The enzymatic activity can be altered in various ways. Intrinsic properties of CYP2D6 such as 
a localized hydrophobic region in the binding pocket (V119, F120, L121, F219, L220, R221, 
V370, P371, L372, V374) or the strong electrostatic field of the two carboxylates (E216 and 
D301) enabling binding and orienting of the ligand, are essential for its unique substrate 
specificity [6–8]. In addition, the ligand flux between the exterior and the buried active side 
is tightly regulated through the formation of tunnels [6]. Environmental conditions have been 
shown to contribute to the metabolic capacity of the enzyme, too. Its redox partner the 
cytochrome P450 reductase (CPR/POR) provides the electrons needed for the redox reaction 
[7]. The presence of other isoforms is also important as it has been observed that P450s 
(including CYP2D6) are able to form homomeric and heteromeric complexes [8]. In addition, 
the polarity and organization of the membrane is essential for proper anchoring and 
enzymatic function [9]. How all these factors exactly influence and modify CYP2D6 function 
on the molecular level is still poorly understood.  
Using in silico methods for extending our understanding of the enzyme’s essential bond-
forming capabilities, channel formation and overall plasticity is burgeoning [10–17]. This 
trend is driven by the growing amount of structural data (the majority of available mammalian 
CYP2D6 x-ray structures have been released after 2014) as well as ever increasing 
computational power allowing to reach the millisecond time scale of the molecular dynamics 
(MD) simulations [18]. Such simulations are the method of choice for studying the 
biomolecular structural and dynamical aspects on atomic level (based on its thermodynamics 
and kinetics) and conveniently complement experimental investigations [19,20]. In general, 
MD simulation studies (varying from 5 ns to 250 ns) that focused on CYP2D6 and different 
variants (CYP2D6*34, CYP2D6*17-2, CYP2D6*17-3, CYP2D6*53, CYP3D6*2, CYP2D6*10, 
CYP2D6*14A, CYP2D6*51, CYP2D6*62) showed that the global structural fold remains 
similar for all [12,15,17]. However, local changes mainly found at the loop regions were 
demonstrated to alter the flexibility (increased/decreased) of one particular variant and they 
are thought to correlated with the enzyme activity [12,15,21]. Moreover, the CD-, GH-, FG-, 
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and BC loops displayed increased or decreased flexibility compared to the wild-type. 
Especially the last two loops are positioned close to several important tunnels (2a/2ac/4 and 
2b/2e/2c respectively) which allows the regulation of ligand flux between the outer 
environment and the buried active site. If the loops become more rigid or flexible upon a 
particular amino acid mutation this will translate into different thermodynamics and altered 
enzyme activity [17]. It is known that enzymatic reactions occur on the millisecond-to-second 
time scale, hence the need to prolong the MD simulation studies to a longer time scale in 
order to capture an improved overall framework of the links between enzyme structure, 
movement and its catalytic action [22]. Improved information and any novel insights 
regarding CYP2D6 polymorphs could also potentially contribute to minimizing the 
interindividual differences in pharmacological and toxicological responses to a drug (e.g. 
altered binding mode of a drug in the binding pocket of an allelic variant) during drug 
discovery and translate into more focused  pharmacovigilance [23–25]. 
Our pioneering study focuses on exploring such dynamic phenomena contributing to 
enzyme activity on a larger time scale (1 µs) for CYP2D6 wild-type (WT) and five allelic variants 
(CYP2D6*2, CYP2D6*10, CYP2D6*17, CYP2D6*4 and CYP2D6*53) (Table 3.1). The selection 
criteria of the CYP2D6 variants were procured based on (i) the functional activity and clinical 
relevance, for each phenotype at least one variant was selected (Table 1.1). At the moment, 
only one CYP2D6 variant with increased in vitro activity is identified. A list containing all  
currently identified allelic CYP2D6 variants (> 100) can be found at www.pharmvar.org. (ii) 
the location and overlap of the mutations within the CYP2D6 structure (Figure 3.1): except 
for CYP2D6*53 (increased activity) all the other selected variants have at least one mutation 
in common. Furthermore, three substrates and two inhibitors were selected in order to 
investigate the way they are accommodated in the active site and influence the enzyme 
flexibility. 
The 15 MD simulations performed in this study extend our existing knowledge on the 
structural and functional relationship of CYP2D6 wild-type and five variants. Our results 
suggest that the altered enzyme activity can be attributed to both changes in hydrogen 
bonding network within the active site as well as local structural differences in flexibility, 
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position and shape of the binding pocket – in particular the loop regions (FG and BC) 
essential for the regulation of the ligand access to the heme.  
 
Table 3.1 Overview of all MD simulations performed (1 µs).  
Run ID Description 
wt_a CYP2D6*1 (wild-type) apo enzyme (normal activity) 
V2_a CYP2D6*2 apo enzyme (normal activity) 
V10_a CYP2D6*10 apo enzyme (decreased activity) 
V17_a CYP2D6*17 apo enzyme (decreased activity) 
V4_a CYP2D6*4 apo enzyme (no activity) 
V53_a CYP2D6*53 apo enzyme (increased activity) 
wt_buf CYP2D6*1 (wild-type) enzyme run with bufuralol (substrate) 
wt_vel CYP2D6*1 (wild-type) enzyme run with veliparib (substrate) 
wt_tam CYP2D6*1 (wild-type) enzyme run with tamoxifen (substrate) 
wt_pri CYP2D6*1 (wild-type) enzyme run with prinomastat (inhibitor) 
wt_qui CYP2D6*1 (wild-type) enzyme run with quinidine (inhibitor) 
V17_qui CYP2D6*17 enzyme run with quinidine (inhibitor) 
V17_pri CYP2D6*17 enzyme run with prinomastat (inhibitor) 
V53_qui CYP2D6*53 enzyme run with quinidine (inhibitor) 
V53_pri CYP2D6*53 enzyme run with prinomastat (inhibitor) 
 
Single Nucleotide Polymorphisms (SNPs) of the five CYP2D6 variants 
Binding specificity and enzyme activity is controlled by a diversity of factors as mentioned in 
the introduction. The amino acid constitution of the enzyme contributes largely to its stability 
(e.g. intra-molecular hydrogen bonding network) and function (e.g. more hydrophobic lining 
channel residues regulating typical lipophilic substrate flux to and from the heme) [1]. 
Depending on the location of mutation (e.g. surface, substrate recognition site or active site) 
and its nature (e.g. hydrophobic into hydrophilic) the impact on the enzyme activity and 
stability will be more or less pronounced. For the eight SNPs among the CYP2D6 variants in 
this study (Figures 3.1 and 3.2), half of them caused a polarity change and three reversed 
hydrophobicity or hydrophilicity (Table S3.1). The SNP P34S in CYP2D6*4 and CYP2D6*10 
is known to perturb the proline-rich PPGP motif near the N-terminus site crucial for proper 
folding and membrane anchoring of the enzyme [26]. It has been observed that P34S is solely 
responsible for decreased to almost abolished enzymatic activity [27]. Both F120I and A122S 
SNPs in CYP2D6*53 (increased activity) are located at the BC-loop, in close vicinity of the 
CYP2D6 heme-iron. Several site-directed - and molecular modeling studies have proven the 
relevance of Phe120 to CYP2D6 substrate binding, orientation and regiospecificity of CYP2D6 
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[28–30]. Substitution of Phe120 by Ile is expected to reduce the local stacking interactions 
(increase BC loop flexibility) and to give substrates easier access towards the iron-heme. 
CYP2D6*2 with R296C located at the I-helix (N-terminus side) and S486T located at the b 4-
2 loop, has a similar activity compared to the wild-type [31]. Both the more conserved Ser486 
substitution with Thr and positively charged Arg296 substitution with Cys seem not to have a 
major impact on CYP2D6 [17,32]. 
 
Figure 3.1  CYP2D6 structure showing the positions of the single nucleotide polymorphisms (SNPs). The 
SNPs are highlighted in red. SNPs in CYP2D6*2 are R296C and S486T, in CYP2D6*10 are P34S, S486T in 
CYP2D6*17 are T107I, R296C and S486T, in CYP2D6*4 are P34S, L91M, H94R and S486T, in CYP2D6*53 F120I 
and A122S (see overview Table 3.2 and Figure 3.2).   
 
These two SNPs are also found in CYP2D6*17 (decreased activity) in addition to the SNP 
T107I. The significant role of the latter residue has been demonstrated by experimental 
research in which decreased enzymatic activity was observed with only the SNP T107I [33]. 
The hydrogen bond forming residue Thr107 is located at the B’ helix in the center of the BC 
loop. It can be assumed that substitution with Ile will increase local hydrophobicity and 
interactions, which in turn will stabilize the structure and reduce the flexibility of the BC loop, 
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potentially resulting in a decreased enzyme activity. Among Caucasians, the average 
identified allelic frequencies are 38%, 18%, 4%, 2%, 0.3%, for the wild-type (CYP2D6*1), 
CYP2D6*4, CYP2D6*2, CYP2D6*10, and CYP2D6*17 respectively [34]. The global 
distribution regarding the allelic frequency of CYP2D6*53 is not yet available. 
 
Table 3.2 Overview of the CYP2D6 allelic variants together with information regarding their relevance 








SRSB Allelic frequency [34] (%)
C: 
Normal Metabolizer (NM)    
 *1 (wild-type) None Normal  Americans (50%), Caucasians (38%) 
 *2 R296C, S486T Normal 6 Asians (central, 30%), Caucasians (4%) 
 Intermediate Metabolizer (IM)          
*10 P34S, S486T Decreased 5/6 Asians (east, 43%), Caucasians (2%) 
*17 T107I, R296C, 
S486T 
Decreased 1/3/4/6 Africans (19%), Caucasians (0.3%) 
Poor Metabolizer (PM)    
 *4 P34S, L91M, 
H94R, S486T 
Inactive 5/6 Caucasians (18%) 
Ultrarapid Metabolizer (UM)    
 *53 F120I, A122S Increased 1 Global frequency data incomplete 
A data obtained www.pharmvar.org accessed on 20.12.2017, B Substrate Recognition Site (SRS), c the population identified 
to have the highest occurrence regarding the CYP2D6 allele is indicated first, followed by the occurrence found for 
Caucasians.   
 
Figure 3.2. Overview of the CYP2D6 sequence, the secondary elements and the amino acid mutations for 
the five variants. (A) The CYP2D6 sequence is shown together with the location of the substrate recognition 
site (SRS1-SRS6) and the location of the mutations. (B) The table displays the CYP2D6 allelic variants and their 
mutations.  
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Materials and methods  
PDB selection 
It has been observed that the presence of a ligand in the binding pocket induces 
conformational changes mainly at helices A, B, F, G, the first b-sheet, and loops BC, AB, and 
FG. The distance between the later three loops and the position of their connecting helices 
determine a more closed/open protein conformation (Figure 3.3) [21,35].  
 
 
Figure 3.3 CYP2D6 x-ray structures illustrating the conformational diversity (open/closed). The apo 
structure 2F9Q (left) shows a more open conformation as defined by the distances between the FG- (grey), BC- 
(cyan) and AB- (pink) loops. The holo 3QM4 complex (with prinomastat, right) represents one of the most closed 
CYP2D6 conformations, whereas the holo 4WNU complex (with quinidine, middle) a semi-closed conformation.  
 
A start conformation with an overall fold that is semi-closed was preferred for this study and 
the CYP2D6 quinidine complex 4WNU was selected [36]. As with all available mammalian 
CYP2D6 x-ray structures, part of the N-terminus (till G31) was truncated to increase its 
solubility and facilitate the crystal growing process. Furthermore, residues 38-52, 145-147 
and 498-501 all located outside the active side, were missing in chain A. In our model the 
missing residues were filled in using Prime [37]. The iron-heme was modelled as Fe3+. This 
oxidation state corresponds with the active catalytic ferrous state [38]. The Schrodinger 
Protein Preparation Wizard was used for pre-processing of the x-ray structure [39]. Cofactors 
(5 molecules) that were within the binding pocket were replaced (at their oxygen atom 
positions) with water molecules: glycerol (replaced with 3 waters) and DMSO (replaced with 
2 waters). To optimize the geometry of residues P41 and G42 in the x-ray structure, an 
additional loop refinement for residues 31-58 was performed using Prime. The resulting 
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structure was minimized using a hybrid method of the steepest decent and the limited 
memory Broyden-Fletcher-Goldfarb-Shanno (LBFGS) algorithms with a convergence 
threshold of 0.3 kcal mol-1 Å-1. Subsequently, this structure was used for generation of all the 
CYP2D6 variants. After the applied mutations to the structure, each new protein structure 
was minimized again with the same parameter settings as for the wild-type.  
 
Ligands 
The ligand selection was based on several criteria: (i) classical CYP2D6 binder; (ii) if there was 
data available for the ligand from previous computational/experimental studies; (iii) clinical 
relevance (Figure 3.4). Bufuralol (b-blocker) and quinidine (antiarrhythmic drug) were 
selected as classical CYP2D6 substrate and inhibitor respectively. Next, substrates, 
tamoxifen (estrogen receptor antagonist) and veliparib (PARP inhibitor) were included, as 
any novel (polymorphism) information regarding their binding behaviour would be relevant 
from a clinical perspective and potentially contribute to the future of personalized 
medicine/anti-cancer drug development. In addition, for quinidine and prinomastat (matrix 
metalloproteinase inhibitor) a crystal structure is available which allows comparing of the 
dynamical and docking simulations with their observed native pose (Table S3.3) [40]. 
CYP2D6 metabolizes bufuralol into 1’-hydroxybufuralol [41], tamoxifen into 4-
hydroxyltamoxifen [42], and veliparib into a lactam containing metabolite [43]. Although 
quinidine contains the usual CYP2D6 substrate characteristics (basic nitrogen, and flat 
hydrophobic moiety) it is first metabolized into 3-hydroxy- and O-demethylated quinidine 
when Phe120 is mutated to alanine (or also by E216Q/D301Q) [1,44]. Therefore, the F120I 
mutation can be expected to allow quinidine to be metabolized. The sites of metabolism 
(SoMs) for studied ligands are indicated in Figure 3.4 and their distance to the heme in 
Supplementary Figure S3.5. As a note, the enzyme kinetics is a complex problematic where 
one needs to consider numerous possibilities on how a molecule can bind the enzyme. For 
example, the metabolite of a substrate can act as an inhibitor or, if a substrate has a slow off-
rate, one could argue, if it thereby also acts as inhibitor. However, these effects are outside 
of the scope of this study. A detailed discussion on enzyme binding, the associated terms 
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and kinetics can be found in  the literature [41,42]. The binding pose of the ligands 
tamoxifen, veliparib and bufuralol within the CYP2D6 pocket used for MD simulations was 
generated using our in-house docking software (DOLINA) [45]. The generation of the ligand 
poses is based on pharmacophore matching and allows for local induced-fit changes by 
combinatorial rearrangement of the binding site side chains. The highest ranked pose was 
selected as a start conformation for MD simulations. For both prinomastat and quinidine the 





Figure 3.4 Overview of the CYP2D6 ligands. Three substrates (tamoxifen, veliparib, and bufuralol) and 
two inhibitors (prinomastat and quinidine) were used in this study. The red asterisk indicates the primary 
site of metabolism (SoM, Figure S4), and the black asterisk a secondary SoM. Quinidine might be metabolized 
in CYP2D6*53, hence the known SoMs are indicated as well. 
 
Molecular Dynamics simulations 
Each prepared CYP2D6 variant was solvated using TIP3P water model in an orthorhombic 
box with 10.0 Å cut-offs from the protein in each dimension, and the net system charge was 
neutralized by adding counterions (sodium ions). The OPLS_2005 force field as implemented 
in Desmond (version 2016-4) was used [46]. The system was minimized using a steepest 
decent algorithm until a gradient threshold of 0.1 kcal mol-1 Å-1. The dimension of the box 
for each prepared CYP2D6 variant system (after minimization) were on average 86 x 82 x 87 
Å3. The production simulations with the total duration of 1.0 µs (NPT ensemble and standard 
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conditions T = 300 K, p = 101.325 kPa) and with frames sampled every 100 ps (in total 10 
000 frames were saved per simulation) were performed. The simulations were performed 
under NPT ensemble, and the Nose-Hoover thermostat at a relaxation time of 1.0 ps with 
the Martyna-Tobias-Klein barostat were combined with a relaxation time of 2.0 ps at 300 K. 
The Particle Mesh Ewald (PME) method was used to treat the long-range interactions, the 
cutoff for short-range interactions was set to 9 Å. Bonds to hydrogen atoms were constrained 
with the M-SHAKE algorithm and no hydrogen mass partitioning was applied. The two 
replica simulations were started with different initial velocities. On average one microsecond 
simulation took 10 days to finish (61195 atoms) on one GeForce GTX Titan GPU. 
 
 
Results and Discussion  
 
Overall fold and system equilibration 
The root mean square deviation (RMSD) measured over the whole trajectory (1 µs) shows 
that the wild-type (CYP2D6*1) and all other CYP2D6 variant simulations reached equilibrium 
at or below the RMSD of 6 Å from the starting structure (Figure 3.5). Figure S3.2 displays 
only the last 100 ns and Figure S3.3 an additional 400 ns of simulation time (1,4 µs simulation 
in total, only ran for the wild-type apo structure) confirming that all systems were properly 
equilibrated. In addition, two replica simulations were performed with the apo wild-type 
using different starting velocities to assure the integrity of the system (Table S3.4). The 
RMSD and RMSF values of the two replica were calculated and compared to the wild-type 
showing that the intrinsic properties of the system remained conserved in the replicas. Time 
to convergence varied between 20 ns ≤ t ≤ 250 ns. Fast convergence (t ≤ 50 ns) is observed 
for most of the wild-type simulations (wt_apo, wt_pri, wt_vel, wt_buf) as well as for CYP2D6*2 
(V2_a). The dynamic global and local fluctuations of CYP2D6*2 (mutations R296C and S486T) 
are expected to be similar to the wild-type as they share the same enzyme activity. All other 
apo CYP2D6 variants (V10_a, V17_a, V4_a and V53_a) needed longer time (100 ns ≤ t ≤ 250 
ns) before reaching equilibrium. This is likely related to the mutations applied, causing local 
structural instabilities requiring longer times to converge (equilibrate). In general, simulations 
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run with a ligand reached plateau in a short time (t ≤ 50 ns). Wild-type simulations run with 
quinidine (wt_qui) and tamoxifen (wt_tam) needed longer time (100 ns and 250 ns 
respectively) to reach equilibrium.  
From the apo state simulations, CYP2D6*53 showed the largest conformational change 
followed by CYP2D6*17, whereas CYP2D6*2, CYP2D6*10 and CYP2D6*4 resembled the 
dynamics of the wild-type. Furthermore, except for CYP2D6*53 with quinidine (V53_qui), the 
simulations including the inhibitors prinomastat and quinidine (wt_qui, wt_pri, V17_qui, 
V17_pri and V53_pri), and the substrate veliparib (wt_vel) led to a more consistent protein 
conformation (RMSD curves 1 Å to 2 Å bellow the wild-type apo). CYP2D6*53 with quinidine 
(V53_qui) shows more conformational transitions (higher RMSD values) compared to 
prinomastat (V53_pri). In the CYP2D6*17 simulations, the presence of both inhibitors 
(V17_qui, V17_pri) showed a similar conformational stability.  
 
Figure 3.5 Backbone root mean square deviation (RMSD) graphs for all CYP2D6 simulations. The wild-type 
simulation is shown black in all graphs. The convergence time varied between 20 ns ≤ t ≤ 250 ns. Compared 
to the wild-type apo simulations; low degree of fluctuation was observed for wild-type veliparib (wt_vel), 
quinidine (wt_qui), and prinomastat (wt_pri) and the most flexible variant was CYP2D6*53 apo (V53_a) followed 
by CYP2D6*17 apo (V17_a).  
 
For all apo simulations the start conformation and the most populated (representative) 





Figure 3.6 The CYP2D6 starting - and most representative conformation during MD simulations for 
CYP2D6*1 (wild-type) and the five variants. Structural elements relevant for defining a more open or closed 
conformation are the regions of the BC loop colored cyan, AB loop colored pink, and FG loop colored black. 
(Top) For all apo CYP2D6 variants, the surface of the start conformations is shown at the beginning (t = 0 µs) 
of the simulation. All CYP2D6 variants displayed a similar start conformation with an average distance of 13 Å 
between the FG loop region and AB loop region. (Bottom) For all apo CYP2D6 variants, the most populated 
conformation (obtained by the RMSD clustering) during the simulation are displayed, revealing a semi-closed 
fold compared to the start conformation. The surface (transparent) is overlaid with the cartoon representation 
of the selected regions. The alignment in the first image shows that the FG, BC and AB loops are at different 
positions in the most prevalent conformation for all the CYP2D6 variants.   
 
Overall RMSD values between the CYP2D6 variant apo start conformation and the most 
populated cluster conformation (cluster #1, occurrence > 60%) calculated for all CYP2D6 
variant simulations (backbone carbon atom alignment) varied between 2.2 Å and 3.3 Å. 
CYP2D6*17 featured the highest ∆RMSD (3.3 Å) whereas CYP2D6*17 with quinidine the 
lowest (2.2 Å) ∆RMSD was seen. Though the start conformations are very similar to each 
other (∆RMSD < 1.3 Å) the clustered conformations are locally more diverse and display a 
semi-closed fold (∆RMSD > 3.3 Å). The active site volume increased upon reaching 
equilibrium, mainly attributed to a rearrangement of the FG-, BC-, and AB- loops and the 
connecting helices (F, G, I A, and B) as determined in other studies as well (Table S3.2) [14]. 
Compared to the apo wild-type, CYP2D6*2, CYP2D6*10, CYP2D6*17 and CYP2D6*53 were 
found to display a more confined fold of the active site, whereas CYP2D6*4 showed a 
different arrangement mainly of the FG loop and AB loop (more towards the outside) leading 
to a less confined cavity (more open substrate access state) and a lower volume (8% decrease 
compared to wild-type apo). The volumes for the wild-type holo conformations varied largely 
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compared to the apo wild-type (from -11% to 26%) suggesting not all ligands possess equal 
capabilities to favorably engage with the active site and stabilize the protein structure upon 
binding. The F120I mutation in the active site of CYP2D6*53 contributed to larger observed 
volumes compared to all others (on average +35%).  
Protein structure dynamics (e.g. its folding and overall stability) is known to have an impact 
on its function [47]. The enzymatic catalysis of CYP2D6 can be indirectly influenced by the 
distribution of the charged residues at the solvent accessible surface (by for example 
influencing the overall stability of the protein or the ligand access or egress through long-
range electrostatics) and the non-polar solvent accessible surface (also known as buried 
solvent area, BSA). Therefore, the differences in solvent accessible surface area (SASA) 
(polar/apolar) and BSA were investigated for the wild-type and allelic variants to explore if 
there were any patterns observed that could be correlated with the altered activity of the 
variants (Table S3.2). The ratios within each variant between total surface area, SASA 
(polar/apolar) and BSA seemed to be consistent within the variants. In general, the SASA 
was found to vary between -2% and +5%, with one outlier: CYP2D6*53 apo had an increased 
SASA of 8% compared to the wild-type. An explanation for this larger value might be related 
to the fact that increased enzyme activity is also achieved by an enlargement of the access 
tunnel(s) connecting the surface with the active site. At the same time, the catalytic efficiency 
is retained by optimal alignment of the active site with reduced steric hindrance of F120I, 
allowing to offer larger active site volumes and a higher through-put of substrates compared 
to the wild-type. Within the apo variants, only CYP2D6*4 showed a remarkable decrease 
(13%). The BSA analysis of the holo conformations showed very large volume changes, 
varying between -38% (wt_tam) and +70% (V17_pri), which makes it difficult to assign any 
meaning to the observed BSA values other than that enzyme active site is very plastic and 
can accommodate various ligand shapes and adjust for an optimal interaction. However, 
considering the known differences among CYP families in charged surface areas which is 
linked to the binding of CPR, further studies focused on surface properties might prove 
valuable for deciphering enzyme activity and allostery [48–50].   
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Local flexibility differences  
To gain insight in the local structural differences among the CYP2D6 variant simulations, the 
root mean square fluctuation (RMSF) calculations were performed excluding first 250 ns of 
the overall trajectory, (the average determined equilibration time). The values were 
normalized and plotted by subtracting the wild-type simulation values from the CYP2D6 
variant simulation. Fluctuations around the N-terminus should be interpreted with caution, 
since this is the site where CYP2D6 is normally anchored to the membrane which would 
normally stabilize and reduce the local flexibility. Since the simulations are performed without 
the membrane, higher RMSF fluctuations are expected for this region.  
 
 
Figure 3.7 Root mean square fluctuation (RMSF) graphs for all CYP2D6 simulations, excluding the average 
equilibration time (first 250 ns). In the RMSF graphs, the curves were normalized by subtracting the wild-type 
RMSF values from the CYP2D6 variant simulation. The grey areas indicate the position of the loop regions. The 
Largest RMSF fluctuations were found at the B helix and around the loop regions, especially AB, FG, GH and 
KL loops.  
 
For the apo variant simulations (Figure 3.7, first row), all loop regions showed larger 
fluctuations compared to the wild-type, in particular AB, FG, GH and KL loops. In addition, 
CYP2D6*4, CYP2D6*17 and CYP2D6*53 displayed a larger peak (≥ 4 Å) at the b-2-1, b-2-2 
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(within the KL loop). CYP2D6*53 displayed the highest flexibility for the KL loop region (P430, 
E431 and A432). The position of the B helix fluctuated the most for all the CYP2D6 variants, 
which is likely too high due to the absence of the membrane normally surrounding and 
stabilizing this site.  
Similar flexibility patterns were found for the wild-type simulations ran with ligands (Figure 
3.7, second row). However, the ∆RMSF peaks were in general less intensive which suggests 
that the presence of a ligand leads to a more stable complex which is in agreement with 
other studies [12,15]. From all the wild-type holo simulations, quinindine (inhibitor, wt_qui) 
and veliparib (substrate, qui_vel) induced the largest ∆RMSF peaks (± 3 Å) around the FG 
and GF loop region, and only bufuralol (wt_buf) showed a pronounced peak (3 Å, D349) 
located at the J’ helix.  
The inhibitor CYP2D6 simulation series (Figure 3.7, third row) showed similar flexibility RMSF 
patterns and intensities compared to the wild-type holo simulations. CYP2D6*17 with 
quinidine (v17_qui) showed a peak close to the N-terminus side of the L-helix, as observed 
for wild-type with tamoxifen (wt_tam). In addition, CYP2D6*53 with quinidine displayed 
higher flexibility around the b 2-1, b 2-2 region (within the KL loop). Considering the 
important function of the FG- and BC loop in determining the fold and access towards the 
iron-heme, in-depth analysis for these two loops were performed separately (Figure S3.1) 
and are commented on bellow.  
 
Intra-molecular hydrogen bonding network analysis  
Hydrogen bonding analysis for the mutated amino acids was performed to deduce any 
significant structural changes that could affect the enzyme stability for the CYP2D6 variants 
compared to the wild-type (Table 3.3). Default Maestro hydrogen bonding criteria were 
applied (maximal distance from the hydrogen atom to the acceptor atom: 2.8 Å, minimum 
donor hydrogen bonding angle: 120°, and minimum acceptor Hydrogen bonding angle: 
90°). For each variant the hydrogen bonding partners of the mutated residues were identified 
and compared with the wild-type. The two SNPs found in CYP2D6*2 (R296C, S486T) showed 
no significant impact on the hydrogen bonding interactions.  
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Table 3.3 Hydrogen bonding network analysis of CYP2D6 variants, focus on mutated amino acids. 








CYP2D6*2 similar (R296C, S486T)  CYP2D6*10 decreased (P34S, S486T) 
wt R296 + 
D252 
65%  wt P34 + none  
  + 
A300 
71%      
CYP2D6*2 C296 + 
A300 
93%  CYP2D6*10 S34 + none  
wt S486 + V480 100%  wt S486 + V480 100% 
  + L484 29%    + L484 29% 
CYP2D6*2 T486 + V480 100%  CYP2D6*10 T486 + V480 100% 
       + I312 62% 
CYP2D6*4 none (P34S, L91R, H94R, S486T)  CYP2D6*17 decreased (T107I, R296C, S486T) 
wt P34 + none   wt T107 + N255 58% 
CYP2D6*4 S34 + G36 31%  CYP2D6*17 I107 + F122 86% 
  + W75 27%    + L110 38% 
wt L91 + R88 36%  wt R296 + D252 65% 
       + A300 71% 
CYP2D6*4 M91 +V87 74%  CYYP2D6*17 C296 + A300 83% 
wt H94 + G44 34%  wt S486 + V480 100% 
  + R440 72%    + L484 29% 
CYP2D6*4 R94 + A90  30%  CYP2D6*17 T486 + V480 100% 
  + E383 33%      
wt S486 + V480 100%      
  + L484 29%      
CYP2D6*4 T486 + V480 100%      
CYP2D6*53 increased (F120I, A122S)      
wt F120 + R101 92%      
  + 
D301 
100%      
CYP2D6*53 I120 + 
D301 
98%      
wt A122 + R441 100%      
CYP2D6*53 S122 + none       
 
 
The two major backbone – backbone (BB – BB) interactions observed most of the time (> 
70%) for the wild-type (Arg296 with Ala300 and Ser486 with Val480) were also observed for 
CYP2D6*2. Indeed, Cys296 with Ala300 and Thr486 with Val480 were also identified for 
CYP2D6*17 (R296C, S486T, T107I) the majority of the time (> 70%). Our observation is that 
the latter interaction facilitates in stabilization of the b-sheet (b 4-1, b 4-2). The wild-type 
hydrogen bonding interaction of Thr107 with Asn255 (G-helix, side-chain(SC)-SC, 58%) was 
altered for CYP2D6*17. The mutated Ile107, located at the BC loop, interacted most of the 
time with Phe112 (86%) and for a smaller time period with Leu110 (38%). This could be an 
indication that in this variant the BC loop is less flexible due to the extended hydrophobic 
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network compared to the wild-type and indirectly contributes to a more flexible FG loop due 
to the missing N255 bond (as supported by the FG – and BC loop RMSD analysis, see Figure 
S3.1). Based on this data, we propose that the substrate access through the closest tunnels 
(2c/2e) is hindered in this variant, which might translate to the decreased activity of the 
enzyme. Handa et al. performed similar analysis for wild-type and CYP2D6*17, though only 
over a 5 ns MD trajectory [17]. For the T107I mutation different hydrogen bonding 
interactions were observed for the wild-type (L110, G11, F112 and V104) and CYP2D6*17 
(G111 and F112). For the R296C mutation the wild-type interacted with D252 which is in 
agreement with our observation, though the A300 interaction is missing in both cases. S486T 
formed for both wild-type and CYP2D6*17 a hydrogen bond with V480 as seen in our 
simulations. The difference in results can be attributed to a rather short simulation time of 
the previous modeling study.   
The decreased activity of CYP2D6*10 (P34S, S486T) is mainly caused by the SNP P34S as 
explained in our SNP section. Though as in the wild-type no hydrogen bonding interactions 
were observed, it is known that this proline-rich motif (PPGP) is crucial for protein folding 
[26]. In addition, the hydrogen bonding results for this residue should be treated with caution 
since our simulations lack the membrane, which would normally stabilize the N-terminal part 
of the enzyme (including Pro34). This is also valid for the P34S mutation found in CYP2D6*4 
(P34S, L91M, H94R, S486T).  
An interesting observation for CYP2D6*4 was found for the SNP H94R located at the BC 
loop. Earlier studies indicate that a conserved arginine found in P450s is acting as a 
gatekeeper of the water tunnel; if interacting with the heme propionates, water molecules 
are prevented from accessing the active site from the surface [51,52]. Proper regulation of 
water molecules supply at the active site is crucial for efficient enzyme functioning. In 
CYP2D6 there are two conserved arginines (R440, R441). In the wild-type His94 interacts the 
majority of the time with Arg440 (72%, BB-SC), whereas the mutated Arg94 interacted with 
Glu383 and Ala90 for around 30% of the time. No compensating hydrogen bonding partners 
were identified for Arg440 in this variant, meaning the side-chain is free to move around and 
might thereby interfere with the normal functioning of this water channel. Another MD 
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simulation study of 250 ns duration suggested that the hydrogen bonding interactions of the 
protein with the heme also largely contribute to proper embedding of the heme group within 
the enzyme [12]. The loss of interactions between the heme and the enzyme (including 
Arg441) likely worsens the heme recognition and incorporation which in turn might lead to no 
enzyme activity as observed by experiment for CYP2D6*62 [53]. However, analysis of Arg441 
of both wild-type and CYP2D6*4 showed similar hydrogen bonding interaction profiles (with 
V119, A122, and the heme porphyrin ring of the heme, > 60%). In addition, no weakened 
interactions between the heme and the protein were found for CYP2D6*4 and the wild-type. 
Therefore, we suggest that the absence of activity for this variant could be related to both (i) 
the the disruption of the proline rich motif by the SNP P34S preventing optimal enzyme 
folding and interaction with the membrane, and in addition (ii) the SNP H94R might decrease 
efficient regulation of the water tunnel by its large positively charged side-chain in such a 
way hat it decreases enzyme activity. 
For the SNP A122S in CYP2D6*53 (F120I, A122S) the Ala122 interaction with Arg441 found in 
the wild-type (100%) was lacking for Ser122. No compensating protein hydrogen bonding 
interactions were identified for Arg441. Phe120 interacted with Asp301 and Arg101 in the wild-
type (> 92%). Though the latter was lacking for Ile120, the more important interaction with 
Asp301, known to be essential for the specificity of CYP2D6, was maintained [54]. RMSD 
analysis of the BC loop showed a 1.5 Å increase in flexibility on average for the BC loop 
compared to the wild-type (Figure S3.1). We would therefore propose that the increase in 
enzyme activity for CYP2D6*53 is potentially related to the loss of the otherwise BC-loop-
stabilizing hydrogen bonding interactions observed in the wild-type.  
 
CYP2D6 Ligand Analysis  
RMSD calculations were performed for each ligand with the starting coordinates being used 
as the reference. Most stable dynamics were found for the wild-type with veliparib, quinidine 
and bufuralol (wt_vel, wt_qui, wt_buf) (Figure S3.4). Prinomastat showed the lowest stability 
among all wild-type holo simulations. Comparison of variants CYP2D6*17 and CYP2D6*53 
revealed that the latter induced the largest change from the initial conformation (V53_pri, 
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V53_qui). The spike for prinomastat in CYP2D6*53 around 0.3 µs is due to a shift of the 
pyridyl ring, which later on is followed by a movement (after 0.5 µs) of the inhibitor closer 
towards the heme (6 Å). In the wild-type and CYP2D6*17 this displacement of prinomastat 
did not occur. Instead, during the whole simulation time it remained close to the initial pose 
with small fluctuations of the pyridyl ring. Despite the reduced steric hindrance by the F120I 
substitution, quinidine was not found to move closer towards the heme during simulation 
with CYP2D6*53. In all three simulations (wt_qui, V53_qui, V17_qui) it kept its position 
constant. In the following sections, the functional groups or atoms described in the 
parenthesis always refer to the ligand.  
 
Prinomastat 
The time-averaged binding mode of prinomastat (inhibitor) in a similar binding mode as 
observed in the x-ray structure for the wild-type, CYP2D6*17 (3.6 Å) and CYP2D6*53 (Figure 
3.8, A-C). Dominant hydrogen bonding interactions with D301 (hydroxyl group of the 
hydroxamic acid), E216 and Q244 (with one of the sulfonyl oxygens) were most of the time 
(> 70%) present in all three cases (wt_pri, V17_pri, V53_pri). Other hydrogen bonding 
interactions observed for the wild-type for a shorter period of time (25%-50%) included 
G212, S217, I369, and A482. For CYP2D6*17 and CYP2D6*53 an additional hydrogen 
bonding interaction was observed with R221 (with oxygen of the hydroxamic acid). During 
the simulation, the pyridyl nitrogen which is known to be coordinated towards the heme iron 
for its inhibitor effect [55], was found more often for CYP2D6*17 and CYP2D6*53 in close 
vicinity (6 Å or 7 Å on average) of the heme than for the wild-type (11 Å on average). 
Stabilizing hydrophobic interactions included L110, F112, F120, L213, F247, A300, V308, 
F483, and L484 observed during all three simulations.  
 
Quinidine 
The quinuclidine moiety of quinidine was pointing in all three cases (wt, V17, V53) towards 
the heme and the quinolone ring into the direction of the F- and G helices (Figure 3.8, D-
F). Hydrogen bonding interactions were observed in all three cases with E216 (with the 
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protonated nitrogen of the quinuclidine moiety and the hydroxyl hydrogen), Q244 (with the 
hydroxyl oxygen and the ether oxygen), S304 (with the protonated nitrogen of the 
quinuclidine moiety) and G212 (with the hydrogen of the hydroxyl group). Only for the wild-
type and CYP2D6*17 a hydrogen bonding interaction was observed between D301 and the 
protonated nitrogen. Hydrophobic ligand protein contacts were observed for all three cases 
with I106, L110, F112, F12, L121, L213, F247, L248, I297, A300, V308, and F483. The SNP 
F120I did not force the SoM of quinidine to move closer to the heme in order to form the 3-
hydroxyquinidine metabolite as known for the F120A mutation (Figures 3.8F and S3.5) [44]. 
Substitution of Phe120 with Ile120 is likely to form a similar steric hindrance energy barrier 
considering the similarity in size and hydrophobicity of the two.  
 
Bufuralol, tamoxifen and veliparib 
The three substrate wild-type simulations all pointed the SoM in direction of the heme during 
the whole simulation time (Figure 3.8, G-I). Bufuralol and tamoxifen had an average SoM to 
heme distance of 6.0 Å and 4.4 Å respectively, whereas veliparib was kept more distant (10.4 
Å) (Figure S3.5). Hydrogen bonds between E216 (protonated nitrogen and the hydrogen of 
the hydroxyl group) and between the oxygen of the hydroxyl group and Q244, D301 and 
S304 were observed for bufuralol.  
For tamoxifen only two hydrogen bonds were observed: D301 (protonated nitrogen) and 
S304 (with the oxygen). Veliparib formed hydrogen bonds with G212 (hydrogens of the 
amine group near the oxygen), E216 (hydrogens of the protonated nitrogen), R221 (nitrogen 
of the imidazole), Q244 (hydrogen of the amine group near the oxygen), D301 (hydrogens 
of the protonated nitrogen) S304 and E215 (both with the hydrogens of the nitrogen in the 
imidazole). Furthermore, L110, F112, F120, L121, L213, F247, A305, V308, and F483 were 






Figure 3.8 Dominant ligand conformations during 1 µs MD simulation. (A-C) Prinomastat (inhibitor) binding 
mode is displayed for wild-type (A), CYP2D6*17 (B) and CYP2D6*53 (C). (D-F) quinidine (inhibitor) binding 
mode is displayed for wild-type (D), CYP2D6*17 (E) and CYP2D6*53 (F). (G-I) The wild-type binding mode is 
shown for the substrates bufuralol (G), tamoxifen (H) and veliparib (I).  
 
Crystal structure comparison 
To assess the dynamic behaviour of six key active site residues (F120, E216, Q244, D301, 
S304 and F483) in the presence of different ligands and among the different variants, the 
most prevalent conformation was aligned with the x-ray structure (PDB ids: 4WNU or 3QM4) 
(Figure S3.5).  
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The side-chain of F120 and S304 did show variation in the torsion angles. A reversed 
positioning of the S304 side chain was observed compared to the x-ray structure for 5 of the 
15 conformations (wt_apo, V17_apo, wt_pri, wt_tam, V53_qui). E216 showed a small 
displacement in most conformations. Largest displacements among all conformations were 
found for F483 and Q244. Both residues are located at more flexible regions of the CYP2D6. 
As previous research indicated, F483 (located at the b 4-2 sheet and SRS 6) is known to fulfil 
an important role in the binding of the ligand, and also to be close to the solvent channel 
[10,15,56]. Experiment showed that the F483I mutant was able to metabolize testosterone, 
whereas wild-type was not [56]. Prinomastat (wt_pri, V53_pri) and veliparib (wt_vel) both 
show F483 to be moved further away compared to the x-ray position. These two ligands are 
considerably large and contain several bulky groups. We propose that the binding 
energetics (unfavourable interactions) will induce F483 to move away and the ligand size will 
have a determining role in the location of F483 within the active site. The flexibility and 
displacement of Q244 (located at the FG loop or extended G helix and SRS 3) is coupled to 
the flexibility of the FG loop. For instances, the wild-type simulation with bufuralol and 
prinomastat showed overall a more stable behaviour of the enzyme with no extreme 
fluctuations of the FG loop (Figure 3.7), which is reflected in the similar position compared 
to the x-ray structure. On the other hand, the wild-type with veliparib showed larger 
fluctuations of the FG loop which in turn led to larger displacement of Q244.   
 
Conclusion  
This long time-scale (1 microsecond) MD simulation study confirmed earlier observed 
CYP2D6 dynamics and provided additional insights on the structure-function relationship of 
the enzyme. The wild-type MD simulations showed a stabilizing effect of the ligand on the 
structure. The folding of primarily the FG loop and secondary the AB- and BC loop around 
the active site is reshaped upon the ligand binding, which contributed also to the larger 
identified volumes and a more closed (semi-closed) state. Differences in flexibility and 
arrangement of the key residues lining the active site, together with the intra- and 
intermolecular forces among the variants with changed enzymatic activity, suggest the need 
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for a precise positioning of these factors to control optimal proceeding of the catalytic 
reaction, which is tightly coupled to the kinetics of the enzyme. The location (e.g. at the 
active site, or SRS) and type (conservation) of amino acid mutation appears to be relevant 
for maintaining a functional structural fold as well as for the regulation mechanisms (e.g. 
hydrogen binding network) the enzyme employs to steer the binding of ligands and 
cofactors. Hence, simulating the enzyme dynamics on a long time scale in the presence of 
explicit solvent is important for a proper understanding of the activity of the enzyme under 
various conditions (e.g. substrate, inhibitor, polymorphs, etc.). Such mechanistic information 
is of particular relevance for the drug development process as it can be directly utilized within 
the design of drugs in order to rationally avoid or at least limit the cytochrome liability. The 
observed differences among wild-type and clinically relevant allelic variants justify the need 
of their detailed screening using in silico approaches based on docking and MD simulations. 
In addition, considering the importance of the thermodynamics of the catalytic reaction, 
additional polymorphism studies focused on determining the free-energy barrier changes 
would be valuable to improve the link between differences in observed dynamical behaviour 
and enzyme activity. Undoubtedly, an important limitation of this study is the missing anchor 
part. Since CYP2D6 is anchored to the membrane at the N-terminus site, we expect less 
fluctuations and possibly slightly altered arrangement of the domains in the close vicinity of 
the membrane bilayer. We assume that this could have impact also on the tunnel structure 
and function. Therefore, we aim at performing additional CYP2D6 studies with protein 
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Table S3.1 Overview of amino acid property change by each mutation 
CYP2D6 






1. P34S nonpolar to 
polar 
√ hydrophobic to hydrophilic √ neutral to 
neutral 
-- 
2. L91M nonpolar to 
nonpolar 
x hydrophobic to hydrophobic x neutral to 
neutral  
- 
3. H94R neutral/basic 
polar to basic 
polar 
x hydrophilic to hydrophilic x neutral to 
positive 
none 
4. T107I polar to neutral 
nonpolar 
√ hydrophilic to hydrophobic √ neutral to 
neutral 
++ 
5. F120I nonpolar to 
nonpolar 
x hydrophobic to hydrophobic x neutral to 
neutral 
+ 
6. A122S nonpolar to 
polar 
√ hydrophobic to hydrophilic √ neutral to 
neutral 
- 
7. R296C basic polar to 
nonpolar 
√ hydrophilic to hydrophilic x positive to 
neutral 
++ 






Table S3.2 MD simulations parameter calculations for all CYP2D6 variants. The Solvent Accessible Surface 
Area (SASA) (FreeSASA v2.0.2), buried solvent area (PISA webserver) and overall volume (POVME v2.0) 





































wt_a 22195 93.8 9494 40.1 12701 53.7 1463 6.2 635 na 2.2 
V2_a 21862 93.9 9248 39.7 12614 54.2 1408 6.1 716 na 2.6 
V10_a 22283 93.7 9588 40.3 12694 53.4 1487 6.3 797 na 1.9 
V17_a 22603 93.7 9783 40.6 12819 53.1 1522 6.3 663 na 2.8 
V4_a 22072 94.6 9333 40.0 12738 54.6 1271 5.4 582 na 2.2 
V53_a 24022 94.2 10132 39.7 13890 54.5 1471 5.8 836 na 2.8 
wt_tam 22477 96.1 9274 39.7 13203 56.5 902 3.9 734 4.4 2.4 
wt_vel 22398 94.0 9134 38.3 13264 55.7 1427 6.0 567 10.4 2.3 
wt_buf 23246 94.6 10025 40.8 13221 53.8 1319 5.4 707 6 1.8 
wt_pri 21745 90.3 8998 37.3 12748 52.9 2348 9.7 671 14 2.6 
V17_pri 22779 90.1 9385 37.1 13394 53.0 2496 9.9 790 7 1.8 
V53_pri 22584 90.2 9651 38.6 12933 51.7 2440 9.8 905 6 2.8 
wt_qui 22579 91.5 9450 38.3 13128 53.2 2088 8.5 801 6 2.6 
V17_qui 22018 90.5 9324 38.3 12694 52.2 2300 9.5 721 11.2 1.8 
V53_qui 22600 91.3 9348 37.7 13252 53.5 2163 8.7 892 10.8 2.4 
4wnu (qui) 20373 89.0 8612 37.6 11761 51.4 2509 11.0 856 na na 
2f9q (apo) 20762 86.0 8885 36.8 11878 49.2 3369 14.0 814 na 0.6 







Table S3.3 Overview ligand properties1  
 
Ligand PSA (Å2) 
LogP LogS HDon HAcc #Bondrotatable Molar volume 
(cm3) 
tamoxifen 12.5 7.1 -5.6 0 2 8 356 
veliparib 83.8 1.1 -3.0 3 3 2 192 
bufuralol 45.4 3.2 -3.9 2 3 5 245 
prinomastat 112.3 1.7 -4 2 6 4 307 
quinidine 45.6 2.8 -3.0 1 4 4 266 










SD Mean RMSF 
(Å) 
SD 
wt_a 5.4 0.6 1.53 1.19 
wt_a_R1 5.6 0.6 1.59 1.21 










Figure S3.1 Box-and-whisker plots for the BC and FG loops calculated over the whole trajectory for all 
CYP2D6 variants. The distribution of the data points: the pink boxes indicate the upper - and lower quartile 
(25% of the data is greater than or less than this value), the caps indicate the greatest and the smallest value 
excluding outliners. The outliners represent more than or less than 3/2 times the upper or lower quartile, and 






Figure S3.2 Backbone root mean square deviation (RMSD) graphs for all CYP2D6 simulations – last 100 
ns. The wild-type simulation is shown black in all graphs. The RMSD graphs of the last 100 ns that confirm that 






Figure S3.3 Backbone root mean square deviation (RMSD) graph for the apo CYP2D6 wild-type calculated 
over 1.4 µs. The additional 400 ns simulation ran for the wild-type simulation (black) confirms that the 




Figure S3.4 RMSD calculated over 1.0 µs for the holo CYP2D6 variants (A) and SoM-heme distance (B). (A, 
top) RMSD curves for the wild-type CYP2D6 simulations with quinidine (wt_qui, black), prinomastat (wt_pri, 
red), tamoxifen (wt_tam, yellow), veliparib (wt_vel, teal), and bufuralol (wt_buf, indigo). (A, center) RMSD curves 
for prinomastat with wild-type (wt_pri, black), CYP2D6*17 (v17_pri, red), and CYP2D6*53 (v53_pri, black). (A, 
bottom) RMSD curves for quinidine with wild-type (wt_qui, black), CYP2D6*17 (v17_qui, red), and CYP2D6*53 
(v53_qui, blue). For the wild-type, prinomastat (inhibitor) demonstrates the highest flexibility, whereas veliparib 
(substrate) and quinidine (inhibitor) the lowest. The CYP2D6*53 variant with increased enzyme activity shows 
increased flexibility (±2Å) for both prinomastat and quinidine compared to the wild-type. (B, top) Distances 
between the heme and the site of metabolism (measured as nearest carbon atom) of quinidine with with wild-
type (wt_qui_S1, black, wt_qui_S2, grey), CYP2D6*17 S1 (V17_qui_S1, red, V17_qui_S2, pink), and CYP2D6*53 
S1 (V53_qui_S1, blue, V53_qui_S2, cyan). (B, bottom) Site of metabolism shown for wild-type with bufuralol 








Figure S3.5 Key residues (E216, D301, F120, F483, S304 and Q244) located in the active site of each 
CYP2D6 most prevalent conformation compared to the x-ray structures (ligands are left out for clarity).  
The active site is shown for the most prevalent conformation in cyan, and the x-ray structure in white (A-C: 
3QM4, D-I: 4WNU). (A-C) Prinomastat (inhibitor) with wild-type (wt) (A), CYP2D6*17 (V17) (B) and CYP2D6*53 
(V53) (C), (D-F) Quinidine (inhibitor) with wild-type (wt) (D), CYP2D6*17 (V17) (E) and CYP2D6*53 (V53) (F), (G-









































Molecular dynamics simulations reveal structural 
differences between allelic variants of membrane-
anchored cytochrome P450 2D6 
 
 
                               Based on the article: 
 
Molecular dynamics simulations reveal structural differences between allelic variants 
of membrane-anchored cytochrome P450 2D6 
 
 
André Fischer, Charleen G. Don & Martin Smieško. 
 
J. Chem. Inf. Model.20185891962-1975 
  
Chapter  




Cytochrome P450 2D6 (CYP2D6) is an enzyme that is involved in the metabolism of roughly 
25% of all marketed drugs and therefore belongs to the most important enzymes in drug 
metabolism. CYP2D6 features a high degree of genetic polymorphism that can significantly 
alter the individual metabolic activity. This can either lead to abolishment of the therapeutic 
effect of a drug or to enhanced plasma levels potentially causing adverse effects. In this 
study, starting from the crystal structure, we built a full-length membrane-anchored model 
of wild-type CYP2D6 as well as five variants with different enzymatic activity. We validated 
our models with available experimental data and compared their structural properties. The 
main focus of this study was to identify differences that could mechanistically explain the 
altered activity of the variants and improve our understanding of their functionality. We 
observed differences in the opening frequencies and minimal diameters of tunnels that 
connect the buried active site to the surrounding solvent environment. The variants 
CYP2D6*4 and CYP2D6*10 associated with missing or decreased activity showed lower 
opening frequencies of the tunnels compared to the wild-type. Furthermore, the altered fold 
in the N-terminal anchor region and the decreased volume of the active site cavity of 
CYP2D6*4 offer an explanation for the absence of metabolic activity. On the other hand, the 
mutations in CYP2D6*53 contributed to a significant enlargement of an important ligand 
tunnel and an extension of the active site cavity. This could explain the altered metabolic 
profile of this particular variant. 
 
Introduction 
The clearance of many orally administered drugs is largely influenced by the metabolic 
capacity of the individual [1]. A variability of drug metabolism among individuals can lead to 
a change in the plasma concentration which could either obliterate the effect of the drug or 
potentially lead to adverse effects. Cytochrome P450 2D6 (CYP2D6) metabolizes around 
25% of all marketed drugs and therefore belongs to the most important enzymes involved 
in the phase I biotransformation [2]. Besides that, CYP2D6 is of interest to the field of enzyme 
engineering, where its site-directed mutagenesis resulted in a significantly increased 
127  
metabolic rate for several substrates promising, optimized enzymatic production of 
designated metabolite [3]. A special hallmark of CYP2D6 among cytochromes (CYPS) 
involved in drug metabolism is that its function can be altered due to genetic polymorphism 
leading to substantial interindividual differences in metabolism.  
Four general phenotypes are known for CYP2D6: poor metabolizer (PM), intermediate 
metabolizer (IM), normal metabolizer (NM), and ultrarapid metabolizer (UM) [4]. These 
phenotypes arise from point mutations, single base-pair deletions or additions, gene 
rearrangements, gene duplications, and gene deletions [2,5]. 
The impact of the amino acid mutations within allelic variants on the structure and function 
of the enzyme is not clearly understood. Overlapping amino acid mutations among the four 
phenotype categories increase the complexity of correlating structural particularities with 
enzyme activity. Examples for such allelic variants are CYP2D6*2, CYP2D6*4, CYP2D6*10, 
CYP2D6*17, and CYP2D6*53 (Table 4.1). The positions of amino acid mutations present in 





Figure 4.1 Structural overview of CYP2D6. The position of amino acid mutations, that CYP2D6 is prone to, 
are shown on its structure. Secondary structural elements of importance are indicated by different colors. 
We used the wild-type enzyme to compute the figure. 
 
CYP2D6*2 is an allelic variant that shows a comparable activity to the wild-type suggesting 
a neglectable influence on the enzyme structure. The comparable activity results in the 
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declaration as NM phenotype, while CYP2D6*10 and CYP2D6*17 with decreased activity fall 
into the IM phenotype [6,7]. CYP2D6*10 harbors the P34S amino acid mutation causing the 
disruption of a conserved proline-rich segment near the N-terminus [6,8]. It is the most 
prevalent allele in the Asian population with frequencies up to 50% depending on the region, 
whereas CYP2D6*17 is more prevalent in Africans. The T107I mutation in CYP2D6*17 might 
lead to an altered active site structure [2]. CYP2D6*4 belongs to the most important alleles 
causing PM phenotype in Caucasians and also exhibits the P34S mutation [6]. Even though 
the absence of metabolic activity is believed to arise from effects on the level of RNA splicing 
three out of four amino acid mutations in this variant were shown to be degrading enzymatic 
activity independent of effects on the level of protein biosynthesis [9]. Furthermore, the four 
amino acid mutations also occur in other variants such as CYP2D6*74 and CYP2D6*82 
[10,11]. CYP2D6*53 features the F120I mutation located directly in the active site, which is 
suspected to change the regiospecificity of metabolic reactions. Further on, CYP2D6*53 
shows increased metabolic rates depending on the substrate suggesting a possible UM 
phenotype [6,12].  
 
Table 4.1 Overview on the allelic variants studied. For each variant, the amino acid mutations and their 
impact on the enzymatic activity are displayed. 
Variant amino acid mutations[A] enzyme activity [A] 
CYP2D6 WT none normal 
CYP2D6*2 R296C, S486T normal 
CYP2D6*4 P34S, L91M, H94R, S486T none 
CYP2D6*10 P34S, S486T decreased 
CYP2D6*17 T107I, R296C, S486T decreased 
CYP2D6*53 F120I, A122S increased 
 
  
[A] This data is accessible on www.pharmvar.org (accessed on January 31, 2018). 
 
Along with polymorphism studies, CPY2D6 also started attracting attention of the molecular 
modeling research community [13]. This can be partly attributed to the increasing number 
of crystal structures of human CYP2D6 solved in the past decade [14-18]. However, available 
structures lack at least 30 N-terminal residues. The reason for this lies in the crystallization 
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procedure. The N-terminal truncation is required to increase enzyme solubility, because this 
α-helical segment anchors the enzyme to the membrane of the endoplasmic reticulum 
[14,19,20]. As the active site of CYP2D6 is buried in a cavity inside the core of the enzyme, 
it is suggested that tunnels leading to the active site actually govern the kinetics and 
specificity of the enzyme. This makes them a suitable target for selective modifications 
aiming on modifying either of these properties [21]. Since most drugs are rather lipophilic in 
nature and microsomal CYPs are membrane-anchored, an established theory exists that 
ligands might access the enzyme from the membrane [22-24]. Additionally, the structural 
motifs lining various tunnels are known to be in contact with the membrane and have been 
shown to modify the diversity of enzyme tunnels [20]. This highlights the need of 
investigating the access and egress pathways in the presence of a membrane as its natural 
environment. Since enzyme tunnels are influenced by the dynamic nature of the protein, it 
is crucial not only to investigate a single structure but also to use a time-evolved ensemble 
of structures representing the dynamic motion of the protein. This motion then translates 
into the opening or closing of tunnels that cannot be observed in a static crystal structure 
[21,25]. Molecular Dynamics (MD) simulations are a suitable and widely employed 
computational technique to produce such dynamic ensembles [25-27]. Furthermore, the 
growing number of CYP2D6 alleles being discovered, already exceeding 100, urges for more 
practical methods to support experiments with atomistic details. The activity of CYPs is 
further influenced by their electron donor Cytochrome P450 oxidoreductase (POR). The 
electrons are needed in order to perform the wide spectrum of oxidative reactions [28]. The 
interaction of the POR with CYPs is also suspected to influence the opening of enzyme 
tunnels [29]. The residues of the POR binding site were experimentally determined for 
CYP2B4 [30]. 
Until today, membrane-bound models for CYP1A2, CYP2A6, CYP2C9, CYP2D6, CYP2E1, 
CYP2U1, and CYP3A4 have been published [20,22-24,31,32]. These models were built and 
refined by the use of molecular dynamics (MD) simulations and membrane positioning 
protocols. In this context, most groups employed simplified coarse-grained or united-atom 
MD simulations to equilibrate the position of the enzyme in the membrane. However, those 
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models are not available to the public making it impossible to perform additional 
computational studies. Results from other CYPs cannot be expected to be directly applicable 
to CYP2D6 since CYPs greatly vary in substrate specificity despite having a similar fold. 
Moreover, neither of these studies focused on effects caused by genetic polymorphism 
related to CYP2D6. For instance, it was shown for CYP2C9 that the superficial entry points 
of presumed access tunnels agree with the energetically favored position of ibuprofen in the 
membrane [24]. Other groups showed that tunnels in CYP2U1 as well as CYP3A4 point 
toward the membrane and suggested the uptake of lipophilic substrates from the 
membrane-enzyme interface [23,31]. De Waal et al. proposed that some changes in the 
enzymatic activity of CYP2D6 can be explained by the accessibility of the active site for 
ligands [12]. In their study, they compared the tunnel opening and protein flexibility of the 
variants CYP2D6*17 and CYP2D6*53 in the absence of a membrane. They observed different 
degrees of tunnel opening between the analysed variants and differences in the local protein 
flexibility that might be related to the enzymatic activity. 
In this study, we created a membrane-bound model of wild-type human CYP2D6 and the 
five allelic variants CYP2D6*2, CYP2D6*4, CYP2D6*10, CYP2D6*17, and CYP2D6*53. We 
investigated the enzyme tunnels together with other structural properties with the help of 
all-atom MD simulations in a cumulative length of 5.7 μs in order to find differences that 
could explain the altered activity of the variants. Furthermore, we analyzed the water access 
to the active site and the possibility of the POR binding to the wild-type model. Our findings 
revealed diverse dynamic behavior among the allelic variants. Most remarkably, the 
CYP2D6*53 variant showed an increased active site volume and an enlargement of turns 2b, 
which is an important ligand tunnel, that we suspect to be caused by the F120I mutation. 
This supports its pending designation as a cause for the UM phenotype. To our best 
knowledge, this is the first study to explore enzyme tunnels combined with structural 
hallmarks in the presence of a membrane. The uncovered structural features related to ligand 
tunnels, the role of individual residues, and the fold of the protein help to better understand 
the function of this particular CYP and five of its most important variants. Our insights 
regarding the cause of substrate-dependent activity between the allelic variants may 
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contribute to optimize processes in the field of enzyme engineering. Furthermore, the 
differences between the variants may be of value for the personalized drug therapy field.  
 
Methods 
Model Building and Description. Figure 4.2 schematically depicts the procedure of model 
building. We retrieved the structure of human CYP2D6 from the Protein Data Bank (PDB ID: 
3TDA) [18] and processed it using the Protein Preparation Wizard within the Maestro Small-
Molecule Drug Discovery Suite (v.2017-2) [33]. We added hydrogen atoms, assigned bond 
orders, and kept the crystallographic water molecules. The two zinc ions were replaced with 
one water molecule each. Since the N-terminal residues 31−33 were engineered for 
crystallization purposes, we reconstructed this short sequence to match the wild-type 
enzyme using the 3D Builder in Maestro. The sequence of the wild-type CYP2D6 was 
retrieved from UniProt [34]. After that, we refined the hydrogen-bonding network and 
performed a heavy atom-restrained minimization with the OPLS_2005 force field which is 
recommended to be used [33] and was previously employed for CYP2D6 [35]. The initial 
positioning of the structure in the membrane was predicted using the Orientations of 
Proteins in Membranes (OPM) Web-based protocol called PPM server [36]. The PPM server 
accepts a structure in PDB format as input and generates a new file with pseudoatoms that 
describe the membrane position taking into consideration energetic contributions. The 
structure was then embedded in a 1-palmitoyl-2-oleoylphosphatidylcholine (POPC) 
membrane using the Desmond system builder. We used the Desmond (v.2016-4) simulation 
package from Schrödinger for MD with the OPLS_2005 force field in an NPT ensemble. In 
this context, we combined the Nose-Hoover thermostat at a relaxation time of 1.0 ps with 
the Martyna-Tobias-Klein barostat with a relaxation time of 2.0 ps at 300 K. Prior to the 
simulation stage we applied the default Desmond relaxation protocol consisting of seven 
stages (Table S4.1). 
Long-range interactions were treated with the Particle Mesh Ewald (PME) method, while the 
cutoff for short-range interactions was set to 9 Å.  Bonds to hydrogen atoms were 
constrained with the M-SHAKE algorithm, and no hydrogen mass partitioning was applied. 
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We chose the TIP3P water model to solvate the orthorhombic boxes of the periodic 
boundary systems throughout this study [37]. With the resulting system, we performed a 100 
ns MD simulation to equilibrate the position of the enzyme in the membrane. This simulation 
will be referred to as MemAs from hereafter. We built the missing transmembrane helix from 
Met1 to Ala30 according to the wild-type sequence using the 3-dimensional (3D) Builder in 
Maestro which allows to generate a segment with a predefined topology.  
As a preparation for the positioning of the membrane on the helix, we applied the Web-
based protocols TMHMM (v2.0) AmphipaSeek [38], and TMSEG to get an estimate of the 
membrane-bound residues in CYP2D6 based on its sequence. The three mentioned 
methods accept a protein sequence in FASTA format as input and deliver a residue-based 
readout. TMHMM predicts residues that are part of transmembrane helices based on a 
Markov Model and incorporates hydrophobicity, helix length, and charge bias into the 
prediction [38]. AmphipaSeek is a method that predicts amphipathic in-plane membrane 
anchors of monotopic membrane proteins based on pattern recognition [39]. We chose this 
method to get an alternative prediction in contrast to the other methods that do not 
specifically predict in-plane anchors. Protein Predict Open provides the TMSEG method 
predicting trans- membrane helices in a segment-based neural network approach [40]. The 
minimal amount of residues to place a POPC membrane on a peptide in Desmond is 20. We 
therefore used Gly2 and Met23 as border residues for the membrane placement considering 
the results of the Web-based protocols shown in Table S4.2. After embedding the α-helix, 
we performed a 200 ns MD with the resulting system referred to as AnchorSim hereafter. 
The products of both simulations were combined by connecting the catalytic domain and 
the transmembrane anchor with a covalent bond. Furthermore, we removed the ligand from 
the catalytic domain. After minimization, the resulting system was again equilibrated for 200 
ns by MD with frames being collected every 200 ps. As a control, we performed multiple 
simulations similar to AnchorSim and MemAs differing in the positioning of the membrane 
on the respective structures. Likewise, we designed three more systems consisting of the 
anchor linked to the catalytic domain. For these simulations, the structures with different 
orientations of the anchor were extracted from the trajectory and linked to the catalytic 
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domain. These exploratory simulations varied in duration. For all control simulations, we 
calculated several parameters for comparison including the location of two residues in 




Figure 4.2. Flowchart of the model building procedure. (A) The catalytic domain was placed in POPC 
based on OPM prediction and equilibrated. (B) The helix was embedded in POPC and equilibrated. (C) 




Production runs. For further analysis, we continued the simulation of the previously derived 
system of wild-type membrane-anchored CYP2D6 from 200 to 300 ns leading to the system 
referred to as CYP2D6 WT. We also prepared two structures for simulations without 
membrane. One structure was simulated for 300 ns with the inhibitor prinomastat bound 
(referred to as WT inhibitor) and the other one without inhibitor respectively (referred to as 
WT nolig). Further on, we introduced polymorphism-related amino acid mutations to the 
merged system of the wild-type simulation before it was equilibrated. We focused on the 
five alleles CYP2D6*2, CYP2D6*4, CYP2D6*10, CYP2D6*17, and CYP2D6*53. We  obtained  
the  necessary data  about  the variants from the Pharmacogenetics Variation Consortium 
(http://www.pharmvar.org) [41]. With the resulting five systems, we performed another 200 
ns equilibration run followed by a 100 ns production phase. For these simulations, we 
retained the same settings that we previously used for the CYP2D6 WT system. The 
mutations related to the allelic variants are shown in Table 4.1. The time step for saving 
frames in all the stated production simulations was 200 ps. To assess the significance of our 
results, we performed 12 replica simulations with a duration of 100 ns each. We started two 
simulations per system (wild-type and five variants) from two structures that were extracted 
with the trajectory_extract_frame.py script provided by Schrodinger. In this context, we 
selected a structure five frames before and five frames after each production simulation as 
starting point meaning the structures were pre-equilibrated. For MD, we used the same 
parameters as for the production simulations stated above. To assess the convergence of 
the simulations regarding structure, we used the trajectory_average_structure.py script also 
provided by Schrodinger to generate an average structure of the respective 100 ns 
simulations. Using the 3D Builder in Maestro, we then removed the membrane as well as the 
31 initial residues corresponding to the flexible membrane anchor. Finally, we employed the 
superposition protocol in Maestro to calculate the RMSD (root-mean-square deviation) 
difference between the average structures from the simulations. We compared the replicas 
of each variant among themselves and then compared each replica to the production 
simulation that was included in the analysis. The resulting RMSD differences were 
summarized in a table, and averages for each variant were calculated. 
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Model validation. As previously We validated the CYP2D6 WT model using experimental 
data as well as data from previously published models of CYP2D6, CYP2C9, and CYP2U1 
[20, 23, 24, 31, 42-46]. The heme tilt angle is often used to generally evaluate a model of a 
membrane-bound CYP. It is defined as the angle between the plane of the porphyrin 
nitrogens of the heme group and the membrane normal (z- axis). We determined the burying 
depth of the protein in the membrane according to Ducassou et al. They measured the 
distance between the mass center of the protein α-carbons and the mass center of the POPC 
C1-carbons in CYP2U1 [31]. The complete production phase was included into the 
calculation for both parameters stated above. Additionally, we determined the membrane-
buried residues depending on the position of the protein α-carbons relative to the 
membrane after 200 ns of MD equilibration. For this purpose, we defined the headgroup 
region to be located between the mass centers of the C2-atoms and the N-atoms of the 
POPC molecules. To estimate the volume of the active site cavity, we used the Pocket 
Volume Measurer (POVME, v2.0) [47]. We analyzed the last 100 frames of the production 
phase for each system. With the aim to optimize the results from POVME, we used PyMol to 
visualize the results. A distance cutoff of 1.4 and a grid spacing of 1.0 were found to deliver 
optimal results. We equally performed these calculations with the replica simulations. 
We identified the substrate-recognition site residues (referring to CYP2C9 and CYP2B4) 
employing sequence alignment using UGENE48 (v1.29) with the ClustalW algorithm [49]. 
We visualized the alignment results using JalView (v2.10.2) [50]. Finally, we determined the 
number of hydrogen bonds for the mutated amino acids in each variant for the complete 
300 ns trajectories as well as all replica simulations. 
 
Tunnel Analysis. For the analysis of possible access and egress tunnels in the enzyme we 
employed CAVER 3.0 [26]. CAVER is widely used to identify and characterize transport 
pathways within enzymes [12,22,25]. Prior to the tunnel analysis, we aligned 500 frames from 
the MD trajectories that were generated during the production runs. In order to perform the 
calculation, we determined the starting point using the tool CAVER Analyst 1.0 [51] by 
including the two active site residues Glu216 and Asp301 as well as the heme [18]. We then 
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performed the tunnel analysis using a probe radius of 0.9 Å and a clustering threshold of 4.5. 
All other parameters were left on default. We generated a heatmap, as well as a graph, for 
the opening frequency of the tunnels with the obtained data. We considered a tunnel to be 
open if its bottleneck radius was above 1.2 Å. Based on the generated data we were able to 
determine important bottleneck residues and the bottleneck radii. For the replica 
simulations, we likewise calculated the bottleneck residues, the average bottleneck radii, and 
the tunnel opening frequencies. The tunnel nomenclature was adapted from Wade et al. 
[21]. In addition, we developed a program in C-programming language to identify the water 
molecules that were approaching or leaving the active site through tunnels during the 
production phase of the CYP2D6. 
 
WT simulation. We observed water molecules inside protein cavities to travel significantly 
slower than when they are free in bulk. Our program evaluated the position of each water 
molecule along the trajectory based on its distance to the active site, its current velocity, and 
how often both of these values would reach below a certain threshold in consecutive frames 
(“strikes”). We then manually analyzed the sorted output of the program and visually 
followed the respective waters in the Desmond trajectory viewer to determine their location 
in respect to the enzyme tunnels. 
 
 
Results and Discussion 
Model Building and Description. The MemAs simulation showed a stable RMSD of 
approximately 2 Å reaching a plateau after 40 ns of simulation time (Figure S4.1). On the 
other hand, the AnchorSim simulation showed higher fluctuations peaking at 6.3 Å due to 
the large movements of the non-constrained helix inside the membrane. Due to this 
flexibility, in the systems combined with the anchor, we calculated the RMSD only for the 
catalytic domain of the protein in order to get meaningful results. The simulations with the 
merged, membrane-bound models showed RMSD values ranging from 1.5 to 2.5 Å, and all 
of them readily reached equilibrium during the first 50 ns (Figure S4.2). According to the 
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root-mean-square fluctuation (RMSF) profiles the most flexible regions in all simulations were 
the transmembrane anchor, the FG loop, the HI loop, the BC loop, and the GH loop in 
decreasing order (Figure S4.3). Our CYP2D6 WT model reached a heme tilt angle of 43° 
after the 200 ns equilibration run and an average of 47 ± 5° during the production phase 
(Table 4.2 and Figure S4.4).  
 
Table 4.2 Overview on the variants, tunnel dynamics, and the associated structural parameters used for 
the validation of the respective model. 
Variant tunnel average bottleneck radius [A, B] 







 2b 2c 2e 4    








37.7±1.2 Å 47.1±5.4° 0 








38.7±1.1 Å 59.3±4.3° + 








38.9±1.2 Å 47.1±4.7° - 







36.6±1.2 Å 64.5±4.8° + 








38.8±1.5 Å 44.2±4.9° + 








41.2±1.3 Å 48.4±4.9° + 
[A] The standard deviation for the average bottleneck radii was between 0.1 Å and 0.3 Å. 
[B] Averaged values over all frames during the production phase. 
[C] Percentage of frames in which the tunnel bottleneck radii were above 1.2 Å. 
[D] Volume of the active site cavity estimated with CastP compared to the wild-type. 
[E] Tunnel not present in the respective variant. 
 
Hence, it was in agreement with the experimentally determined range of 38−78° for CYPs 
[43]. Berka et al. published the only other membrane-bound model of CYP2D6 and 
determined the heme tilt angle in their model to be 72° significantly differing from our value 
[20]. This could be due to a different membrane composition, the different crystal structure, 
or due to the united-atom MD approach they used. Experimental measurements in CYP3A4 
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bound to POPC nanodiscs revealed an average heme tilt angle of 59.7° [23]. Ducassou et 
al.  determined the burying depth of CYP2U1 into the membrane to be decreasing from 43 
to 38 Å during their simulation [31]. Similar calculations for CYP2C9 presented a value of 40 
Å [24]. There is only one experimental value available regarding the height of a CYP above 
the membrane. It was determined for CYP2B4 by atomic force microscopy with an average 
of 35 ± 9 Å [44]. The burying depth of our CYP2D6 WT model calculated between the 
protein α-carbons and POPC C1-atoms converged from 44 Å at the beginning of the 
simulation to 36 Å after 300 ns (Figure S4.5). During the production phase, the burying 
depth averaged at 38 ± 1 Å. Our results therefore are in the same range as the literature 
values. It is accepted that the F-G loop in different CYPs is involved in the anchoring of the 
enzyme to the membrane [14,19, 22, 42].  
Our model showed a good correlation (Table S4.3) to the experimental data except for a 
few discrepancies that may be explained by the different enzymes (CYP2B1, CYP2B4, and 
CYP2C2) that were used in these experiments. Membrane proteins mediate their contacts 
over specific protein−membrane interactions [52]. In our model Arg25, Arg115, Ser116, 
Lys239, and Arg242 were shown to be strongly interacting with POPC molecules via salt 
bridges and hydrogen bonds (Figure S4.7). Overall, our model is in good agreement with 
experimental data. All control simulations of the protein with the membrane showed a heme 
tilt angle that is in accordance with the experimentally determined range except for one 
(Table S4.4). The burying depth in most simulations ranged between 36 Å and 41 Å. One 
simulation showed a value of 34.7 Å significantly differing from the other values and was 
therefore not considered for additional simulations. The location of the Arg28 at the 
protein−membrane interface varied throughout the simulations, while the position of Gln27 
remained within the headgroup region. We chose the AnchorSim, MemAs, and CYP2D6 WT 
simulations to be  optimal after  the  visual inspection of  the structures and careful  analysis  
of the calculated validation parameters. The replica simulations were used to assess the 
convergence of the structures in individual MD simulations. This was done by superimposing 
average structures of the respective simulations. From the  superposition, we could review 
the RMSD differences that are shown in Table S4.5. The average differences for each system 
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varied from 0.51 to 1.48 Å for the backbone atoms and from 0.63 to 1.55 Å for all heavy 
atoms of the globular domain. Only CYP2D6*2 and CYP2D6*4 showed values higher than 
1 Å. The high values for CYP2D6*4 might be explained by the structural instability of the N-
terminal residues. Indeed, if the RMSD difference was calculated separately from residue 
32−70 and 71−497 the values were significantly higher in the N-terminal segment with 1.49 
Å compared to 0.95 Å on average. For CYP2D6*2 the comparably high differences might 
be explained by the rather flexible character of this variant. When the RMSF profiles 
between the variants are compared, CYP2D6*2 displayed a high flexibility, especially 
around the F-G loop. Overall, the results prove that all production simulations maintained a 
satisfying structural convergence. 
 
POR Accessibility and Solvent Access. As mentioned in the introduction, the POR acts as 
electron donor to CYP2D6 and therefore plays a crucial role in its catalytic cycle [30]. In this 
study, one of the main focuses was to investigate if the binding site for the POR in our 
models would be accessible in a similar fashion as it was observed for CYP2B4. Bridges et 
al. identified the POR binding site on CYP2B4 in a site-directed mutagenesis study [30]. To 
be able to translate their conclusions to our model, we aligned CYP2B4 to our CYP2D6 WT 
model as it is presented in Figures S4.8 and S4.9.  We observed the binding site for the 




Figure 4.3 The passage of water molecules through enzyme tunnels. We divided the passage in access 
and egress considering the direction of their path. Percentages for each tunnel were calculated based on the 
total number of observed water molecules. 
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The binding site was also found to be in close vicinity to the water tunnel and faced the 
cytosol. This demonstrated that the POR would have the ability to bind to our model, since 
it is proposed to bind to a part of the enzyme that faces the cytosol [52]. It was further 
proposed that the POR could be involved in the opening of the water tunnel to desolvate 
the active site and enable ligand binding [29]. In this context, the tunnel is thought to allow 
passage due to a side-chain movement of a conserved arginine residue that weakens its 
interaction with the 7-propionate group of the heme moiety. This assumption can be 
supported by the fact that we observed only 12 water molecules passing through the water 
tunnel during the production phase (Figure 4.3) in the absence of the POR and without any 
ligand binding events. The total number of observed water molecules accessing the enzyme 
was 317. In our simulation, interaction between Arg441 and the heme remained stable 
during 99% of the production phase. As displayed in Figure 4.4, we did not observe any 
water molecules directly passing by the the heme propionates. Instead, an alternative path 




Figure 4.4 Overview of the water egress: through (A) the solvent tunnel and (B) the water tunnel. 
Snapshots of the trajectory were superimposed to represent the position of the water molecules at different 
time points. Secondary structure regions at the mouth of the tunnel are shown in blue. The paths of the water 
molecules are indicated by arrows. 
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We observed tunnel 2b and tunnel 2c to be the main pathways for active site hydration. In 
fact, we only observed 10 water molecules to pass the solvent tunnel. This indicates that the 
solvent tunnel shares a similarly low activity as determined for the water tunnel. This is also 
reflected by our results of the tunnel analysis since the solvent tunnel and the water tunnel 
turned out to be in a mostly closed state during the production phase (Table S4.6) 
Taking into account the higher diffusion rates of the TIP3P water model [53], the absolute 
number was possibly even biased toward higher values. Hence, the water tunnel as well as 
the solvent tunnel turned out to be of minor importance for active site hydration in our 
setup. This is in agreement with results for other CYPs in the literature [12,29]. Based on the 
data from CAVER, we identified the lining residues of the identified tunnels and compared 
their hydropathic character (Table S4.7) according to Kyte et al. [54]. Interestingly, the 
average hydropathic index of the water tunnel and the solvent tunnel presented the exact 
same value confirming their similar roles in transport. It is also worth mentioning that the 
lining residues in tunnel 2b are less hydrophobic than in tunnel 2c. After considering the 
throughput of water molecules, one could assume that water molecules naturally prefer a 
less hydrophobic tunnel environment to enter the active site. 
 
Tunnel Analysis. As previously mentioned, tunnels that connect the active site to its 
surrounding environment are thought to modulate substrate specificity as well as kinetic 
properties of the enzyme. For the analysis of enzyme tunnels, we compared the production 
simulations of the wild-type with and without ligand as well as the five allelic variants.  In all 
simulations, the most prominent tunnels were tunnels 2b and 2c followed by tunnels 2e and 
4 (Table S4.6). This is in agreement with a previous MD study on CYP2D6 without the 
membrane [12]. Figure 4.5 shows that tunnels 2b, 2c, 2d, 2e, and 4 are pointing toward the 
membrane, whereas the other tunnels face the cytosol in our CYP2D6 WT model. A detailed 
overview of the spatial distribution of all tunnels in the wild- type is given in Figure S4.10. 
Tunnel 6 has only been described once in the literature to our knowledge. It is located 
between the helices I and K as well as the β4-sheet in CYP2A6 [55]. Even though we 
identified this tunnel, we consider it to be of secondary importance, since it rarely occurred 
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in seven of eight total simulations (Figure 4.6). Also, the maximal bottleneck radii were very 
narrow (always below 1.2 Å) during all the simulations with membrane apart from 
CYP2D6*17. In this variant the bottleneck radius for tunnel 6 reached values above 1.5 Å 
for a short period of 1.6 ns. In the WT nolig simulation without membrane, it was open in 
97% of the frames with an average bottleneck radius of 1.3 Å. We considered a tunnel to 
be present if it occurred in at least five frames during the production phase. According to 
this limitation, the WT inhibitor system presented the highest number of tunnels (Fig S4.11).  
 
 
Figure 4.5 Distribution of tunnels relative to the membrane in CYP2D6 WT. The system is shown after 300 
ns production phase. The membrane is colored in a transparent yellow, while membrane phosphorus atoms 
are shown in sphere representation. Water molecules are not shown for simplicity. 
 
 
In total, we observed 13 of the 14 known tunnels in this system. Together with the 
observations on tunnel 6, this indicates an effect of the membrane on the diversity of 
tunnels. Berka et al. similarly observed a lower total number of tunnels in the presence of 
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the membrane for CYP2D6 [20]. An effect of lipids on the tunnels is likely, since the majority 
are in close vicinity to the membrane-binding regions of the protein. Experiments showed 
a stabilizing effect on the protein caused by the presence of membrane lipids [56]. This 
offers a possible explanation for the observations regarding the number of tunnels in the 
membrane-anchored CYP2D6 models. CYP2D6*2 showed a similar tunnel profile compared 
to the wild-type (Figure 4.6) approving their similar enzymatic activity. It is the only variant 
that presented an equal degree of opening for tunnel 2c compared to the wild-type. 
CYP2D6*4 exhibited a similar diversity of tunnels compared to the wild-type, even though 
the allele is associated with the PM phenotype. However, a closer look at the data revealed 
that the important tunnels overall showed a low open frequency during the production 
phase (Table S4.6). CYP2D6*4 showed the lowest degree of opening for tunnel 2b 
compared to all other variants. Even though tunnel 2b was one of the most important overall 
paths according to our data, our observations related to enzyme tunnels do not sufficiently 
explain the complete absence of metabolic activity in this variant. This implies the 
contribution of additional factors restraining the function of this variant on the level of amino 
acid mutations. 
The complete absence of tunnel 2c in CYP2D6*10 was caused by the close positioning of 
the BC loop toward the G-helix which blocked this tunnel during the simulations. In fact, we 
observed this to be the main closing mechanism in the variants that showed a low opening 
frequency of this tunnel (Figure 4.6). Such a closing movement could also impair active site 
hydration, since we observed tunnel 2c to be one of the major pathways in this context. The 
only tunnel that showed a consistent open state in CYP2D6*10 was tunnel 2b. Indeed, this 
variant shows a substrate-dependent decreased activity [7] indicating the possibility that 
some of the tested substrates would prefer tunnel 2c as an access path. De Waal et al. 
observed an increased presence of tunnel 2b as well as a significantly lower occurrence of 
tunnel 2c in CYP2D6*17 compared to the wild-type [12]. Our results confirm their 
observations, since we also discovered a low occurrence of tunnel 2c as well as an increased 
opening frequency combined with a small enlargement of tunnel 2b compared to the wild- 
type (Tables S4.6 and S4.8). Since tunnel 2c was rarely present, the substrate-dependent 
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decreased activity [57,58] of this variant could again be explained by the nearly complete 
absence of this tunnel without any compensatory paths. Experiments measuring the affinity 
of different substrates related to these two variants could give more insights in this context. 
The mutation T107I in CYP2D6*17 is located at the center of the B-C loop, and thus lining 
tunnel 2e. This tunnel showed the lowest opening frequencies in CYP2D6*17, even though 




Figure 4.6 Opening degree of enzyme tunnels in CYP2D6. The heat maps are based on bottleneck radii 
showing the degree of opening for eight of the most prominent tunnels. We considered the production 
phases including 500 frames for the analysis. This corresponds to a simulation time of 100 ns. 
 
This indicates that the mutation at position 107 could be locally altering in the properties of 
the B-C loop due to the loss of a hydroxyl group (next section). Tunnel 3 was identified as a 
secondary exit route for ligands by the use of random expulsion MD [59]. Both CYP2D6*10 
and CYP2D6*17 did exhibit this tunnel in less than five frames during the production phase. 
The near absence of tunnel 3 could be contributing to the altered activity profiles of these 
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variants. Even though CYP2D6*53 showed only a minimal opening of tunnel 2c, it 
compensated this limitation by a 2-fold enlarged bottleneck radius of tunnel 2b compared 
to the wild- type. This significant enlargement can be explained by the fact that the F120I 
mutation replaces one of the major bottlenecks residues (Table S4.9) in tunnel 2b. The 
reduced steric hindrance of isoleucine compared to phenylalanine leaves more space for 
potential ligands to access the active site.  
Based on our data, we propose that Phe120 forms a gate together with Phe483 that can be 
opened through a wing motion [25] regulating the opening of tunnel 2b (Figure 4.7). 
 
Figure 4.7 Overview of tunnel gating. Tunnel 2b shown in (A) an open state and (B) a closed state. The 
heme moiety as well as the involved residues are shown. The path of tunnel 2b in the open state is indicated 
by a pink arrow. 
 
Previous studies also showed tunnel 2b to be the most open in this variant [12]. An 
enlargement of this tunnel could also enhance its throughput of water molecules since we 
measured it to be the major pathway of active site hydration in the wild-type. In our study, 
Phe120 not only was determined as a major bottleneck residue for tunnel 2b but was also 
shown to be the most prominent bottleneck residue in several other tunnels during the 
production phase (Table S4.9). It was involved in the regulation of four other tunnels 
including tunnel 4 suggesting similar effects on them. Indeed, our data shows that tunnel 4 
presented the highest opening frequency for this variant (Table 4.2).  Even though Phe120 
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was determined to be a bottleneck residue for tunnel 2c and the water tunnel, it only 
maintained this function in a small amount of frames during the production phase. 
 
We already discussed different mechanisms for the regulation of tunnel 2c to take place on 
a globular level. Therefore, we believe this is the reason for missing effects of the F120I 
mutation in the gating of other tunnels. The second amino acid mutation in this variant is a 
replacement of alanine with serine at position 122 that is located at the B-C loop. This leads 
to the possibility that tunnel 2e could be affected by this mutation since its path is localized 
within this region. In contrast, we did not observe a significant difference in the opening of 
this tunnel compared to the wild-type indicating a secondary role for this mutation. As 
expected, the F120I mutation did not influence the opening of tunnel 2e due to its low 
frequency as a bottleneck residue (below 1% of the frames). Overall, our results support the 
fact that this variant shows an increased metabolic rate depending on the substrate. Even 
though, other amino acids prone to mutations at positions 91, 94, 296, and 486 are involved 
in lining various tunnels, the only major difference we observed was a slightly decreased 
opening of the solvent tunnel if the S486T mutation was present. Since this mutation is 
located at the mouth of the tunnel, these observations could be explained by steric effects 
related to the introduction of an additional methyl group at this position. For the other 
affected residues, we did not observe any significant differences related to the tunnels that 
could be correlated to the enzyme activity or active site hydration. 
The replica simulations showed a good convergence regarding the average bottleneck radii 
(Table S4.8). The deviations among the production simulations and the replicas were within 
the standard deviation of the respective average values. The important bottleneck residues 
determined in the production phases remained stable except for Val308 and Val370 that 
showed a reduction in the number of tunnels which were bottlenecking in one replica 
simulation each (Table S4.9). This might have been caused by a rather high degree of 
freedom of this valine residue compared to the aromatic residues that are usually involved 
in tunnel gating [25]. Additionally, these two residues are located at the end of the tunnels 
close to the heme and therefore might be exchangeable to some degree. Despite the stable 
bottleneck radii of the replicas, the largest differences between the production and the 
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replica simulations were found in the analysis of the tunnel opening frequency based on the 
opening threshold of 1.2 Å (Table S4.6). While the variants CYP2D6*10 and CYP2D6*17 did 
not show any large differences, the values of some tunnels in the four other simulations 
showed significant differences. The replica simulations with CYP2D6 WT showed higher 
opening frequencies for tunnel 2b and tunnel 2c compared to the production simulations. 
This increase further substantiates the functionality of the wild-type enzyme structure. The 
system with the variant CYP2D6*2 previously showed rather high RMSD values in the 
assessment of the structural convergence of the replicas that were potentially caused by the 
increased flexibility of this variant. This was also reflected by the tunnel opening frequency 
of tunnel 2b and tunnel 2e in one replica simulation each. Despite the difference in these 
two values, the average values of the two replica simulations of CYP2D6*2 were shown to 
be quite similar to the production simulation. We could observe the largest deviation of 
tunnel opening for CYP2D6*4 in the respective replica simulations. As previously 
mentioned, we suspect this to be caused by the generally unstable fold of this variant. The 
slight deviations regarding tunnel 4 in several variants such as CYP2D6*53 might be related 
to the flexibility of the respective tunnel entrance, which is defined by the flexible F-G loop 
and might therefore open and close with an increased frequency. 
 
Structural Comparison of Variants. The RMSD and RMSF profiles during the CYP2D6*2 
simulation remained fairly comparable to the ones of the wild-type (Figures S4.2 and S4.3). 
This was to be expected, since the S486T mutation is not known to cause any significant 
alterations to the structure or function of CYP2D6 [57]. However, the R296C mutation also 
occurs in alleles with decreased function and is shown to cause structural instabilities in 
experiments [60]. Indeed, our analysis of the average number of hydrogen bonds showed 
both CYP2D6*2 and CYP2D6*17 to have lost one hydrogen bond because of the switch 
from arginine to cysteine in the production as well as the replica simulations (Table S4.10). 
This indicates that the fold of the enzyme could be locally destabilized. However, the 
combination of R296C with S486T does not influence the function in the CYP2D6*2 variant, 
and our previously mentioned data also indicates a function similar to the wild-type. In 
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CYP2D6*1, the mutations at positions 296 and 486 are combined with the mutation T107I 
which is suspected to be contributing to the altered activity of this variant [57]. Bapiro et al. 
determined that the mutation at position 107 alone cannot cause the observed reduction 
of activity in CYP2D6*17 [58]. It seems that the combination of all three mutations is the 
cause for the altered properties of this variant [7, 57]. Likewise, our results from the 
hydrogen bond analysis do support this data. The loss of the hydroxyl group caused by the 
mutation from threonine to isoleucine also resulted in the loss of a hydrogen bond over the 
average of the trajectory. In a different computational study with CYP2D6*17 it was shown 
that the mutations T107I and R296C caused a lower number or a complete loss of hydrogen 
bonds [35]. It is debated if residue Thr107 is involved in ligand binding and in this way alters 
the active site structures [2, 57, 58].  
The analysis of the native crystal structure (PDB ID: 3TDA) revealed a distance of 5.6 Å to 
the closest heavy atom of the bound inhibitor prinomastat (Figure 4.8) indicating a rather 
weak interaction.  
 
Figure 4.8 Active site and nearby regions in the native crystal structure of CYP2D6. The mutated amino 
acids are shown in orange, while the ligand prinomastat (PNT) is shown in pink. The closest distance 
between two heavy atoms of T107 and the ligand is shown in cyan. 
 
This crystal structure therefore does not directly support this hypothesis. In addition, the 
estimated active site volume also did not indicate an altered active site structure (Table 
S4.11). The mutation at position 486 is known to have no significant impact on the enzyme 
activity in CYP2D6*17 [58]. Additionally, all mutations in CYP2D6*17 are located at substrate 
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recognition sites (SRS) providing another indication for the substrate-dependency of the 
observed effects [57,58]. Contrary to previous observations in the absence of the membrane 
[12], our data shows that CYP2D6*17 reached its RMSD equilibrium faster than any other 
system. Other groups previously discussed that CYPs with faster equilibration times display 
higher stability in vitro [12]. This points toward a more stable structure of this variant in 
comparison to others. The RMSF profile of this variant displayed a decreased flexibility in 
the region of the F-G loop essential for the formation of enzyme tunnels of the subclass 2 
in our structures. This rigidity could disable substrate uptake, since it is known that residues 
in enzyme tunnels need to sterically adapt in order to allow ligand transport [12, 24]. On the 
other hand, the rigidity could result in a more stable global structure. It is worth mentioning 
that we observed higher flexibility on the RMSF profile in the region of helix Jʹ contrary to 
the observations of a generally more rigid structure. The P34S mutation is widespread in 
individuals with a reduced or absent functionality of CYP2D6 [41]. As previously mentioned, 
it is located in a highly conserved region of the protein [8,60] and it might serve as a hinge 
between the transmembrane anchor and the catalytic domain [7].   
Experimental data suggest that this region plays an important role for correct folding and 
heme incorporation [61]. This was supported by two other groups who measured lower 
expression levels in the presence of the P34S mutation alone [60, 62]. As previously 
mentioned, the complete absence of metabolic activity in CYP2D6*4 is thought be caused 
by the mutation from guanine to adenine at position 1934 resulting in incorrect splicing. 
Unfortunately, our computational setup does not allow for investigation of effects taking 
place on the level of protein biosynthesis but still allowed the investigation of the related 
amino acid changes that are sufficient to abolish enzymatic activity independent of splicing 
[9]. We visually compared the fold in the region of the N-terminus for both alleles containing 
the P34S mutation. CYP2D6*4 was shown to have an altered structure between residues 
Arg25 and Asp67 confirming the experimentally observed phenomena. In CYP2D6*10, on 
the other hand, we observed fewer alterations in this region. This suggests that the 
observed differences in CYP2D6*4 might not be explained by the P34S mutation alone. 
Indeed, experiments showed that the mutation at position 34 does not suffice to completely 
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abolish the enzymatic function [62]. The CYP2D6*10 allele is an impeccable example for this 
observation, since it harbors the P34S mutation but still shows enzymatic activity [2]. The 
analysis of the enzyme tunnels delivered evidence for the observed activity profile. Several 
tunnels presented lower opening frequencies compared to the wild-type suggesting a 
decreased accessibility of ligands to the active site. In addition, we calculated the average 
heme tilt angle during the production phases as it is presented in Table 4.2. We observed 
a value of 65 ± 5° for CYP2D6*10 which significantly differs from the values in the wild-type 
model, even though they are still within the experimentally determined boundaries [43]. 
Such a pronounced change in the  heme tilt angle can impair the interaction with the POR32  
and also points toward structural defects. We determined the same parameter in CYP2D6*2 
to be 59 ± 4° suggesting that certain discrepancies in this range are tolerable regarding the 
enzymatic function. In the literature it is proposed that CYP2D6*10 shows an unstable fold, 
and in vitro experiments showed thermal instability for this variant at 39.5 °C [63]. The RMSD 
of CYP2D6*10 during the production run also presented higher values compared to other 
variants suggesting a certain degree of instability, even though the differences were rather 
small. In the N-terminal region, this variant displayed an increased flexibility in the vicinity 
of residue 60 further confirming our observations related to the structural abnormalities. We 
propose that the observed effects in this variant are mainly caused by the P34S mutation, 
since it is only accompanied by the mutation S486T that previously could not be associated 
with any aberrations. The CYP2D6*4 variant also harbors the P34S mutation combined with 
three others including S486T. The literature provides only little information concerning the 
other two mutations L91M and H94R [41]. An analysis on genetic polymorphisms in the 
Uygur population revealed another variant of CYP2D6 harboring exactly these two 
mutations [64]. The results of this study indicate that both mutations can also occur in 
individuals with normal enzymatic activity, although more data will be needed to confirm 
this observation. Upon the mutation of histidine to arginine, the amino acid at position 94 
retains its basic properties. This is also reflected in predictions that were made for these 
mutations using two online tools, where only L91M was shown to be capable of altering the 
protein activity [64]. 
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Figure 4.8 shows the positions 91 and 94 to be located far away from the active site 
suggesting a role in substrate recognition rather than in substrate binding. This also became 
apparent with the sequence alignment to CYP2C5 as we identified the SRS in CYP2D6 [58]. 
The results showed that both Leu91 and His94 are flanking SRS1 supporting our suggestion. 
Overall, we propose that the mutation P34S is the main cause for the observed differences 
in CYP2D6*4 with a possible secondary impact by the L91M mutation. The impact of the 
P34S mutation has also been shown in experiments with different DNA constructs [9]. On 
the RMSF profile of CYP2D6*4 we identified similar additional peaks to the ones found for 
CYP2D6*10 in the N-terminal region. This again confirms our visual observations related to 
the altered fold of CYP2D6*4. Our results regarding the active site volume estimated with 
POVME provide further indications toward the loss of activity in this variant (Table 4.2 and 
Table S4.11). In the last 100 frames of the MD production phase, the volume of the active 
site cavity of CYP2D6*4 was relevantly lower compared to the wild-type or other variants. 
This further points toward the hypothesis that not one single mutation but the combination 
of all four mutations is responsible for the alteration of the structure of the enzyme. 
Differences in the tunnel opening frequency (Table S4.6) compared to the wild-type and 
the similar variant CYP2D6*10 provide additional evidence for this hypothesis. 
 
Regarding the active site volume, the replica simulations mostly showed deviations that 
were within the standard deviation of the average values (Table S4.11). One of the replica 
simulations of CYP2D6*2 was an exception with a comparably high value. A visual inspection 
of the residues in the active site in two frames with different volumes revealed Phe219, 
Gln244, and Phe483 to vary in position potentially contributing to the deviation between 
this replica and the production simulation. The differences in the hydrogen bond analysis 
between the replicas and the production simulations were within the error of the standard 
deviation (Table S4.10). The tunnel analysis already showed a significant enlargement of 
tunnel 2b in CYP2D6*53, yet additional factors could lead to the enhanced catalytic activity 
of this variant. The residue Phe120 is known not to be critical for the enzymatic activity of 
the variant, even though it directly interacts with ligands over π−π interactions. In fact, it is 
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proposed that the absence of this specific interaction combined with a reduced steric 
hindrance could lead to different poses of substrates in the active site and thus cause 
changes in the metabolic profile [65,66]. These assumptions are based on findings with a 
variant featuring the mutation F120A. This mutation replaces the bulky phenylalanine 
residue by a smaller, similarly hydrophobic residue making it comparable to the F120I 
mutation. Interestingly, the F120A variant of CYP2D6 is able to metabolize quinidine which 
is an inhibitor in the wild-type form [67]. Also, the regiospecificity of certain metabolic 
reactions with common drugs changes compared to the wild-type [66]. 
The pose of prinomastat in the crystal structure showed Phe120 to be oriented toward the 
aromatic groups of the ligand. In addition, CYP2D6*53 also showed the highest active site 
volume of all simulations. We therefore support the hypothesis that the mutation to a less 
bulky amino acid could lead to a larger conformational freedom of the ligand inside the 
active site cavity based on our results regarding the active site volume. Still, additional 
molecular docking studies and MD simulations exploring the binding modes of substrates 
will be needed to confirm this hypothesis. The RMSD and RMSF profiles of CYP2D6*53 
suggest a rather flexible structure compared to the wild-type. There are additional peaks 
denoting increased mobility at residues 145, 166, and 178 and compared to the wild-type. 




In this study, we employed all-atom molecular dynamics simulations in order to identify 
differences between the wild- type and five allelic variants CYP2D6*2, CYP2D6*4, 
CYP2D6*10, CYP2D6*17, and CYP2D6*53. We built full-length membrane-anchored 
models, equilibrated them, and focused on differences among them considering enzyme 
tunnels as well as the overall fold. We validated our membrane-bound model with available 
experimental data and other published models of membrane-bound CYPs. In our model, 
the protein mediated its contact to the membrane with the transmembrane anchor, Aʹ 
anchor, A helix, and the FG loop over specific protein−membrane interactions. We showed 
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that the binding site for the POR in our models was accessible from the cytosol and not 
hidden in the membrane. The water tunnel as well as the solvent tunnel were able to 
transport water molecules but were shown to be only minor paths for active site hydration 
in our simulation conditions. To our best knowledge, we are the first group to identify tunnel 
6 in CYP2D6 offering an additional possible path for ligands. As expected, the CYP2D6*2 
variant demonstrated a similar tunnel profile compared to the wild-type and no major 
differences in the overall structure except for the loss of a hydrogen bond due to the 
exchange of arginine with cysteine at position 296. The overall structure in the nonfunctional 
CYP2D6*4 variant was shown to be altered considering our data regarding the active site 
volume and the change in the N- terminal fold. We propose the P34S mutation to be the 
major cause for the observed alterations based on our results and the available literature. 
The structural differences in this variant correlated with a generally decreased opening of 
the most prominent ligand tunnels. CYP2D6*10 is another variant that harbors the P34S 
mutation and showed similar changes in the N-terminal fold as CYP2D6*4 providing 
additional evidence for the structural impact of this mutation. Furthermore, the B-C loop in 
CYP2D6*10 and CYP2D6*17 shifted toward the helix G leading to the closure of tunnel 2c 
without any compensatory pathways. We believe this phenomenon leads to the 
experimental observations of substrate-dependent decreased activity in both variants. 
Although it is suggested in the literature, the T107I mutation in CYP2D6*17 was not shown 
to have an impact on ligand binding in our analysis. Instead, it led to the loss of a hydrogen 
bond in addition to the one it lost due to the R296C mutation. Even though we did only 
observe a minor opening of tunnel 2c in CYP2D6*53, this variant could compensate this 
restriction by a 2-fold enlargement of tunnel 2b likely due to the mutation of phenylalanine 
with isoleucine at position 120. Additionally, the two amino acid mutations in this variant 
led to an enlarged active site volume providing another possible explanation for the altered 
metabolic profile. To summarize, this supports the discussed and pending designation as a 
cause for the UM phenotype. In the future, studies employing site-directed mutagenesis 
experiments with the allelic variants combined with the exposure to differently sized and 
shaped ligands could provide a clearer picture for some of the findings. Experimental 
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determination of the 3D structure of allelic variants, as well as the full-length protein, could 
help to validate our results. In conclusion, we discovered several structural differences in the 
variants that could explain their altered metabolic activity compared to the wild-type on an 
atomic level with replica simulations displaying satisfying convergence. In the age of 
personalized medicine, the conclusions from this study could be integrated into virtual 
screening protocols, which are almost exclusively guided by the molecular docking of 
compounds into the active site, thereby neglecting the influence of tunnels. Furthermore, 
atomistic insights into the structure and function of the enzyme tunnels could be of interest 
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Table S4.1 The stages of Desmond MD relaxation and simulation prior to the actual MD 
simulation. 
 
Desmond Stage Procedure 
Stage 1 Task (reading files, initializing parameters) 
 
Stage 2 Simulate, Brownian Dynamics NVT, T = 10 K, small time steps, and restraints 
on solute heavy atoms, 100 ps 
Stage 3 Simulate, NVT, T = 10 K, small time steps, and restraints on solute heavy 
atoms, 12 ps 
Stage 4 Simulate, NPT, T = 10 K, and restraints on solute heavy atoms, 12 ps 
 
Stage 5 Solvate pocket 
   
Stage 6 Simulate, NPT and restraints on solute heavy atoms, 12 ps 
 
Stage 7 Simulate, NPT and no restraints, 24 ps 
   








Table S4.2 Predictions for membrane-bound residues from web-based protocols. 
 
Protocol Prediction N-terminus 




Three web based protocols were employed to get an estimate of the membrane-bound residues in 



















Table S4.3 Experimental validation of the CYP2D6 WT model adapted from Cojocaru et al.  
 
Residues in CYP2D6 
(CYP2C9*) 
Result Correlation Experimental 
result* 
Experimental method* 
1-35 (1-30) M-HG-C + Inaccessible Site-directed antibody 48 
18-32 (17-28) M-HG-C b 0 Accessible Site-directed antibody 49 
27-41 (23-37) HG-C-HG-M + Accessible Site-directed antibody 48 
43-51 (39-47) M-HG-C + Inaccessible Site-directed antibody 48 
64-75 (60-71) C-HG-M + Accessible Site-directed antibody 48 
96-101 (92-97) C - Inaccessible Site-directed antibody 48 
111-122 (107-115) HG-C + Accessible Site-directed antibody 48 
129-138 (121-130) C + Accessible Site-directed antibody 48 
194-201 (185-192) C + Accessible Site-directed antibody 48 
218-229 (210-222) HG-M + Inaccessible Site-directed antibody 48 
231-238 (224-231) M-HG - Accessible Site-directed antibody 48 
322-330 (314-322) C + Accessible Site-directed antibody 48 
404-414 (397-407) C + Accessible Site-directed antibody 48 
40 (36) M + M Trp fluorescence quenching 46  
73 (69) C a 0 M Trp fluorescence quenching 46 
387 (380) C - M Trp fluorescence quenching 46 
84, 128, 198, 246, 355 
(80,120, 189, 239, 347) 
C + C (HG) Trp fluorescence quenching 46 
232 (225) M - C (HG) Trp fluorescence quenching 46 
1. Column: Residues in CYP2D6 data based on sequence alignment to CYP2C9. The corresponding residues in 
CYP2C9 are shown in brackets.  
2. Column: Location of the residues in our model related to the membrane. The order of the location is given 
from N-terminus to C-terminus. The residues can either be positioned in the membrane (M), headgroup region 
(HG), or cytosol (C). 
3. Column: Correlation of our results with the experimental data: (+) indicates a correlation, (0) indicates 
inconclusive results, and (-) indicates a missing correlation. 
4. Column: Experimental results on the location and accessibility of the related protein regions. Data from site-
directed antibodies is divided in “accessible” and “inaccessible”, while data from tryptophan fluorescence 
quenching directly indicates the location of the residues. 
5. Column: The experimental methods used to produce the mentioned data on the residue location. The referred 
references are listed in the main article. 
 
*data directly adapted from Cojocaru et al.18  
a not inside membrane, but buried inside the protein. 
































AnchorSim 200 ns Used for final system n/a n/a HG HG angled, not straight 
Anchor1 129 ns Different burying 
depth 
n/a n/a HG S angled, straight 
Anchor2 40 ns Different burying 
depth 
n/a n/a HG S angled, not straight 
Anchor3 
 
200 ns Different burying 
depth 
n/a n/a HG S angled, not straight 
Anchor4 
 
200 ns Different burying 
depth 
n/a n/a HG HG angled, straight 
Anchor 5 200 ns Different burying 
depth 
n/a n/a HG HG angled, not straight 
MemAs 100 ns Used for final system 64.4° 41.4 Å - -  
Mem1 100 ns Different burying 
depth 
77.9° 37.1  Å - -  
Mem2 100 ns Different burying 
depth 
56.1° 39.9  Å - -  
CYP2DT 
WT 
300 ns Used for final system 44.4° 36.1 Å HG HG  
Fusion1 47 ns Different linkage d 64.3° 
 
36.3 Å S S  
Fusion2 65 ns Different linkage d 39.5° 
 
41.0 Å HG HG  
Fusion3 200 ns Different linkage d 50.1° 
 
34.7 Å HG HG anchor moved away 
from protein 
a Background of the simulations. 
 
b Final value after the whole simulation. 
 
c The location of two selected residues at the protein-membrane interface was determined in the last 
frame of the respective simulation. Divided in HG (head groups) and S (solvent). 
 











Table S4.5 RMSD differences of the replica simulations to assess structural convergence. 
 
Compared Simulations a 
Backbone 
RMSD (Å) b 
Heavy atom 
RMSD (Å) b 
Replica 1 to Replica 2 0.59 0.72 
Replica 1 to CYP2D6 WT 0.41 0.51 
Replica 2 to CYP2D6 WT 0.52 0.67 
Average CYP2D6 WT 0.51 0.63 
Replica 3 to Replica 4 0.70 0.89 
Replica 3 to CYP2D6*2 1.26 1.43 
Replica 4 to CYP2D6*2 1.20 1.32 
Average CYP2D6*2 1.05 1.21 
Replica 5 to Replica 6 0.92 1.00 
Replica 5 to CYP2D6*4 1.97 2.02 
Replica 6 to CYP2D6*4 1.55 1.64 
Average CYP2D6*4 1.48 1.55 
Replica 7 to Replica 8 0.92 1.03 
Replica 7 to CYP2D6*10 0.64 0.76 
Replica 8 to CYP2D6*10 0.74 0.89 
Average CYP2D6*10 0.76 0.89 
Replica 9 to Replica 10 0.69 0.83 
Replica 9 to CYP2D6*17 0.88 1.02 
Replica 10 to CYP2D6*17 0.80 0.91 
Average CYP2D6*17 0.79 0.92 
Replica 11 to Replica 12 0.63 0.84 
Replica 11 to CYP2D6*53 0.77 0.89 
Replica 12 to CYP2D6*53 0.62 0.70 
Average CYP2D6*53 0.67 0.81 
 
To assess the structural convergence of the simulations we compared average structures from the 100 ns 
trajectories and compared their RMSD on two different atomic levels. 
 
a The production phase was used in the assessment for the simulations that were no replicas. 
 



















Tunnel opening frequency (%) 
2b 2c 2e 4 S W 
CYP2D6 WT 73.0 20.2 13.8 9.0 5.4 0.0 
Replica 1 97.6 48.6 9.6 19.2 9.2 0.8 
Replica 2 82.2 73.4 16.4 16.6 4.4 0.0 
Average Replicas 89.9 61.0 13.0 17.9 6.8 0.4 
CYP2D6*2 94.2 78.0 23.4 35.2 0.0 0.0 
Replica 3 65.2 73.6 21.8 46.2 3.8 0.2 
Replica 4 92.4 80.8 6.8 n/a 14.6 0.6 
Average Replicas 78.8 77.2 14.3 n/a 9.2 0.4 
CYP2D6*4 45.6 37.4 29.6 37.2 3.2 0.0 
Replica 5 79.0 53.0 41.9 58.4 4.6 0.2 
Replica 6 63.0 10.4 21.6 34.2 3.0 0.0 
Average Replicas 71.0 31.7 31.8 46.3 3.8 0.1 
CYP2D6*10 98.8 0.0 4.0 39.0 0.0 0.0 
Replica 7 97.6 0.0 0.6 n/a 0.0 0.0 
Replica 8 n/a n/a n/a 26.2 0.6 0.0 
Average Replicas n/a n/a n/a n/a 0.3 0.0 
CYP2D6*17 100.0 1.6 1.2 54.2 0.4 0.2 
Replica 9 100.0 0.8 0.2 41.6 0.2 0.2 
Replica 10 100.0 1.6 1.0 41.8 0.2 0.4 
Average Replicas 100.0 1.2 0.6 41.7 0.2 0.3 
CYP2D6*53 98.6 1.2 15.0 65.2 11.8 0.0 
Replica 11 98.8 0.0 27.0 83.3 2.8 0.0 
Replica 12 98.2 0.6 20.0 25.0 0.8 0.0 
Average Replicas 98.5 0.3 23.5 54.2 1.8 0.0 
 
The tunnel opening frequencies in percent for six highest ranked tunnels. A tunnel was considered to be open if 
its bottleneck radius was above 1.2 Å. 
 

















Table S4.7 Average hydropathic index of tunnel lining residues. 
 













We calculated the average hydropathic index of the tunnel lining residues if a tunnel cluster was present in at 
least 50 frames of the related simulation. The values were averaged over the variants and the wild-type. 
 
* no standard deviation given since tunnel fitting the calculation criteria only occurred in one variant 
 





Average bottleneck radii of tunnels (Å) 
2b 2c 2e 4 
CYP2D6 WT 1.4 ± 0.2 1.5 ± 0.2 1.1 ± 0.1 1.1 ± 0.1 
Replica 1 1.7 ± 0.2 1.3 ± 0.3 1.1 ± 0.1 1.1 ± 0.2 
Replica 2 1.4 ± 0.2 1.4 ± 0.3 1.1 ± 0.1 1.1 ± 0.2 
CYP2D6*2 1.8 ± 0.2 1.4 ± 0.2 1.2 ± 0.2 1.4 ± 0.3 
Replica 3 1.8 ± 0.3 1.4 ± 0.2 1.2 ± 0.2 1.7 ± 0.4 
Replica 4 1.8 ± 0.3 1.4 ± 0.2 1.1 ± 0.2 n/a 
CYP2D6*4 1.2 ± 0.2 1.2 ± 0.2 1.1 ± 0.1 1.2 ± 0.2 
Replica 5 1.4 ± 0.2 1.3 ± 0.2 1.2 ± 0.2 1.3 ± 0.2 
Replica 6 1.3 ± 0.2 1.1 ± 0.1 1.1 ± 0.2 1.1 ± 0.2 
CYP2D6*10 1.9 ± 0.2 0.0 ± 0.0 1.1 ± 0.2 1.3 ± 0.3 
Replica 7 1.8 ± 0.2 0.0 ± 0.0 1.0 ± 0.1 n/a 
Replica 8 n/a n/a n/a 1.3 ± 0.2 
CYP2D6*17 1.8 ± 0.2 1.0 ± 0.1 1.0 ± 0.1 1.4 ± 0.2 
Replica 9 1.9 ± 0.2 1.0 ± 0.1 1.0 ± 0.1 1.4 ± 0.2 
Replica 10 1.8 ± 0.2 1.0 ± 0.1 1.0 ± 0.1 1.4 ± 0.3 
CYP2D6*53 2.6 ± 0.3 1.1 ± 0.3 1.1 ± 0.2 1.3 ± 0.2 
Replica 11 2.7 ± 0.2 1.0 ± 0.1 1.2 ± 0.2 1.4 ± 0.2 
Replica 12 2.5 ± 0.2 1.0 ± 0.2 1.1 ± 0.2 1.1 ± 0.2 
 
The average bottleneck radii of enzyme tunnels in the wild-type and the five variants. We chose to compare the 
four highest ranked tunnels. The average values are given with standard deviation. 
n/a: The clustering performed by CAVER did not allow the correct calculation of parameters of the tunnel in the 
respective simulation. 
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Number of tunnels per residue 
120 305 308 370 374 483 
Production 
phases 
5 3 3 4 5 3 
Replica 1 5 2 3 2 4 2 
Replica 2 4 3 1 4 5 4 
 
Bottleneck residues involved in the regulation of multiple tunnels are shown together with the number of tunnels 









Average number of hydrogen bonds per residue 
34 91 94 107 120 122 296 486 
CYP2D6 WT 0.6 ± 0.5 1.2 ± 0.8 3.4 ± 0.9 2.1 ± 0.5 2.5 ± 0.6 1.3 ± 0.5 2.5 ± 0.7 1.9 ± 0.5 
Replica 1 0.7 ± 0.5 1.2 ± 0.8 3.6 ± 0.9 2.9 ± 0.8 2.0 ± 0.1 1.6 ± 0.6 2.8 ± 0.7 2.8 ± 0.7 
Replica 2 0.7 ± 0.5 1.7 ± 0.5 4.1 ± 0.9 2.1 ± 0.3 2.0 ± 0.1 1.6 ± 0.6 2.9 ± 0.7 2.1 ± 0.4 
CYP2D6*2 - - - - - - 0.7 ± 0.9 2.1 ± 0.4 
Replica 3 - - - - - - 1.6 ± 1.0 2.5 ± 0.5 
Replica 4 - - - - - - 1.3 ± 1.0 2.4 ± 0.5 
CYP2D6*4 0.4 ± 0.5 0.9 ± 0.5 3.2 ± 0.6 - - - - 1.8 ± 0.5 
Replica 5 0.0 ± 0.2 1.3 ± 0.5 3.6 ± 0.7 - - - - 2.4 ± 0.5 
Replica 6 0.4 ± 0.6 1.3 ± 0.5 3.5 ± 0.7 - - - - 2.3 ± 0.5 
CYP2D6*10 0.9 ± 0.4 - - - - - - 2.1 ± 0.5 
Replica 7 0.9 ± 0.2 - - - - - - 2.3 ± 0.6 
Replica 8 0.9 ± 0.3 - - - - - - 2.0 ± 0.2 
CYP2D6*17 - - - 1.1 ± 0.7 - - 1.1 ± 0.5 2.6 ± 0.8 
Replica 9 - - - 1.5 ± 0.7 - - 1.4 ± 1.0 3.1 ± 0.3 
Replica 10 - - - 1.6 ± 0.8 - - 1.7 ± 1.0 3.0 ± 0.3 
CYP2D6*53 - - - - 2.4 ± 1.0 2.3 ± 0.7 - - 
Replica 11 - - - - 2.0 ± 0.6 2.5 ± 0.8 - - 
Replica 12 - - - - 2.0 ± 0.4 2.2 ± 0.8 - - 
 
The data was calculated for all mutated amino acids in the wild-type as well as for the mutated amino acids in the variants. 





















CYP2D6 WT 674.9 ± 83.6  
Replica 1 634.0 ± 64.9 589.7 ± 62.6 
Replica 2 545.4 ± 52.9  
CYP2D6*2 739.6 ± 76.4  
Replica 3 776.4 ± 64.5 898.0 ± 172.0 
Replica 4 1019.6 ± 95.6  
CYP2D6*4 398.6 ± 46.1  
Replica 5 514.0 ± 77.1  455.2 ± 83.2 
Replica 6 396.3 ± 40.7  
CYP2D6*10 883.0 ± 80.7  
Replica 7 947.3 ± 80.5 978.0 ± 43.3 
Replica 8 1008.6 ± 66.8  
CYP2D6*17 687.9 ± 66.1  
Replica 9 557.8 ± 55.1 628.1 ± 99.4 
Replica 10 698.4 ± 60.3  
CYP2D6*53 1092.3 ± 108.3  
Replica 11 1074.9 ± 88.2 1086.3 ± 16.1 
Replica 12 1097.7 ± 66.7  
 
The volumes of the active site cavities in CYP2D6 WT and its related variants. The volumes were estimated with 
POVME (v2.0) based on the last 100 frames of the production phase. The values are given with standard deviation 





Figure S4.1 Backbone RMSD plots of the simulations MemAs and AnchorSim. 
 
 
The backbone RMSD values for (A) the MemAs simulation and (B) the AnchorSim simulation. The values are 






Figure S4.2 Backbone RMSD profiles of the membrane-bound simulations and the WT nolig 




The backbone RMSD values of membrane-bound simulations as well as the WT nolig simulation. The values are 


















The backbone RMSF values of membrane-bound simulations, as well as the WT nolig simulation. The values are 















The heme tilt angle of the membrane-bound simulations. It is defined as the angle between the heme plane and 












The burying depth of the enzyme in the membrane was calculated according to Ducassou et al. It is defined as 
the distance between the mass centers of POPC C1 atoms and protein α-carbons. The values are shown for the 















Figure S4.6 Residues in contact with the membrane, the head group region, or the cytosol in the 




Residues of the CYP2D6 WT model that are in contact with the membrane, the head group region, or the cytosol. 
We defined he head group region to be between mass centers of the C2-atoms and the N-atoms of the POPC 









The distance between selected atoms of protein residues and membrane molecules plotted against the 
















Figure S4.8 Sequence alignment of CYP2D6, CYP2B4, and CYP2C9. 
 
 
A sequence alignment of CYP2D6, CYP2B4, and CYP2C9. This was done in order to identify the residues of the 
POR binding site and to translate experimental results for the model validation. The residues corresponding to 





Figure S4.9 Structural alignment of CYP2B4 to CYP2D6 with focus on the POR binding site. 
 
 
Protein structure alignment of CYP2B4 to CYP2D6. This was done to identify the binding site of the POR on 
CYP2D6. The residues in CYP2B4 were established in experiments. The structure of CYP2D6 represents a 






















Identified enzyme tunnels in all production simulations. We considered a tunnel to be present if it occurred in at 



















































Pharmacogenetics in silico study of CYP2D6 focused on the 
pharmacovigilance of herbal antidepressants 
 
               
                
 
                               Based on the submitted manuscript: 
 




Charleen G. Don & Martin Smieško 
  
Chapter  




The annual increase in depression worldwide together with an upwards trend in the 
use of alternative medicine as treatment asks for developing reliable safety profiles of 
herbal based medicine. A considerable risk on adverse reactions exists when herbal 
remedies are combined with prescription medication. Around 25% of the drugs, 
including many antidepressants, depend on the activity of CYP2D6 for their 
metabolism and corresponding efficacy. Therefore, probing CYP2D6 inhibition by the 
active substances in herbal based medicine within the wild-type enzyme and clinically 
relevant allelic variants is crucial to avoid toxicity issues. In this in silico study several  
compounds with herbal origin suggested to have antidepressant activity were analysed 
on their CYP2D6 wild-type and CYP2D6*53 inhibition potential using molecular 
docking. In addition, several pharmacokinetic properties were evaluated to assess their 
probability to cross the blood brain barrier and subsequently reach sufficient brain 
bioavailability for the modulation of central nervous system targets as well as 




Depression as a mood disorder has significantly increased (~18%) during the last 
decade affecting over 300 million people as estimated by the world health 
organisation (WHO) (1). Concurrently, an upward trend is seen in the use of 
antidepressants worldwide [2–4] in parallel with the use of complementary and 
alternative medicine (CAM) [5–7] . A recent study reported that in Europe (21 surveyed 
countries) 30% of the affected individuals used CAM to treat depression of which 10% 
included herbal medicine (natural products) [7]. Antidepressants as neurotherapeutics 
must be able to cross the blood-brain barrier (BBB) in order to modulate the function 
of the central nervous system (CNS). The compound exchange between the blood and 
the nervous tissue is strictly controlled by a continuous layer of endothelial cells which 
are kept together by tight junctions with a total estimated surface of around 20 m2 [8]. 
From a medicinal chemistry perspective, physiochemical properties of CNS modulators 
(e.g. molecular weight, lipophilicity, hydrogen acceptor and donor counts) therefore 
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need to fall within a narrower range compared to regular drugs in order to be 
absorbed, dissolved and permeate across the brain-barrier to reach the CNS (passive 
transport, non-energy required). More hydrophilic modulators (or other compounds) 
may still cross the barrier through carrier systems, transporters or endocytosis (active-
transport, ATP required) [9,10]. However, good BBB permeation does not guarantee 
that the efficacious concentration of the compound in the CNS compartment is 
reached [11]. For the design of a novel neurotherapeutically acting drug or natural-
derived compound, predicting its BBB permeability, partitioning, P450 cytochrome 
association (inhibitor/substrate/none) and off-target binding in the early development 
stage is essential in order to develop a compound that will have sufficient brain 
bioavailability ensuring that the desirable therapeutic effect is acquired and maintained 
at a concentration sufficient to modulate the CNS system without inducing adverse 
reactions. Safety profiles of antidepressant drugs are studied by many groups and 
unfortunately are known to include also serious side effects [12–14]. The safety profiles 
of herbal medicine products (from plant sources) are much less studied despite of 
being frequently concomitantly administered with another (synthetic) drug and bear a 
considerable risk for herbal-induced toxicity issues [15–17]. Herbal-drug interactions 
(HDI) can lead to harmful adverse events as they may alter the pharmacokinetics (PK; 
adsorption, distribution, metabolism or excretion) and pharmacodynamics (PD; 
pharmacological effect is changed in a synergetic, additive or antagonistic way) profile 
of the concomitantly administered drug [18].  
The prediction of interactions of the natural compounds with one major class of drug 
metabolizing enzymes, cytochromes P450, especially the family member CYP2D6, is 
of particular interest. This isoform is responsible for biotransformation of about 25% of 
all the marketed drugs, and displays a very high polymorphism rate [19,20]. Inhibition 
or induction of CYP2D6 metabolism can alter the pharmacokinetic profile of the 
concomitantly administered drug and potentially can lead to toxicity or affect the drug 
efficacy [17]. During the catalytic reaction, interference of the substrate binding to the 
heme, the binding of molecular oxygen, or the biotransformation step in which the 
substrate is oxidized are prone to induce adverse reactions upon inhibition [21]. Based 
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on these three interference mechanisms, inhibitors can be divided into three 
categories; (i) reversible binders (competitive or noncompetitive), (ii) quasi-irreversible 
binders (also referred to as suicide inhibitors) in which the inhibitors interact directly 
with the heme-iron and (iii) mechanism-based inhibitors, which irreversibly bind to the 
protein and accelerate degradation or oxidative fragmentation of the heme [21–23]. 
Compounds which inhibit the enzyme before the oxidative events occur are usually 
reversible competitive or noncompetitive inhibitors. Mechanism-based or suicide 
inhibitors more often act upon the oxygen transfer event or subsequent to this step 
[22]. The latter category can have severe consequences; the complete inactivation of 
the enzyme means that for several hours to days the plasma concentrations of drugs 
which depend on the enzyme activity to become metabolized will increase, which in 
turn increases the risk on adverse reactions [24]. Previous identified CYP2D6 
mechanism-based inhibitor drugs include paroxetine, 3,4-Methylenedioxy
methamphetamine  (MDMA), (1-[(2-ethyl-4-methyl-1H(-EMTPP-imidazol-5-yl)-methyl]-
4-[4-(trifluoromethyl)-2-pyridinyl]piperazine (EMTPP) and 5-Fluoro-2-[4-[(2-phenyl-1H-
imidazol-5-yl)methyl]-1-piperazinyl]pyrimidine (SCH66712) [25–27]. Also compounds 
from several natural sources such as St. John’s wort, common sage and 
goldenseal/berberine have been identified to exercise a moderate to strong inhibition 
effect on CYP2D6 wild-type (WT) and also on allelic variants (e.g. CYP2D6*10) [28–30]. 
Hence there is an urgent need for cost- and time-efficient methods which can help to 
determine the safety profile not only of (new) drugs but also of natural compounds with 
regard to their potential to inhibit CYP2D6 WT and clinically relevant allelic variants. 
An advantageous combination of methods used for identification of  herbal 
compounds that potentially inhibit CYP2D6 consists of an in silico approach for a first 
fast screening, whereas resulting hits can be further verified by experimental in vitro/in 
vivo studies [31,32]. Recently, Hochleiter and co-workers successfully demonstrated 
the potential and relevance of a combined in silico - in vitro based workflow (including 
pharmacophore screening and docking) to identify new compounds derived from a 
natural source that inhibited CYP2D6 WT [31].  
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In this in silico study the safety profile of several compounds from herbs which are 
known or suggested to have antidepressant activity are assessed by: (i) determining 
their inhibitory effect on CYP2D6 WT and the clinical relevant CYP2D6*53 (F120I, 
A122S) allelic variant [33] and (ii) assessing their physiochemical properties along with 
several toxicity-related descriptors in order to define their brain bioavailability potential 
and off-target binding. The CYP2D6*53 allelic variant has been only identified among 
the Japanese with an allele frequency of 0.2% [33]. Moreover, it is the only allelic 
variant associated with increased metabolism activity (4-fold increase in CLint value) for 
the typical CYP2D6 substrate bufuralol. The increased activity is suggested to be 
caused by the F120I mutation which is positioned close to the heme. Therefore, 
investigating and comparing the docking poses of the wild-type and CYP2D6*53 can 
provide insight regarding the role of the F120I mutation. The safety profiles compiled 
for each herbal compound will give a first indication if any toxicity issues might arise 
when they are used to treat depression, especially in multidrug therapy. It has to be 
mentioned that the focus of this study is on herbal compounds which are drug-like in 
terms of size and physiochemical properties. The herbal compounds which were not 
included in the analysis because they did not comply with the library filtering criteria 
applied, might still be suitable as antidepressant as they might cross the BBB and 
modulate the CNS system using any of the active transport mechanisms. However, 
evaluating their safety profile is much more complex and this falls outside the scope of 
our study. 
 
Materials and methods  
Compound Library selection 
The anti-depressant natural compound library was obtained from ChemFaces 
(accessed July 2019), a high-purity natural products manufacturer (Wuhan, P.R. China). 
The 3D coordinate files were obtained from ChemSpider. For the 19 out of 51 
compounds which passed filtering, a literature search was performed using PubMed 
and Scopus to verify their suggested antidepressant activity.  
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CYP2D6 structure selection 
For the available co-crystalized structures (Protein Data bank (PDB) IDs: 3QM4, 3TDA, 
4WNT, 4WNU, 4WNV, 4WNW, 3TBG) it has been shown that the all-atom root-mean-
square deviation (RMSD) of the superimposed binding sites is lower than 1 Å [34]. A 
major motivation of this study is to help avoiding the CYP2D6 toxicity within a co-
therapy context, hence competitive binding. At the moment, there is only one protein-
ligand complex structure available with a co-crystalized substrate molecule: 
thioridazine (a typical antipsychotic drug, PDB ID: 4WNW). Therefore, 4WNW was 
primarily used for docking and the binding mode analysis of the herbal compounds. 
However, two additional structures (PDB IDs: 4WNT and 4WNU), co-crystalized with 
the natural inhibitors ajmalicine and quinidine respectively, were used as well in order 
to verify consensus of the most favorably scored binding mode.  
 
 
Library and protein preparation 
The structures were processed using the standardized ligand preparation procedure 
as implemented in the software LigPrep (Schrödinger LLC.) The preparation procedure 
included bond order assessment, tautomeric state, protonation evaluation (at pH 7.4), 
and chemical structure consistency checks. For all the compounds, the program 
MacroModel was used for the minimization of the starting geometries. The three 
selected CYP2D6 crystal structures (PDB IDs: 4WNW, 4WNU and 4WNT, chain A) were 
retrieved from the PDB database and processed using the Protein Preparation Wizard 
of Maestro small-molecule drug discovery suite (v. 2017-2). Missing residues and 
hydrogen atoms were added (at pH 7.4), bond orders were assigned, and the co-
crystalized ligand and co-factors were removed. No crystal waters are resolved in 
4WNW and the crystal waters in 4WNU and 4WNT were deleted. Compound state I 
was modelled (Fe3+ bound to O2-, zero-order bond). The distance between the iron and 
the oxygen atoms was set to 1.97 Å. For the allelic variant CYP2D6*53 the two residues 
of the wild type structure were mutated (F120I, A122S) subsequently the mutated 
structure was fully minimized. 
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Toxicokinetic parameters and descriptor calculations 
For each studied ligand, the QikProp program by Schrödinger was used to calculate 
the Lipinski’s rule of 5 (hydrogen bond donor and acceptor counts, molecular weight, 
logarithm of the partition coefficient), Veber rules (polar surface area, number of 
rotatable bonds) and several other absorption, distribution, metabolism and excretion 
(ADME) and toxicity related descriptors offered by Schrödinger (QP logHERG, QP PCaco, 
QP logBB, QP PMDCK, Human Oral Absorption and CNS activity score). The models 
behind the calculations assume absorption through passive permeation. The 
descriptions can be found in Table S5.6. Most psychoactive (CNS) drugs need to cross 
the BBB for the modulation of a target neurotransmitter system [35]. Improved BBB 
permeation is usually obtained for such drugs by following narrower Lipinski ranges 
compared to other drugs [36,37]. Two prominent CNS studies which defined the 
pharmacokinetic properties (including Lipinski’s rules) were used as filtering guideline 
and an overview of them can be found in Table 5.1. In addition, the online tool 
Molinspiration (www.molinspiration.com/cgi-bin/properties) was used to assess 
structural similarity and thus potential biological activity towards six important drug 
classes (G-protein coupled receptor (GPCR) ligands, ion channel modulators, kinase 
inhibitors, nuclear receptor ligands, protease inhibitors, enzyme inhibitors).  
 
Autodock smina docking  
Smina, a fork of Autodock Vina (v.1.1.2) was used for docking. Smina is focused on 
improving scoring and minimization and includes several convenient functions which 
can be accessed from the command line such as calculating the box dimensions based 
on one or several existing ligand(s) [38]. The prepared library and CYP2D6 prepared 
protein structures (WT and CYP2D6*53) were used for the docking. The residues F112, 
F120 (or I120 in the variant), E211, E215, E216, R221, Q244, R296, I297, D301, S304, 
and F483 of CYP2D6 were defined as flexible residues (side chains) during the docking. 
The random seed number was set to 0 and an additional 8 Å buffer space was added 
to the auto-generated box. All other settings were kept at their default values.  
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Results and discussion  
 
Figure 5.1 The in silico safety profiling approach of the natural product antidepressant library.  
 
Pharmacokinetics descriptor based filtering 
The ChemFaces antidepressant compound library contained 51 molecules for which 
all pharmacokinetic descriptors were calculated using the program QikProp 
(Schrödinger LLC.). Filtering criteria were based on pharmacokinetic property 
guidelines specific for CNS therapeutic agents (Figure 5.1). Earlier CNS 
pharmacokinetics analysis studies demonstrated that CNS drugs fit within a smaller 
range (Table 5.1 – Lipinski non-CNS column) compared to the general Lipinski 
guidelines (Table 5.1 – Lipinski CNS column) [36]. 
 
Table 5.1 Guidelines for the physicochemical properties associated with improved blood-brain-









a) based on 317 approved CNS drugs, b) based on consensus of several studies discussed in the paper, 
c) derived from a set of 1500 drugs filtered from United States Adopted Names (USAN) or International 
Nonproprietary names (INN) for good CNS penetration by Lipinski. 
 
 
Pajouhesh et al. provided guidelines for CNS drugs based on the consensus of several 
studies discussed in their paper [36]. Other CNS focused physicochemical analyses 
 Ghosea Pajouheshb Wagerc Lipinski 
Descriptor min max  (max) CNSd non-CNS 
MW 141 452 < 450 £ 360 (500) £ 400 < 500 
donorHB 0 3 < 3 £ 0.5 (3.5) £ 3 < 5 
accptHB 1 8 < 7 - £ 7 < 10 
log P o/w 0.16 6 < 5 £ 3 (5)  £ 5  < 5 
log S -0.4 0.5 - - - - 
PSA  3.8 109 60 - 70 40 – 90* (120) - < 140 
#rotor 0 8 < 8 - - < 10 
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found similar reference values with some variation (Table 5.1). Ghose et al. calculated 
for 317 CNS and 627 non-CNS approved drugs the corresponding physicochemical 
properties and the preferred ranges including several pharmacokinetic descriptors 
using QikProp [37]. Wager et al. analysed 119 CNS drugs and 108 Pfizer CNS 
candidates [39]. An overview of all proposed CNS guidelines can be found in Table 
5.1. For filtering of the compounds, the consensus values of Pajouhesh were applied 
as guidelines. In addition, if one of the descriptors was lying outside the guideline 
range, the other proposed ranges (Ghose or Wagner, Table 5.1) were used to validate 
if the value was still acceptable. Compounds with one violations of the Pajouhesh 
guidelines are highlighted in Table 5.2. It must be mentioned that the compounds 
which do not comply with the used filter criteria might still be able to cross the BBB 
and modulate the CNS system through an active transport.  
 
Table 5.2 Pharmacokinetic properties of the natural antidepressants after filtering for drug-like 
properties. The bold highlighted compounds have one or two violation(s) of the Pajouhesh CNS criteria 
of which at least one is still within the acceptable reference value range proposed by Ghose. 





(-)-Cytisine 190.2 0 1 5 0.7 -0.8 45.1 
4-Hydroxyisoleucine 147.2 5 4 5 -2.5 0.0 90.6 
5-Isopropyl-2 methylphenol 150.2 2 1 1 3.3 -2.3 21.4 
Auraptenol 260.3 5 1 5 2.2 -2.6 60.7 
Chelidonic acid 184.1 2 2 7 -0.6 -1.0 139.5 
D-(-)-Synephrine 167.2 5 3 4 0.2 -0.3 57.8 
Honokiol 266.3 7 2 2 5.0 -4.3 42.3 
Isorhynchopylline 384.5 4 1 8 2.6 -4.0 84.7 
L-Theanine 174.2 6 4 6 -3.0 0.2 111.0 
Magnolol 266.3 7 2 2 5.0 -4.2 42.3 
Naringenin 272.3 3 2 4 1.6 -3.4 100.3 
Orcinol 124.1 2 2 2 0.8 0.1 45.1 
Piperine 285.3 5 0 5 3.3 -3.5 48.0 
Protopine 353.4 0 0 7 1.7 -1.1 59.7 
Psoralidin 336.3 4 2 5 3.0 -5.0 92.2 
Salvigenin 328.3 4 0 5 3.3 -4.1 77.1 
Scopoletin 192.2 2 1 4 0.8 -1.7 70.5 
Trans-Methylisoeugenol 178.2 3 0 2 2.8 -3.7 15.8 
Cannabidiol (CBD) 314.5 7 2 2 5.3 -6 39.1 
 
 
After filtering, the remaining 19 compounds (Figure 5.2) were docked in CYP2D6 WT 
and the CYP2D6*53 allelic variant for the three prepared CYP2D6 structures (PDB IDs: 
4WNW, 4WNU and 4WNT) and several pharmacokinetic descriptors were calculated. 
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In addition, the literature was searched if any evidence existed on CYP2D6 inhibition 
(Table S5.1), P450 (major) isoform metabolism (Table S5.2), and their ability to cross 




Figure 5.2 Overview of the selected natural compounds. The red asterisk indicates that previous 
research found CYP2D6 inhibition (potent to weak) activity for the compound (see table S1 for the 
reference), the red cross no CYP2D6 inhibition activity. For the remaining compounds no CYP2D6 
inhibition data could be found.  
 
 
CYP2D6 inhibition  
 
CYP2D6 WT inhibition activity (varying from weak to potent inhibition) data was found 
for 7 compounds, 4 compounds were identified to have no inhibition activity, and for 
8 no data could be found (Table S5.1). Though the neolignans honokiol and magnolol 
present in magnolia bark extract have been considered to be safe in use by various 
authorities [40] , evidence exists on CYP2D6 inhibition for magnolol (IC50 65.4 µM) [41]  
and weak inhibition for honokiol (Ki 12 µM) [42]. Cannabidiol (CBD) one of the three 
major components in the cannabis plant has been identified as potent atypical inhibitor 
(IC50 6.52 µM) of CYP2D6 [43]. Furthermore, for piperine weak inhibition (IC50 3.2 µM) 
and protopine potent competitive inhibition (Ki 78 nM) has been determined [44,45]. 
Moderate CYP2D6 WT inhibition was found for (-)-cytisine (IC50 28.9 µmol/L) and 
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isorhynchophylline (IC50 44.1 µmol/L) [30]. Literature search confirmed for 13 
compounds that they are able to cross the BBB (Table S5.3). Whether they reach a high 
enough concentration to acquire and maintain their bioactivity within the brain remains 
an open question and needs to be confirmed by additional clinical studies. 
Experimental evidence of CYP-mediated metabolism was found for nine of the 
compounds, one has been assigned no CYP-metabolism dependence, and for other 
nine no data was found (Table S5.2). No literature was found that assigned CYP2D6 as 
major isoform for metabolism for one of the compounds.  
 
Inhibition binding modes from Molecular Docking 
The top 10 binding poses were evaluated on potential CYP2D6 inhibition. The distance 
of the binding pose (distal or proximal) between the heme and the ligand was 
evaluated as well as the functional group and closest atom to the iron heme. If the 
distance between the heme-iron and any atom of the ligand was bellow 6 Å it was 
assigned proximal binding, otherwise it was assigned as distal. Several residues in the 
binding pocket are essential for ligand binding. Glu216 and/or Asp301 are known to 
act as first anchoring point by forming salt bridges with the commonly protonated 
aliphatic nitrogen atom (at physical pH) present in most typical CYP2D6 substrates. 
Subsequently Phe120 which resides in close proximity of the heme can further steer 
the orientation of the ligand by interacting with the aromatic part of the substrate 
through π-π stacking interactions [46–48]. An example of inhibition can be observed in 
the crystal CYP2D6 structure (PDB ID: 4WNU) where quinidine (inhibitor) binds distal 
from the heme and its protonated nitrogen forms electrostatic interactions with both 
E216 and D301 [48]. Based on this knowledge docking binding modes were assigned 
to potentially inhibit CYP2D6 if (i) a functional group (known not to be normally 
metabolized) was interacting directly with the iron heme, (ii) the distal binding from the 
heme prevented other ligands to reach the heme and/or blocked interaction with D301 
and/or E216. Furthermore, the binding profile of the pose was evaluated on the 
presence of potential electrostatic interactions, hydrogen bonding, and hydrophobic 
interactions. The docking results can be found in Table 5.3 and a detailed overview of 
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the different interactions types of the best binding modes can be found in Tables S5.4 
and S5.5.  
 
Table 5.3 Overview CYP2D6 WT and CYP2D6*53 docking results. The top 10 docking poses were 
evaluated on potential CYP2D6 inhibition by evaluating its binding distance towards the heme (proximal 
or distal) together with its binding pocket interaction profile.  
 CYP2D6 WT CYP2D6*53 
Compounds   prox dis none prox dis none 
(-)-Cytisine             
4-Hydroxyisoleucine             
5-Isopropyl-2-methylphenol              
S-Auraptenol             
Chelidonic acid             
D-(-)-Synephrine             
Honokiol             
Isorhynchopylline             
L-Theanine             
Magnolol             
Naringenin             
Orcinol             
Piperine             
Protopine             
Psoralidin             
Salvigenin             
Scopoletin             
Trans-Methylisoeugenol             
Cannabidiol (CBC)              
 
Within the top 10, the most productive pose(s) (based on the mentioned criteria above) 
proximal and/or distal from the heme were selected. An interaction profile for the 
herbal compounds that were binding (proximal and/or distal) can be found in the 
supplementary data (Figures S5.1 and S5.2). From the 7 compounds for which 
experimental evidence was found on CYP2D6 WT inhibition activity, the binding poses 
of piperine, protopine, honokiol, magnolol, and cannabidiol were found to potentially 
inhibit CYP2D6 WT and CYP2D6*53; the binding mode of piperine in the wild-type 
was more strongly stabilized by hydrophobic interactions with F120 than with I120 in 
CYP2D6*53 (Figures 5.3 and 5.5B). Protopine formed mainly electrostatic/hydrophobic 
interactions with the heme group. In CYP2D6 WT π-π stacking was observed with F483 




Figure 5.3 CYP2D6 WT and CYP2D6*53 inhibition binding modes for A) piperine and B) protopine. 
The best scored poses are shown docked into 4WNW (cyan), 4WNU (orange) and 4WNT (grey). To keep 
a clearer overview, interactions are not indicated and only the heme of 4WNW is displayed. 
 
The binding modes observed (proximal and also distal) for honokiol and magnolol in 
CYP2D6 WT and CYP2D6*53 were such that one of the two ethylene tails pointed 
towards the heme and one of the hydroxyl groups formed electrostatic interactions 
with either D301 or a stabilizing hydrogen bond with S304 (Figures 5.4 and S5.2). In 
addition, for CYP2D6 WT, hydrophobic interactions with F120 and one of the phenyl 







Figure 5.4 CYP2D6 WT and CYP2D6*53 inhibition binding modes for A) Honokiol and B) 
Magnolol. The best scored poses are shown docked into 4WNW (cyan), 4WNU (orange) and 
4WNT (grey). Interactions were excluded to keep a clearer overview and only the heme of 
4WNW is displayed. 
 
For cannabidiol, the best scored binding modes pointed the aliphatic pentyl tail 
towards the heme and one of the two hydroxyl groups was stabilized by either a 
hydrogen bond (S304, Q244) or electrostatic interaction with D301 in CYP2D6 WT and 
CYP2D6*53 (Figure S5.1B). In CYP2D6 WT stabilizing hydrophobic interactions 
between F120 and the aromatic ring were found for honokiol and magnolol (Figure 
S5.2). For cytisine, a binding pose pointing towards potential inhibition was only 
observed in the CYP2D6 WT; the protonated nitrogen of cytisine formed an 
electrostatic interaction with D301. For isorhynchophylline no reasonable binding 
poses that could explain its inhibitory effect on CYP2D6 were generated.  
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The compounds L-theanine, orcinol, naringenin and psoralidin for which experimental 
studies confirmed no CYP2D6 WT inhibition (Figure 5.2, Table S5.1), docking results 
did neither show any decisive inhibition binding modes in CYP2D6 WT or CYP2D6*53. 
For the remaining 8 compounds for which no experimental CYP2D6 inhibition data was 
found, 4-hydroxyisoleucine, chelidonic acid, salvigenin, and trans-methylisoeugenol 
did not show any CYP2D6 inhibition binding modes in both CYP2D6 WT or 
CYP2D6*53. The proximal binding poses of thymol (5-isopropyl-2-methylphenol) 
formed hydrophobic interactions with F120 and hydrophobic/electrostatic interactions 
with the heme group in CYP2D6 WT. For the distal binding modes of (S)-auraptenol, 
the hydroxyl group formed a hydrogen bond with S304 or/and also electrostatic 
interactions with D301 or E216 in CYP2D6 WT or CYP2D6*53 (Figure S5.1A). In 
addition, π-π stacking between the hydrophobic ring and F120 was observed for the 
highest ranked pose in CYP2D6 WT. For D-(-)-synephrine proximal binding was found 
in CYP2D6 WT with mainly electrostatic stabilizing interactions (E216 and Q244) 
whereas proximal binding in CYP2D6*53 with the protonated nitrogen forming 
electrostatic interactions with D301 (Figure S5.1B). Scopoletin showed a similar 
proximal binding mode in which the oxygen pointed in the direction of the heme group 
in both CYP2D6 WT and CYP2D6*53 (Figure S5.1B).  
 
 
Pharmacokinetic and toxicity-related descriptors 
 
Several Several pharmacokinetic descriptors calculated with QikProp can be found in 
Tables 5.4 and 5.5. Chelidonic acid, L-theanine and naringenin have all a PSA above 
100 Å, and 4-hydroxyisoleucine and isorhynchophylline exceed the number of 
acceptable hydrogen bond donors or acceptors for CNS drugs which could decrease 
their ability to permeate the BBB (Table 5.2), although experimentally evidence for all 
except chelidonic acid exists that they cross the BBB (Table S5.3). From the toxicity-
related calculated QikProp descriptors (Table 5.4), 8 compounds have one or more 
value(s) lying outside the recommended regions. 4-Hydroxyisoleucine, chelidonic acid 
and L-theanine have QP Pcaco and QP PMDCK predicted values indicating potential issues 
with cell permeability, which is also indicated by their predicted low human oral 
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absorption and inactive (below 0) CNS score. Naringenin and psoralidin are also 
predicted to be CNS inactive. Honokiol, magnolol, isorhynchophylline, psoralidin and 
salvigenin are predicted to interact with the hERG channel. Furthermore, the online 
prediction platform Molinspiration (www.molinspiration.com) was used for prediction 
of a bioactivity score towards six of the most important drug classes (GPCRs, ion 
channel modulators, kinase inhibitors, nuclear receptor ligands, protease inhibitors, 
enzyme inhibitors) based on the structure similarity with typical class representatives 
(Table 5.5).  
 




















(-)-Cytisine -3.8 490.6 0.4 253.5 -0.35 79 1 
4-Hydroxyisoleucine -1.5 15.4 -0.6 7.6 -0.99 34 -1 
5-Isopropyl-2-methylphenol -3.6 3696.9 0.1 2032.9 0.06 100 1 
Auraptenol -4.0 1322.6 -0.5 669.3 -0.17 96 0 
Chelidonic acid 0.3 1.3 -1.8 0.6 -1.18 26 -2 
D-(-)-Synephrine -4.8 192.5 -0.3 92.2 -0.61 69 0 
Honokiol -5.8 1614.8 -0.7 830.4 0.57 100 0 
Isorhynchophylline -6.1 263.4 -0.3 129.4 0.20 86 1 
L-Theanine -1.0 5.6 -1.1 4.3 -1.28 23 -2 
Magnolol -5.7 1716.8 -0.6 887.3 0.57 100 0 
Naringenin -5.0 130.0 -1.4 54.5 -0.02 74 -2 
Orcinol -3.3 911.7 -0.4 447.6 -0.54 85 0 
Piperine -4.8 3980.1 -0.1 2201.8 -0.02 100 0 
Protopine -4.4 1297.8 0.7 725.4 -0.42 93 2 
Psoralidin -5.7 311.8 -1.3 140.4 0.37 89 -2 
Salvigenin -5.2 1504.0 -0.5 769.0 0.15 100 0 
Scopoletin -3.8 626.8 -0.6 298.6 -0.48 82 0 
Trans-Methylisoeugenol -3.9 9906.0 0.1 5899.3 0.10 100 1 
Cannabidiol (CBD) -3.8 490.6 0.4 253.5 -0.35 79 1 
 
 
A bioactivity prediction score above 0 indicates a high similarity to existing active 
compound. Considering the fact that GPCRs are paramount for regulation of mood, 
pain, cognition, and neurotransmitter release through synaptic transmission, 
predicted bioactivity towards those receptors would be expected for the modeled 
compounds [49]. Several CNS drugs (e.g. tricyclics such as amitriptyline) modulate ion 
channel activity to reduce depression in human [50,51] hence a bioactivity score for 
ion channel modulation above 0 would be considered as a positive result. For the 
remaining four drug classes (kinase inhibitors, nuclear receptor ligands, protease 
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inhibitors, enzyme inhibitors) no similarity (activity) is desired. Table 5.5 shows that 
cytisine, isorhynchophylline, naringenin, protopine, and CBD are predicted to be 
similar (active) towards the GPCR ligand and/or the ion channel modulator drug class. 
Honokiol, naringenin, psoralidin, and CBD are predicted to be similar (active) towards 
one of the four undesired drug classes.    
 
Table 5.5 Bioactivity prediction score for the 19 compounds towards six important drug classes. 
Favorable predication scores are highlighted yellow, unfavorable red.  
 
 















(-)-Cytisine -0.58 0.39 -0.75 -1.1 -0.62 -0.25 
4-Hydroxyisoleucine -0.72 -0.26 -1.31 -0.96 -0.71 -0.31 
5-Isopropyl-2-methylphenol -1.02 -0.51 -1.15 -0.7 -1.25 -0.56 
Auraptenol -0.24 -0.56 -0.73 0.14 -0.56 0.11 
Chelidonic acid -1.05 -0.56 -0.93 -1.02 -0.92 -0.4 
D-(-)-Synephrine -0.39 0.07 -0.79 -0.51 -0.88 -0.04 
Honokiol 0.04 0.06 -0.08 0.32 -0.2 0.13 
Isorhynchopylline 0.26 0.19 -0.3 0.03 -0.22 0.01 
L-Theanine -0.53 -0.15 -1.15 -1.42 -0.08 -0.4 
Magnolol -0.01 0.05 -0.15 0.2 -0.23 0.07 
Naringenin 0.03 -0.2 -0.26 0.42 -0.12 0.21 
Orcinol -2.26 -1.64 -2.35 -2.1 -2.59 -1.77 
Piperine 0.15 -0.18 -0.13 -0.13 -0.1 0.04 
Protopine 0.2 0.07 -0.35 -0.24 -0.07 0.17 
Psoralidin -0.2 -0.09 -0.17 0.53 -0.15 0.21 
Salvigenin -0.11 -0.27 0.15 0.13 -0.29 0.11 
Scopoletin -1 -0.65 -0.95 -0.81 -1.16 -0.24 
Trans-Methylisoeugenol -0.95 -0.53 -0.98 -0.72 -1.2 -0.53 





In this study the safety profile of 19 natural compounds was evaluated on CYP2D6 
inhibition using an in silico approach. Inhibition was investigated for CYP2D6 WT and 
the allelic variant CYP2D6*53 which is associated with increased metabolism activity 
for bufuralol. The variant contains two amino acid mutations (F120I, A122S) of which 
F120I is positioned in close vicinity of the heme. Comparison of the docking binding 
poses of the wild-type and variant can provide insight on the function of the mutation 
in modulating the accessibility of the compound to the heme. In addition, it may give 
an indication regarding the impact of allelic variants with amino acid mutations close 
to the heme on inducing inhibition. Moreover, it is generally accepted that accurate 
site of metabolism prediction requires to probe the accessibility and the reactivity of 
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the ligand atoms [52]. However, for the aim of this study in which the focus is on 
inhibition, using a time-efficient structure-based method such as docking to investigate 
the compound-CYP interactions and subsequently deduce its inhibition potential has 
previously shown to be a valuable pre-screening strategy [31,34,53]. Subsequently, in 
vitro and in vivo safety studies can be performed for examination of the smaller 
compound set. The results from the natural compound docking correlated 6 out of 7 
experimentally confirmed CYP2D6 WT inhibitors; honokiol, magnolol, cannabidiol, 
piperine, protopine and cytisine. In the allelic variant CYP2D6*53, potent inhibition 
binding modes were observed as well except for cytisine. The docking poses of (S)-
auraptenol and scopoletin in CYP2D6 WT and CYP2D6*53 pointed towards potential 
inhibition activity as well. 5-Isopropyl-2-methylphenol formed electrostatic interactions 
with the prosthetic heme group in CYP2D6 WT only. The mutation F120I enabled for 
some compounds (especially D-(-)-synephrine, scopoletin, (-)-cytisine) to get closer to 
the heme-oxygen. These compounds have in common that they are relatively small 
and less flexible, which restricts their possible binding modes to the heme-oxygen 





Figure 5.5 Mechanism based CYP2D6 inhibition. A) Piperine and protopine both contain a 
methylenedioxyphenyl moiety which has been associated with mechanism-based inhibition of CYP2D6 
(e.g. paroxetine and MDMA are CYP2D6 MBI). B) The best scored binding mode (in 2D) for each is 
shown in CYP2D6 WT and CYP2D6*53. The asterisk indicates the atom closest to the heme-iron. Color 
code: hydrophobic interactions; brown, electrostatics; purple, and hydrogen bonds; blue.  
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An interesting observation was made for the alkaloids piperine and protopine both 
containing a methylenedioxyphenyl moiety (Figure 5.5A). The highest scored docking 
pose of piperine and protopine in both CYP2D6 WT and CYP2D6*53 positioned the 




Natural remedies are often associated with a safe use. Buying herbal supplements 
seems to be harmless as most of the time no special warnings can be found in the 
accompanying information. However, an increasing trend of using natural compounds 
as single antidepressant or in polypharmacy needs to be handled with caution. Toxicity 
issues may arise depending on the dose and therapy and its P450 metabolism 
dependence if the herbal compound or a complex product is not given safety 
clearance by the FDA or another established authority. CYP2D6 inhibition or off-target 
binding are particularly dangerous. The in silico results of this study indicate for several 
of the natural compounds suggested to be used as antidepressant that a potential 
increased risk may exist on adverse reactions triggered by CYP2D6 inhibition or 
another off-target analysed (kinase inhibitors, nuclear receptor ligands, protease 
inhibitors, enzyme inhibitors, hERG binding). From the 19 natural compounds 
analysed, 9 indicated no CYP2D6 inhibition for both CYP2D6 WT and CYP2D6*53 (4-
hydroxyisoleucine, chelidonic acid, isorhynchopylline, L-theanine, naringenin, orcinol, 
psoralidin, salvigenin, trans-methylisoeugenol). The other 10 natural compounds ((-)-
cytisine, 5-isopropyl-2-methylphenol, s-auraptenol, D-(-)-synephrine, honokiol, 
magnolol, piperine, protopine, scopoletin and cannabidiol) showed clearly potential 
for CYP2D6 WT and/or CYP2D6*53 inhibition. If administered with a concomitant drug 
which depends on CYP2D6 activity this may lead to adverse reactions. Further 
experimental investigations are required to confirm the outcome of the in silico 
docking, the off-target predictions and the toxicity descriptors. Especially hERG 
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Table S5.1 Overview of literature sources for CYP2D6 inhibition. 
 
Table S5.2 Overview of literature sources for P450 metabolism. 
 
Table S5.3 Overview of literature sources for blood brain barrier (BBB) crossing. 
 
Figure S5.1 The best scored binding modes (in 2D) for A) (-)-Cytisine, (S)-auraptenol and 5-isopropyl-
2-methylphenol and B) Scopoletin, cannabidiol (CBD) and D-(-)-synephrine are shown in CYP2D6 
WT and CYP2D6*53. 
 
Figure S5.2 The best scored binding modes (in 2D) for honokiol and magnolol are shown in CYP2D6 
WT and CYP2D6*53. 
 
Table S5.4 Overview of the various types of interactions found in the best binding modes for 
CYP2D6 WT. 
 
Table S5.5 Overview of the various types of interactions found in the best binding modes for 
CYP2D6*53. 





































Table S5.1. Overview of literature sources for CYP2D6 inhibition. If literature for a compound on 
the topic could not be found, this is indicated as “unknown”. 
Natural Product CYP2D6 inhibition Reference 
(-)-Cytisine moderate [29] 
4-Hydroxyisoleucine unknown - 
5-Isopropyl-2-methylphenol unknown - 
Auraptenol unknown - 
Chelidonic acid unknown - 
D-(-)-Synephrine unknown - 
Honokiol moderate [48] 
Isorhynchophylline moderate [29] 
L-Theanine none [57] 
Magnolol moderate [47] 
Naringenin none [65] 
Orcinol none [49] 
Piperine weak [44] 
Protopine potent [43] 
Psoralidin none [70] 
Salvigenin unknown - 
Scopoletin unknown - 
Trans-Methylisoeugenol unknown - 




























Table S5.2. Overview of literature sources for P450 metabolism. If literature for a compound on the 
topic could not be found, this is indicated as “unknown”. 
Natural Product P450 metabolism (major isoforms) Reference 
(-)-Cytisine unknown - 
4-Hydroxyisoleucine unknown - 
5-Isopropyl-2-methylphenol CYP2A6 [63] 
Auraptenol unknown - 
Chelidonic acid unknown - 
D-(-)-Synephrine unknown - 
Honokiol CYP1A2, CYP2C8, 
CYP2C9, CYP2C19 
[58] 
Isorhynchophylline CYP2D, CYP1A1, 
CYP1A2, CYP2C 
[40] 
L-Theanine none [57] 
Magnolol CYP2E1, CYP3A4, 
CYP1A2 
[74] 
Naringenin P450-dependent [66] 
Orcinol unknown - 
Piperine unknown - 
Protopine CYP2D1, CYP2C11 [55] 
Psoralidin CYP2C19 [70] 
Salvigenin unknown - 
Scopoletin unknown - 
Trans-Methylisoeugenol P450-dependent [62] 































Table S5.3. Overview of literature sources for crossing of blood brain barrier (BBB). If literature for 
a compound on the topic could not be found, this is indicated as “unknown”. 
 
Natural Product BBB  Reference 
(-)-Cytisine poor [59] 
4-Hydroxyisoleucine unknown - 
5-Isopropyl-2-methylphenol unknown - 
Auraptenol unknown - 
Chelidonic acid unknown - 
D-(-)-Synephrine poor [61] 
Honokiol √ [64] 
Isorhynchophylline √ [72] 
L-Theanine √ [71] 
Magnolol √ [53] 
Naringenin √ [56] 
Orcinol √ [40] 
Piperine √ [68] 
Protopine √ [69] 
Psoralidin unknown - 
Salvigenin √ [54] 
Scopoletin √ [67] 
Trans-Methylisoeugenol unknown - 


















Figure S5.1 The best scored binding modes (in 2D) for A) (-)-cytisine, (S)-auraptanol and 5-
isopropyl-2-methylphenol and B) Scopoletin, cannabidiol (CBD) and D-(-)-synephrine are shown in 
CYP2D6 WT and CYP2D6*53. The asterisk indicates the atom closest to the heme-iron. Color code: 
hydrophobic interactions; brown, electrostatics; purple, and hydrogen bonds; blue. Proximal: distance 






Figure S5.2 The best scored binding modes (in 2D) for honokiol and magnolol are shown in 
CYP2D6 WT and CYP2D6*53. The asterisk indicates the atom closest to the heme-iron. Color code: 
hydrophobic interactions; brown, electrostatics; purple, and hydrogen bonds; blue. Proximal: distance 



























WT  Distance Heme 
  AA Type (Å) (Å) 
Thymol   F120 π stacking ~3.8 4.7 
s-auraptenol  D301 ionic 2.3 7.6 
  S304 H-bond 2.4  
D-(-)-synephrine  01 D301 ionic 2.6 6.1 
  F120 π-stacking ~ 4.7  
                               02 E216 ionic 2.3 5.1 
  Q244 H-bond 2.3  
  F247 π stacking ~ 4.3  
Honokiol              01 F120 π stacking ~ 4.3 4.7 
                                  02 F120 π stacking ~ 3.9 7.6 
  S304 H-bond 2.5  
Magnolol               01 D301 ionic 1.9 6.0 
  F120 π stacking ~ 4.0  
       02 D301 ionic 2.6 5.4 
  S304 H-bond 2.3  
Piperine  F120 π stacking ~3.8 5.4 
  F483 π stacking ~ 4.0  
Protopine  Q244 H-bond 2.4 5.9 
  F120 π stacking 3.1  
  F120 π stacking 6.5  
  F483 π stacking 3.5  
Scopoletin  S304 H bond 2.4 5.3 
  F120 π stacking ~ 3.8  
Cannabidiol         01 Q244 H-bond 2.3 4.7 
  F120 π stacking 3.6  
  02 S304 H-bond 2.4 7.8 

















V53  Distance Heme 
  AA Type (Å) (Å) 
Thymol   F120 π stacking ~3.8 4.7 
(S)-auraptenol  D301 ionic 2.3 7.6 
  S304 H-bond 2.4  
D-(-)-synephrine  01 D301 ionic 2.6 6.1 
  F120 π-stacking ~ 4.7  
                               02 E216 ionic 2.3 5.1 
  Q244 H-bond 2.3  
  F247 π stacking ~ 4.3  
Honokiol              01 F120 π stacking ~ 4.3 4.7 
                                  02 F120 π stacking ~ 3.9 7.6 
  S304 H-bond 2.5  
Magnolol               01 D301 ionic 1.9 6.0 
  F120 π stacking ~ 4.0  
       02 D301 ionic 2.6 5.4 
  S304 H-bond 2.3  
Piperine  F120 π stacking ~3.8 5.4 
  F483 π stacking ~ 4.0  
Protopine  Q244 H-bond 2.4 5.9 
  F120 π stacking 3.1  
  F120 π stacking 6.5  
  F483 π stacking 3.5  
Scopoletin  S304 H bond 2.4 5.3 
  F120 π stacking ~ 3.8  
Cannabidiol         01 Q244 H-bond 2.3 4.7 
  F120 π stacking 3.6  
  02 S304 H-bond 2.4 7.8 






     
Table S5.6 Overview QikProp descriptors with Schrödinger explanation. 
Descriptor Explanation (Schrödinger – QikProp) 
QPlogHERG Predicted IC50 value for blockage of HERG K+ channels 
QPPCaco  Predicted apparent Caco-2 cell permeability in nm/sec. Caco2 cells are a model for the gut-
blood barrier. QikProp predictions are for non-active transport. 
QPlogBB Predicted brain/blood partition coefficient. Note: QikProp predictions are for orally delivered 
drugs so, for example, dopamine and serotonin are CNS negative because they are too polar 
to cross the blood-brain barrier 
QPPMDCK  Predicted apparent MDCK cell permeability in nm/sec. MDCK cells are considered to be a 
good mimic for the blood brain barrier. QikProp predictions are for non-active transport. 
QPlogKhsa Prediction of binding to human serum albumin 
HOA (%)  Predicted human oral absorption on 0 to 100% scale. The prediction is based on a 
quantitative multiple linear regression model.  
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This PhD work explored several aspects of CYP2D6 pharmacogenetics at the atomic 
level using molecular modeling. Various computational techniques were applied in 
order to gain a clearer picture of how amino acid mutations within the CYP2D6 
binding pocket can alter enzyme activity and its selectivity. Deciphering the key factors 
and their contribution in the overall catalytic cycle is essential in order to develop 
accurate metabolism and toxicity prediction tools. Such tools can be used by the 
research community to extend our current CYP2D6 knowledge and also by medicinal 
chemists working in the CADD department to evaluate - from early stage on - the 
chances that a lead compound might interact with CYP2D6 WT or clinical relevant 
allelic variants. This insight can be valuable for the rational design of new drugs and 
lower or prevent treatment failure due to an unfavorable metabolic profile. 
In this work we have shown that a reliable site of metabolism prediction requires the 
assessment of the energetic and steric accessibility of the potential metabolic hot 
spots in the molecule within the active site and the intrinsic reactivity of the metabolic 
hot spot towards the heme-oxygen. The interplay between the residues within the 
binding pocket and the ligand can modulate its access and orientation towards the 
heme as observed in the increased activity variant CYP2D6*53 (F120I, A122S) during 
1 microsecond MD simulations. By studying the hydroxylation of bufuralol using 
QM/MM, we found that the amino acid mutation F120I in close vicinity of the heme 
led to a lower activation barrier for the major site of metabolism. It has been found in 
previous studies that in smaller binding pockets in which the ligand can adopt only a 
limited number of conformations, the steric factors become more relevant. On the 
other hand, in a larger binding pocket, the ligand adopts multiple conformations 
which are in thermodynamic equilibrium, hence the kinetic factor – the activation 
barrier - will be more important in directing the selectivity. Also, the large flexibility of 
CYP2D6 requires for each ligand that the binding pocket is properly adjusted by for 
example induced fit, a short MD simulation based minimization or ensemble docking.   
The MD simulations of membrane-anchored CYP2D6 showed that the formation of 
tunnels, which provide the access and egress pathways for the ligands to and from the 
heme, can be seen as a compound pre-filtering step. The residues lining the tunnel 
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will favor particular ligands over others (e.g. ligands with a more hydrophobic nature, 
small to medium sized). This is also demonstrated by our finding that several natural 
herbal-derived products were, just like drugs, able to bind within the active site and 
inhibit CYP2D6 wild-type and and the allelic variant CYP2D6*53. This shows that as 
long as the compounds share the molecular characteristics that a particular CYP 
isoform favors, there is a higher probability that they will enter the CYP, reach the 
active site and the heme. Hence, there is a need to perform for any compound, 
rational designed or derived from a natural source, a profound safety assessment 
including P450 inhibition screening before approving it as a supplement or 
natural/herb product based therapy.  
As of today, considerable progress has been made in the development of in silico 
CYP2D6 predictive tools especially by application of QSAR, pharmacophore 
modeling, molecular docking, MD simulations, and their integrative use. Nevertheless, 
the complete framework in which these elegant enzymes operate is large and several 
challenges still need to be addressed in future. Within the context of structure-based 
metabolism and toxicity predictions, improvements can be expected for the handling 
of the enzyme flexibility and the incorporation of polymorphism data by using 
methods such as MD simulations or also elastic networks. Furthermore, considering 
the level of expertise often required to be able to use such tools, tailoring the 
approaches into automated implemented protocols, accessible at a user-friendly 
webserver provides benefit also to less-experienced users. A relevant question which 
adds to the complexity of the toxicity predictions is the observation that more than 
one molecule can bind simultaneously within the active site of several isoforms 
including CYP2D6 and CYP3A4. Little information is available on how this will impact 
the binding and enzyme activity. Further studies tackling this phenomenon need to 
be performed in order to know how to deal with this in predictive tools. Furthermore, 
the outcome of computational toxicity predictions need to be interpreted relative and 
not as absolute answer. Any computational outcome is based on a model and every 
model has its inherent limitation. For instance, dose or exposure rates are difficult 
parameters to include into the model. Hence, these techniques will not be able to 
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completely replace the in vivo and in vitro approaches for predicting toxicity. The 
emerging position of the in silico Drug, Metabolism and Pharmacokinetics (DMPK) 
expert which works with medicinal chemists, computational chemists and DMPK 
scientists demonstrates the value of synergistic collaboration in order to intertwine 
















































Our body is daily challenged by a plethora of chemical substances coming from 
diverse sources; cosmetics that are applied to the skin (e.g. phthalates, parabens, and 
volatile fragrances), contaminated food (e.g. with pesticides; organophosphate, 
organochlorine, or carbamate), drugs causing unforeseen adverse reactions, air 
pollution (e.g. ozone, carbon monoxide, and lead), pollutants that are difficult to 
remove from the wastewater (e.g. drugs and heavy metals), and many others found 
sometimes at unexpected sources such as children toys or cashier bills. The elimination 
of such toxins occurs mainly in the liver. Here, a large enzyme family, the P450 
cytochromes (CYPs), is responsible for the breakdown (metabolism) of xenobiotics 
(foreign molecules: drugs, environmental pollutants, carcinogens, and other 
chemicals) and endogenous metabolites (molecules produced by the body: e.g. fatty 
acids, steroids, prostaglandins). Although the compounds are structurally diverse, they 
all share a rather lipophilic character. For elimination from the body, the compounds 
need to be transformed into more hydrophilic (water soluble) molecules. This is the 
task of CYPs; the chemical reactions catalyzed by the CYPs make compounds more 
hydrophilic by adding and/or transforming functional groups, e.g. addition of a 
hydroxyl group to a carbon atom through oxidation. Subsequently, clearance from our 
body occurs mainly through excretion by the kidneys. Unravelling parts of the complex 
framework in which CYPs operate and selectively catalyze compounds has started 
about 60 years ago. Although several discoveries have been paramount for building 
our P450s knowledge, many aspects related to the interplay between the enzyme and 
its environment and the major driving forces of the catalysis reaction within each 
isoform remain unclear. 
One family member, CYP2D6, has been the main focus of many research studies 
primarily due to its high polymorphism rate (gene modification) which can lead to 
serious toxicity issues especially within the context of drug therapies. The research 
described in this work confirms how beautifully complex the enzymes are and 
nevertheless provides some essential clues regarding the CYP2D6 framework and its 
function. This new knowledge may contribute to the development of more accurate 
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in silico CYP P450 mediated metabolism and toxicity prediction and modeling 
software. Last but not least it can potentially aid in the design of more efficient CYP 
biocatalysts.  
In Chapter 1 a basic introduction is given which should provide the reader with the 
fundamental knowledge needed to understand the following chapters. As start, an 
overview of the earliest P450 experiments that led to the discovery of the versatile 
P450 enzyme family is given. Subsequently, P450 family member CYP2D6 is 
introduced, the consequences of CYP2D6 pharmacogenetics on clinical treatment and 
the significance of exploring CYP2D6-drug interactions as early as possible within the 
the drug design process are highlighted. Following section focuses on the P450 
catalytic reaction cycle together with a detailed explanation of the P450 hydroxylation 
reaction pathways. After that, the state-of-the-art modeling techniques used to study 
CYP2D6 and its environment follow. This section is divided into ligand-based and 
structure-based methods. The last part of this chapter contains a comprehensive 
description of the fundamental theory underlying molecular dynamics (MD) 
simulations and quantum mechanics/ molecular mechanics (QM/MM) calculations as 
they were the major computational methods applied within this thesis research.  
In Chapter 2, CYP2D6 pharmacogenetics is investigated by determining the impact 
of amino acid mutations, located in close vicinity of the reactive heme center, on the 
enzyme activity. Two CYP2D6 variants (increased and no activity) are used in addition 
to the wild-type, and bufuralol, a typical CYP2D6 substrate, to study the aliphatic and 
aromatic hydroxylation mechanism within different active site compositions. 
Experimental research identified one major and two minor sites of metabolism (SoM). 
One additional site is included as a negative control. In the first part of the study, 
molecular docking is used for the generation of the poses and well-tempered 
metadynamics (WT-MTD) simulation is employed to investigate the free energy 
surface (FES) profile for each SoM within each CYP2D6 variant. The two collective 
variables (CVs) chosen to drive the WT-MTD simulation are correlated to the transition 
state geometry and thus can provide insight on the following questions:  
214  
(i) is the lowest energy pose of the substrate in the active site also is the pose in which 
the monitored SoM is positioned favourably to the expected transition state (TS) 
geometry, and (ii) is it possible to distinguish major and minor SoMs based on the 
minima in the free energy profiles of each SoM.  
Assessment of the FES profiles indicates that neither the first nor the second question 
can be answered by solely comparing the FES profiles of each SoM within each allelic 
variant. Keeping in mind the accuracy limitations of each individual force field 
describing the free energy landscape, this knowledge may point towards reliability 
issues of SoM toxicity predictions solely based on docking methods. In the second 
part of the study, the contribution of the intrinsic reactivity of the substrate within 
different active site environments on the overall catalytic reaction is explored. In order 
to properly account for the reactivity, a quantum mechanics method is required and 
considering the large size of the system in question, a QM/MM approach is most 
frequently used. The starting structure for each SoM and the control site within the 
wild-type and increased activity allelic variant CYP2D6*53 could be obtained from the 
WT-MTD simulation performed before. The QM region comprised of around 150 
atoms and the MM part the remaining solvated protein. Using a starting structure with 
a geometry closest to the transition state structure, a M06-2X/LACV3P* QM/MM 
minimization was run and from the optimized structure the intermediate structure was 
generated and also QM/MM minimized. Subsequently a transition search was 
performed to localize the transition state geometry. Single point energy calculations 
(M06-2X/LACV3P**) on each minimized structure enabled to define the activation 
barrier for each SoM. The QM/MM results demonstrate first of all that it is crucial to 
define the stereoelectronic complementarity of a ligand for an accurate CYP2D6 
metabolism prediction. Secondly, valuable insight was gained regarding the F120I 
amino acid mutation within the active site that can selectively steer the efficiency of 
the C-H bond activation; the conserved F120I mutation led to a lower activation 
barrier for the major S1 and minor S2 SoM. Nevertheless, the enantioselectivity and 
stereoselectivity remained the same. Hence, we anticipate that a mutation with a 
smaller amino acids, is needed to influence the enantioselectivity as experimentally 
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observed for the F120A mutation. In Chapter 3, apo and holo MD simulations of one 
microsecond were performed in order to evaluate the impact of the amino acid 
location (active site or substrate recognition site) and the type (conservation) on the 
dynamic behaviour of the wild-type and five allelic variants with normal (one), 
increased (one), decreased (two) and inactive (one) activity. The motivation for this 
study was to improve our current knowledge regarding the structure-function activity 
correlation of the wild-type and the five selected allelic variants. Such information can 
be of great value for the rational design of drugs and can aid in the further 
development of CYP2D6 toxicity modeling tools. The selection of the variants was 
based on their clinical relevance and also if they shared at least one common mutation 
with another variant (all four do so except CYP2D6*53). Also the majority or all of the 
amino acid mutations within one variant were located in or within close vicinity of the 
binding pocket (with CYP2D6*4 as exception). Furthermore, to assess the impact of 
substrate or inhibitor on the dynamics of the enzyme fold three substrates (bufuralol, 
tamoxifen and veliparib) and two inhibitors (prinomastat and quinidine) were used. 
Analysis of the trajectories indicated that the presence of a ligand (substrate or 
inhibitor) generally had a stabilizing effect on the enzyme structure. Furthermore, 
investigation of the hydrogen bonding networks in the binding pocket revealed that 
especially non-conserved amino acid mutations located very close to the heme (e.g. 
T107I or A122S positioned at the BC-loop), can modulate the flexibility of two 
important loops (BC- and FG loop) which facilitate the access from three of the major 
access tunnels (2c/2e/2b) to the reactive heme center and vice versa. In comparison 
to the wild-type, missing or additional hydrogen bonds led to increased flexibility of 
one of the loops (depending on the mutation location) and subsequently influenced 
the ligand pathway positively (more accessible) or negatively (more steric hindrance). 
We proposed that such a mechanism may contribute to increased (CYP2D6*53) or 
decreased (CYP2D6*17) enzyme activity. During the course of the project, it was 
recognized that the presence of the membrane to which CYP2D6 is normally anchored 
in its native environment will likely have a stabilizing impact on the structure and 
therefore also influences the dynamics of the pathways which steer the ligand to and 
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from the active site. At this point, Mr. André Fischer joined our research group to 
perform his master thesis project. He was very motivated and agreed on performing 
similar MD simulations as described in this chapter but then with CYP2D6 anchored 
to the membrane. Hence in Chapter 4, the results of the work he did during his master 
project under my supervision can be found. In order to define how the membrane 
influences the dynamics of CYP2D6 wild-type and the five allelic variants, membrane-
anchored CYP2D6 models were constructed, evaluated and used for subsequent MD 
simulations. Next, an in-depth analysis of the tunnels and the overall fold was 
performed to identify differences which may mechanistically explain the changes in 
enzyme activity. The most striking findings were the following; for the allelic variants 
associated with decreased activity, lower opening frequencies of the most prominent 
tunnels (2b/2c) providing access to the heme could be observed. For the allelic 
variants associated with increased activity, it could be shown that for one of the major 
tunnels (2b) an enlargement of the bottleneck part (minimal diameter) occurred 
(related to the F120I mutation), thereby improving the access to the heme, thus 
promoting a higher ligand turn-over. Furthermore, smaller active site volumes could 
be correlated with decreased or no enzyme activity variants whereas larger ones with 
increased enzyme activity. Compared to the study in Chapter 3, the membrane had a 
stabilizing impact on the enzyme, especially its overall fold and decreased the average 
fluctuation of the FG - and BC loops. Both studies confirmed the crucial function of 
the FG- and BC loops to steer the closing and opening mechanism of the tunnels in 
close vicinity of the heme. Chapter 5 focuses as an application study on analysing the 
in silico safety profile of several herbal-based compounds suggested to bear 
antidepressant activity, in particular within the context of CYP2D6 inhibition. Synthetic 
antidepressants are one of the major drug categories which depend on CYP2D6 
activity before reaching any therapeutic effect. Since several years there is an upward 
trend in the depression occurrence within the society and also in the number of people 
that use herbal/natural products in combination therapy as a treatment. However, 
accurate safety profiling studies, as required for any approved drug, are frequently 
incompletely performed if not completely lacking for natural products. This may pose 
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a considerable risk to the patient, as for example inhibition of CYP2D6 may lead to 
accumulation of the concomitantly administered drug and cause severe side effects. 
In addition, CYP2D6 pharmacogenetics is an additional risk factor which can have a 
significant effect on the response and the clearance of the substrate drug. Hence, this 
computational study was performed to indicate which of the natural product 
compounds should be prioritized for further experimental safety studies as they likely 
increase the chance on adverse reactions, in particular through CYP2D6 inhibition. An 
initial dataset of 51 herbal-based products suggested to have antidepressant activity 
was compiled. Subsequently, the products which have little chance, based on their 
physicochemical parameters, to reach the brain through passive transport were 
filtered out. Neurotherapeutic drugs required to cross the blood brain barrier (BBB) 
in order to modulate the central nervous system (CNS). For the design of CNS drugs, 
an adjusted version of the famous Lipinski rules was compiled before that increase 
their chance to be absorbed and reach the brain through passive transport. These 
guidelines were used to filter the initial dataset and 19 herbal-based anti-depressant 
products passed and were further analysed. First, a literature study was performed to 
find any evidence regarding BBB permeability, CYP2D6 inhibition and P450 
metabolism. Subsequently, all compounds were docked into CYP2D6 wild-type and 
the increased activity allelic variant CYP2D6*53. The top 10 best scored poses were 
visually inspected to determine if they could act (bind) as an inhibitor. In addition, 
several toxicity-related descriptors were calculated that could provide hints on off-
target binding. For several of the natural compounds studied the outcome points 
towards an increased risk on adverse reactions due to CYP2D6 inhibition or another 
off-target analysed. Further experimental studies are required to confirm these 
indications. The final chapter, Chapter 6, presents the most important findings from 
this thesis and the future perspectives on the directions of the CYP2D6 
pharmacogenetic modeling field are given. The major challenges are described as well 
as potential approaches that can aid in accelerating new CYP2D6 discoveries and 






CYP2D6           Cytochrome P450 2D6 
MD Molecular Dynamics  
WT-MTD Well Tempered Metadynamics  
QM/MM  Quantum Mechanics/Molecular Mechanics 
DFT Density Function Theory 
CV Collective Variable 
FES Free Energy Surface 
SoM Site of Metabolism 
SRS Site Recognition Residues 
POR Cytochrome P450 Oxidoreductase 
PM Poor Metabolizer 
IM Intermediate Metabolizer 
NM Normal Metabolizer 
UM Ultrarapid Metabolizer 
3D Three-Dimensional 
RMSD Root Mean Square Deviation 
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